iso_3_code,countryname,who_region,year,vaccinecode,vaccine_description,schedulerounds,targetpop,targetpop_description,geoarea,ageadministered,sourcecomment
ABW,Aruba,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,,General/routine,NATIONAL,M2,
ABW,Aruba,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,,General/routine,NATIONAL,M4,
ABW,Aruba,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,,General/routine,NATIONAL,M6,
ABW,Aruba,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,
ABW,Aruba,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,
ABW,Aruba,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,6.0,B_CHILD_W,General/routine,NATIONAL,Y10,
ABW,Aruba,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ABW,Aruba,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ABW,Aruba,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ABW,Aruba,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,healthcare workers
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,healthcare workers
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,healthcare workers
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M1,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M9,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,females only; grade 6 primary schools
ABW,Aruba,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females only; grade 6 primary schools
ABW,Aruba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
ABW,Aruba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health and care workers
ABW,Aruba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
ABW,Aruba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adults with chronic conditions, residents living in long-term care facilities"
ABW,Aruba,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Children living with long-term care facilities
ABW,Aruba,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,students travelling abroad
ABW,Aruba,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,students travelling abroad
ABW,Aruba,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y4,students travelling abroad
ABW,Aruba,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,students travelling abroad
ABW,Aruba,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,students travelling abroad
ABW,Aruba,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12,students travelling abroad
ABW,Aruba,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y1,upon request
ABW,Aruba,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers to specific countries
AFG,Afghanistan,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
AFG,Afghanistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
AFG,Afghanistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
AFG,Afghanistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
AFG,Afghanistan,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,New borns
AFG,Afghanistan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,0-9 months
AFG,Afghanistan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M9,0-9 months
AFG,Afghanistan,EMRO,2023,MEASLES,Measles vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,0-18 months
AFG,Afghanistan,EMRO,2023,MEASLES,Measles vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M18,0-18 months
AFG,Afghanistan,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
AFG,Afghanistan,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
AFG,Afghanistan,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
AFG,Afghanistan,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
AFG,Afghanistan,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 months
AFG,Afghanistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
AFG,Afghanistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
AFG,Afghanistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
AFG,Afghanistan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
AFG,Afghanistan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
AFG,Afghanistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Y15-Y49 (WCBA)
AGO,Angola,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,0-11 mois
AGO,Angola,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,0-11 mois
AGO,Angola,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,0-11 mois
AGO,Angola,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,0-11 mois
AGO,Angola,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,0-7 jours
AGO,Angola,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,M4,0-11 mois
AGO,Angola,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M9,0-11 mois
AGO,Angola,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,9-15 mois
AGO,Angola,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,ADULTS,General/routine,NATIONAL,M15,9-15 mois
AGO,Angola,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,B,0-11 mois
AGO,Angola,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M2,0-11 mois
AGO,Angola,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M4,0-11 mois
AGO,Angola,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,M6,0-11 mois
AGO,Angola,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,0-11 mois
AGO,Angola,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,0-11 mois
AGO,Angola,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,0-11 mois
AGO,Angola,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,0-11 mois
AGO,Angola,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,0-11 mois
AGO,Angola,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse
AGO,Angola,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse
AGO,Angola,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse
AGO,Angola,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
AGO,Angola,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
AGO,Angola,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,15-49 A
AGO,Angola,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,0-11 mois
AGO,Angola,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M9,0-11 mois
AGO,Angola,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,0-11 mois
AIA,Anguilla,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,birth - 11 months
AIA,Anguilla,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,birth - 11 months
AIA,Anguilla,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,birth - 11 months
AIA,Anguilla,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,birth - 11 months
AIA,Anguilla,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,birth - 11 months
AIA,Anguilla,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,birth - 11 months
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,from May 2019
AIA,Anguilla,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-15,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,BOTH,General/routine,NATIONAL,>Y18,and older persons
AIA,Anguilla,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
AIA,Anguilla,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
AIA,Anguilla,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
AIA,Anguilla,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
AIA,Anguilla,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, residents living in long-term care facilities"
AIA,Anguilla,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Adults with chronic conditions, residents living in long-term care facilities"
AIA,Anguilla,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y2,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y15,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18,12 month old and 24 months old
AIA,Anguilla,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,15 yrs
AIA,Anguilla,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
AIA,Anguilla,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,pregnant women
AIA,Anguilla,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6-Y1,pregnant women
AIA,Anguilla,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y4,"Children over 4 yrs of age and older with incomplete vaccinations/history of febrile seizers. Adults travelers, Adults with unknown previous vaccination history"
AIA,Anguilla,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,>Y4,Adults travelers
AIA,Anguilla,AMRO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M15,Adults travelers
AIA,Anguilla,AMRO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y5,Adults travelers
AIA,Anguilla,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ALB,Albania,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers
ALB,Albania,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,travellers
ALB,Albania,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_F,General/routine,NATIONAL,Y2,travellers
ALB,Albania,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_F,General/routine,NATIONAL,M2,travellers
ALB,Albania,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_F,General/routine,NATIONAL,M4,travellers
ALB,Albania,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_F,General/routine,NATIONAL,M6,travellers
ALB,Albania,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_F,General/routine,NATIONAL,B,travellers
ALB,Albania,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,Female from November 2022
ALB,Albania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
ALB,Albania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ALB,Albania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ALB,Albania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ALB,Albania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y9,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ALB,Albania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y9,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ALB,Albania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y9,Children with chronic conditions
ALB,Albania,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
ALB,Albania,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
ALB,Albania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Children with chronic conditions
ALB,Albania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
ALB,Albania,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
ALB,Albania,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y2,Children with chronic conditions
ALB,Albania,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
ALB,Albania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
ALB,Albania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
ALB,Albania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
ALB,Albania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
ALB,Albania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
ALB,Albania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
ALB,Albania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y18,Children with chronic conditions
ALB,Albania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y13,Children with chronic conditions
AND,Andorra,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,Children with chronic conditions
AND,Andorra,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,Children with chronic conditions
AND,Andorra,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M12,Children with chronic conditions
AND,Andorra,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,Females; A partir del 15 de noviembre del 2023 se incluyen en la vacunación los niños tambien
AND,Andorra,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females; A partir del 15 de noviembre del 2023 se incluyen en la vacunación los niños tambien
AND,Andorra,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Females; A partir del 15 de noviembre del 2023 se incluyen en la vacunación los niños tambien
AND,Andorra,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
AND,Andorra,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
AND,Andorra,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
AND,Andorra,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y12,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M13,Children with chronic conditions
AND,Andorra,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
AND,Andorra,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
AND,Andorra,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y3,Children with chronic conditions
AND,Andorra,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M13,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,M3,Embarazadas
AND,Andorra,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Embarazadas
AND,Andorra,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y15,Embarazadas
AND,Andorra,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M15,Embarazadas
AND,Andorra,EURO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y3,Embarazadas
ARE,United Arab Emirates,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,newborn
ARE,United Arab Emirates,EMRO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,B,travellers
ARE,United Arab Emirates,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,travellers
ARE,United Arab Emirates,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,travellers
ARE,United Arab Emirates,EMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers
ARE,United Arab Emirates,EMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,travellers
ARE,United Arab Emirates,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,travellers
ARE,United Arab Emirates,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,risk groups
ARE,United Arab Emirates,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6,travellers
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,risk groups
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,risk groups
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,risk groups
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,travellers
ARE,United Arab Emirates,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ARE,United Arab Emirates,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers
ARE,United Arab Emirates,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,high risk groups
ARE,United Arab Emirates,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,school students
ARE,United Arab Emirates,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,school students
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents in long-term care facilities, other groups"
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents in long-term care facilities, other groups"
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents in long-term care facilities, other groups"
ARE,United Arab Emirates,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
ARE,United Arab Emirates,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,high risk groups
ARE,United Arab Emirates,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>=M6,travellers
ARE,United Arab Emirates,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,Y15-Y16,school students
ARE,United Arab Emirates,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15-Y16,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M6,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,M18,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,Y5-Y6,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers / Pilgrims
ARE,United Arab Emirates,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,risk groups
ARE,United Arab Emirates,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M2,travellers
ARE,United Arab Emirates,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,risk groups
ARE,United Arab Emirates,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M2,travellers
ARE,United Arab Emirates,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,travellers
ARE,United Arab Emirates,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,travellers
ARE,United Arab Emirates,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,M4,adults
ARE,United Arab Emirates,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,school students
ARE,United Arab Emirates,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,risk groups
ARE,United Arab Emirates,EMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,risk groups
ARE,United Arab Emirates,EMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15-Y16,travellers
ARE,United Arab Emirates,EMRO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12,travellers
ARE,United Arab Emirates,EMRO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y5-Y6,travellers
ARE,United Arab Emirates,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y5-Y6,travellers
ARE,United Arab Emirates,EMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,people 50 years old and above
ARE,United Arab Emirates,EMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,people 50 years old and above
ARG,Argentina,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,people 50 years old and above
ARG,Argentina,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Indicaciones especiales: HSH, pacientes con desórdenes de la coagulación, enfermedad hepática crónica, trabajo con el VHA en laboratorios, personal gastronómico, personal de jardines maternales que asisten a niños menores de un año de vida."
ARG,Argentina,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Indicaciones especiales: HSH, pacientes con desórdenes de la coagulación, enfermedad hepática crónica, trabajo con el VHA en laboratorios, personal gastronómico, personal de jardines maternales que asisten a niños menores de un año de vida."
ARG,Argentina,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Indicaciones especiales: HSH, pacientes con desórdenes de la coagulación, enfermedad hepática crónica, trabajo con el VHA en laboratorios, personal gastronómico, personal de jardines maternales que asisten a niños menores de un año de vida."
ARG,Argentina,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Universal
ARG,Argentina,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Universal
ARG,Argentina,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Universal
ARG,Argentina,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Universal
ARG,Argentina,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Huéspedes especiales
ARG,Argentina,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Huéspedes especiales
ARG,Argentina,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Esquema de dos dosis (0-6) aplicado a los 11 años en mujeres nacidas a partir del año 2000 y varones nacidos a partir del año 2006.
ARG,Argentina,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Esquema de dos dosis (0-6) aplicado a los 11 años en mujeres nacidas a partir del año 2000 y varones nacidos a partir del año 2006.
ARG,Argentina,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Esquema de dos dosis (0-6) aplicado a los 11 años en mujeres nacidas a partir del año 2000 y varones nacidos a partir del año 2006.
ARG,Argentina,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
ARG,Argentina,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
ARG,Argentina,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ARG,Argentina,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M24,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ARG,Argentina,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M24,Children with chronic conditions
ARG,Argentina,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
ARG,Argentina,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
ARG,Argentina,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
ARG,Argentina,AMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
ARG,Argentina,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
ARG,Argentina,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
ARG,Argentina,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
ARG,Argentina,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,Y11,Children with chronic conditions
ARG,Argentina,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,11 años se puede iniciar o completar esquema
ARG,Argentina,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,11 años se puede iniciar o completar esquema
ARG,Argentina,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Puérperas. Adultos y niños de poblaciones seleccionadas para actividades intensificadas de vacunación para contención de brote de sarampión.
ARG,Argentina,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Puérperas. Adultos y niños de poblaciones seleccionadas para actividades intensificadas de vacunación para contención de brote de sarampión.
ARG,Argentina,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,También como parte del esquema secuencial con la PS23V para grupos de riesgo
ARG,Argentina,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,También como parte del esquema secuencial con la PS23V para grupos de riesgo
ARG,Argentina,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,También como parte del esquema secuencial con la PS23V para grupos de riesgo
ARG,Argentina,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,También como parte del esquema secuencial con la PS23V para grupos de riesgo
ARG,Argentina,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Grupos de riesgo 1er contacto. También como parte del esquema secuencial con la PC13V para grupos de riesgo
ARG,Argentina,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D21,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,M4,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,HW,Health workers,NATIONAL,+Y5,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M15,También forma parte de la estrategia para huespedes especiales
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y5,También forma parte de la estrategia para huespedes especiales
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,2.0,HW,Health workers,NATIONAL,+M1,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M18,En zonas seleccionadas de riesgo
ARG,Argentina,AMRO,2023,YF,YF (Yellow fever) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,Y11,En zonas seleccionadas de riesgo
ARG,Argentina,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st Contact,Viajeros
ARM,Armenia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,"После рождения в течение 0-48 часа, после роддома  получают до 1 года в поликлинике."
ARM,Armenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,До 11 месяцев 29 дней
ARM,Armenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W12,До 11 месяцев 29 дней
ARM,Armenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W18,До 11 месяцев 29 дней
ARM,Armenia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,До 11 месяцев 29 дней
ARM,Armenia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,До 11 месяцев 29 дней
ARM,Armenia,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y15-Y16,"только  юноши допризывного возраста 15-16 лет, вторая доза через 6 месяцев после первой дозы"
ARM,Armenia,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,+M6,"только  юноши допризывного возраста 15-16 лет, вторая доза через 6 месяцев после первой дозы"
ARM,Armenia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"После рождения в течение 0-24 часа, после роддома моно вакцину против Гепатита В для детей в поликлиниках не получают, в дальнейшем только получают в составе шестивалентной вакцины"
ARM,Armenia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y14,только девочкам  в возрасте 14 лет- две дозы (вторая доза через 6 месяцев после первой)
ARM,Armenia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,только девочкам  в возрасте 14 лет- две дозы (вторая доза через 6 месяцев после первой)
ARM,Armenia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y45,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
ARM,Armenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
ARM,Armenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ARM,Armenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y2,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ARM,Armenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y3-Y5,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ARM,Armenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y3-Y5,Children with chronic conditions
ARM,Armenia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y15-Y16,только  юноши  допризывного возраста 15-16 лет
ARM,Armenia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,лица с повышенным риском заболевания
ARM,Armenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,лица с повышенным риском заболевания
ARM,Armenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,RISKGROUPS,General/routine,NATIONAL,Y15-Y16,"Третью дозу получают только юноши допризывного возраста 15-16 лет, не имеющие 2 дозы"
ARM,Armenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Третью дозу получают только юноши допризывного возраста 15-16 лет, не имеющие 2 дозы"
ARM,Armenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,По эпидпоказаниям
ARM,Armenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,"До 11 месяцев 29 дней, только  юноши допризывного возраста15-16 лет"
ARM,Armenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W12,"До 11 месяцев 29 дней, только  юноши допризывного возраста15-16 лет"
ARM,Armenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W18,"До 11 месяцев 29 дней, только  юноши допризывного возраста15-16 лет"
ARM,Armenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,Y15-Y16,"До 11 месяцев 29 дней, только  юноши допризывного возраста15-16 лет"
ARM,Armenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,лица с повышенным риском заболевания
ARM,Armenia,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,По эпидпоказаниям
ARM,Armenia,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,"От 6 недель до 15 недель для первой дозы, от 16 недель до 32 недель  для второй дозы Ротавирусной вакцины"
ARM,Armenia,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W16,"От 6 недель до 15 недель для первой дозы, от 16 недель до 32 недель  для второй дозы Ротавирусной вакцины"
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y26-Y30,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y36-Y40,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y46-Y50,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y56-Y60,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y66-Y70,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y76-Y80,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,"Лицам с 15 лет до 25 лет, с 26 лет получают только АДС-М"
ARM,Armenia,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y17,только юноши допризывного возраста 17 лет и лицам с повышенным риском заболевания и по эпидпоказаниям с 7-лет
ARM,Armenia,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,только юноши допризывного возраста 17 лет и лицам с повышенным риском заболевания и по эпидпоказаниям с 7-лет
ATG,Antigua and Barbuda,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y5,5yrs
ATG,Antigua and Barbuda,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,M18
ATG,Antigua and Barbuda,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,M18
ATG,Antigua and Barbuda,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,M18
ATG,Antigua and Barbuda,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,M18
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,infants within the first 24 hours of birth
ATG,Antigua and Barbuda,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y13,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,BOTH,HPV administered to females and males,NATIONAL,+Y1,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M35,"Adults with chronic conditions, residents living in long-term care facilities"
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=Y3,"Adults with chronic conditions, residents living in long-term care facilities"
ATG,Antigua and Barbuda,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y3,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y15,Children with chronic conditions
ATG,Antigua and Barbuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,Vaccine given to risk groups >=2 as recommended by the doctor via medical Benefits (eg those with sickle cell disease diabetes ect)
ATG,Antigua and Barbuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Vaccine given to risk groups >=2 as recommended by the doctor via medical Benefits (eg those with sickle cell disease diabetes ect)
ATG,Antigua and Barbuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,Vaccine given to risk groups >=2 as recommended by the doctor via medical Benefits (eg those with sickle cell disease diabetes ect)
ATG,Antigua and Barbuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y15,Pregnant women
ATG,Antigua and Barbuda,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,Y3-Y5,Pregnant women
ATG,Antigua and Barbuda,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
AUS,Australia,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Travellers
AUS,Australia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Travellers
AUS,Australia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,Travellers
AUS,Australia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Travellers
AUS,Australia,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Travellers
AUS,Australia,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M18,"Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia"
AUS,Australia,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y4,"Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia"
AUS,Australia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,Refugee and humanitarian entrants
AUS,Australia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Refugee and humanitarian entrants
AUS,Australia,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18,Refugee and humanitarian entrants
AUS,Australia,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,"Single dose, school grade 7 or age equivalent, all genders"
AUS,Australia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Single dose, school grade 7 or age equivalent, all genders"
AUS,Australia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,"Single dose, school grade 7 or age equivalent, all genders"
AUS,Australia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,"Single dose, school grade 7 or age equivalent, all genders"
AUS,Australia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conidtions, residents living in long-term care facilities"
AUS,Australia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,"Adults with chronic conidtions, residents living in long-term care facilities"
AUS,Australia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y5,Children with chronic conditions
AUS,Australia,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
AUS,Australia,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y14-Y16,Children with chronic conditions
AUS,Australia,WPRO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M2,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M4,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M6,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,MEN_B,Meningococcal B vaccine,4.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M12,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y70,<=Y70 given to adults 70 years and over (not including Aboriginal and Torres Strait Islander adults).
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,<=Y70 given to adults 70 years and over (not including Aboriginal and Torres Strait Islander adults).
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,"M12 dose may be 4th dose if M6 dose is administered to risk groups or for Aboriginal and Torres Strait Islander children in four regions (Queensland, Northern Territory, Western Australia and South Australia)"
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"M12 dose may be 4th dose if M6 dose is administered to risk groups or for Aboriginal and Torres Strait Islander children in four regions (Queensland, Northern Territory, Western Australia and South Australia)"
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,All children medically at risk
AUS,Australia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"M6 given to Aboriginal and Torres Strait Islander children in four regions (Queensland, Northern Territory, Western Australia and South Australia)"
AUS,Australia,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,>=Y50 for Aboriginal and Torres Strait Islander adults (Indigenous adults)
AUS,Australia,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,General/routine,SUBNATIONAL,Y4,"Aboriginal and Torres Strait Islander children in four regions (Western Australia, Northern Territory, South Australia, Queensland)"
AUS,Australia,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Y4 for all children with specified medical risk conditions
AUS,Australia,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Y4 for all children with specified medical risk conditions
AUS,Australia,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Y4 for all children with specified medical risk conditions
AUS,Australia,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y12-Y13,Y4 for all children with specified medical risk conditions
AUS,Australia,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y12-Y13,Pregnant women
AUS,Australia,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y70-Y79,and includes time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUS,Australia,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,Y71-Y79,Time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUT,Austria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,M2,Time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUT,Austria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,CATCHUP_A,General/routine,NATIONAL,M4,Time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUT,Austria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,CATCHUP_A,General/routine,NATIONAL,M10-M11,Time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUT,Austria,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y15,Free catch up until Y14
AUT,Austria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y21,Females and males; free catch up until Y21 sing 01.02.2023
AUT,Austria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y21,Females and males; free catch up until Y21 sing 01.02.2023
AUT,Austria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,Females and males
AUT,Austria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
AUT,Austria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
AUT,Austria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
AUT,Austria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
AUT,Austria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
AUT,Austria,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
AUT,Austria,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
AUT,Austria,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
AUT,Austria,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y13,Children with chronic conditions
AUT,Austria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_A,Catch-up adults,NATIONAL,Y10-Y13,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y10-Y13,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,CATCHUP_C,General/routine,NATIONAL,+M3,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,General/routine,NATIONAL,M9,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M12-M14,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W6,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M2,Catch-up for everybody regardless of age
AUT,Austria,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",4.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y8,Catch-up for everybody regardless of age
AZE,Azerbaijan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,час 12
AZE,Azerbaijan,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,час 12
AZE,Azerbaijan,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,час 12
AZE,Azerbaijan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,час 12
AZE,Azerbaijan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,час 12
AZE,Azerbaijan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,час 12
AZE,Azerbaijan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,час 12
AZE,Azerbaijan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,час 12
AZE,Azerbaijan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
AZE,Azerbaijan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
AZE,Azerbaijan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Adults with chronic conditions
AZE,Azerbaijan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y18,Adults with chronic conditions
AZE,Azerbaijan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y18,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
AZE,Azerbaijan,EURO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
BDI,Burundi,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,naissances vivantes
BDI,Burundi,AFRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,12-23 mois
BDI,Burundi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
BDI,Burundi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
BDI,Burundi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
BDI,Burundi,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
BDI,Burundi,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,0-23 mois
BDI,Burundi,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M18,0-23 mois
BDI,Burundi,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,B,0-11 mois
BDI,Burundi,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
BDI,Burundi,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
BDI,Burundi,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
BDI,Burundi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
BDI,Burundi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
BDI,Burundi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
BDI,Burundi,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
BDI,Burundi,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 mois
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 mois
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 mois
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 mois
BDI,Burundi,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 mois
BDI,Burundi,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,voyageurs
BEL,Belgium,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W8,voyageurs
BEL,Belgium,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W12,voyageurs
BEL,Belgium,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W16,voyageurs
BEL,Belgium,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,voyageurs
BEL,Belgium,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,"Y5-Y6 in Wallonia, Y6 in Flanders"
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,1st contact,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y14,"Y12 in Flanders, Y13-Y14 in Wallonia. For both males and females."
BEL,Belgium,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Y12 in Flanders, Y13-Y14 in Wallonia. For both males and females."
BEL,Belgium,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"The guidelines recommend vaccination for those ≥65 years of age. This age group takes priority group for receiving influenza vaccine; the guidelines also mention explicitly that, thereafter and depending on the availability of the vaccine, the flu vaccine is useful for healthy persons aged 50 and older."
BEL,Belgium,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
BEL,Belgium,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
BEL,Belgium,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BEL,Belgium,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
BEL,Belgium,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,<M18,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Asylumnseekers asap after arrival: <5 months normal schedule, >5 months catch-up vaccination"
BEL,Belgium,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"This vaccine replaced Men C in the schedule, starting from August 2023 in Flanders and September 2023 in Wallonia/Brussels"
BEL,Belgium,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y15,"This vaccine replaced Men C in the schedule, starting from August 2023 in Flanders and September 2023 in Wallonia/Brussels"
BEL,Belgium,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,This vaccine was in the schedule until July 2023 in Flanders and August 2023 in Wallonia/Brussels. Afterwards the schedule was changed to Men ACYW.
BEL,Belgium,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,2nd dose: Y9-10 in Flanders; Wallonia: 2 cohorts for the last 4 years due to the change of age in the schedule Y7-Y8 + Y11-Y12 (from sept 2024 only Y7-Y8).
BEL,Belgium,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y7-Y12,2nd dose: Y9-10 in Flanders; Wallonia: 2 cohorts for the last 4 years due to the change of age in the schedule Y7-Y8 + Y11-Y12 (from sept 2024 only Y7-Y8).
BEL,Belgium,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"During 2022, following the outbreak, it was possible for at risk groups to get vaccinated (full NITAG recommendation: https://www.hgr-css.be/file/download/8fe2ee8e-2d1b-42cb-b633-347398576d66/hGTUOQaHTrGqDcF6XmGLVzTuq9LSbnRlW7sP3RQ3d.pdf). The Flemish regional government decided to stop the vaccination campaign after December 2022 and in 2023 it was not possible to get the mpox vaccine in Flanders, but preventive vaccination was still possible in Wallonia and Brussels for high risk groups."
BEL,Belgium,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W16,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W16,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Since January 2023 either PCV13 or PCV15 can be used, without preference. PCV15 is not free however, while PCV13 is."
BEL,Belgium,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Children born before 37w of gestation get an extra dose at 12 weeks
BEL,Belgium,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,Both RV-1 and RV-5 used; vaccination is recommended but not free (not in programme - partially reimbursed)
BEL,Belgium,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W12,Both RV-1 and RV-5 used; vaccination is recommended but not free (not in programme - partially reimbursed)
BEL,Belgium,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,Both RV-1 and RV-5 used; vaccination is recommended but not free (not in programme - partially reimbursed)
BEL,Belgium,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W12,Both RV-1 and RV-5 used; vaccination is recommended but not free (not in programme - partially reimbursed)
BEL,Belgium,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W16,Both RV-1 and RV-5 used; vaccination is recommended but not free (not in programme - partially reimbursed)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y25,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y16,Y14 in Flanders and Y15-Y16 in Wallonia
BEL,Belgium,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14-Y16,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEN,Benin,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 mois
BEN,Benin,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,Survivants
BEN,Benin,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,Survivants
BEN,Benin,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,Survivants
BEN,Benin,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,Dans 24 première heures de la naissance
BEN,Benin,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,W14,Survivants
BEN,Benin,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,PW,General/routine,NATIONAL,M9,Survivants
BEN,Benin,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,PW,General/routine,NATIONAL,M9,Survivants
BEN,Benin,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,B,0-11 mois
BEN,Benin,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W6,0-11 mois
BEN,Benin,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W10,0-11 mois
BEN,Benin,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,W14,0-11 mois
BEN,Benin,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,Survivants
BEN,Benin,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,Survivants
BEN,Benin,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,Survivants
BEN,Benin,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,Survivants
BEN,Benin,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,Survivants
BEN,Benin,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,Survivants
BEN,Benin,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
BEN,Benin,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
BEN,Benin,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
BEN,Benin,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
BEN,Benin,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
BEN,Benin,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,Survivants
BFA,Burkina Faso,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Naissance vivante
BFA,Burkina Faso,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W8,0-11 mois
BFA,Burkina Faso,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W12,0-11 mois
BFA,Burkina Faso,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W16,0-11 mois
BFA,Burkina Faso,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,Naissance vivante
BFA,Burkina Faso,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Filles de 9 ans
BFA,Burkina Faso,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W16,0-11 mois
BFA,Burkina Faso,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,0-11 mois
BFA,Burkina Faso,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,FEMALE,General/routine,NATIONAL,M15,12-23 mois
BFA,Burkina Faso,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,0-11 mois et 15-18 mois
BFA,Burkina Faso,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,0-11 mois et 15-18 mois
BFA,Burkina Faso,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,0-11 mois
BFA,Burkina Faso,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W8,0-11 mois
BFA,Burkina Faso,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W12,0-11 mois
BFA,Burkina Faso,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W16,0-11 mois
BFA,Burkina Faso,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W8,0-11 mois
BFA,Burkina Faso,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W16,0-11 mois
BFA,Burkina Faso,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M9,0-11 mois
BFA,Burkina Faso,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W8,0-11 mois
BFA,Burkina Faso,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W12,0-11 mois
BFA,Burkina Faso,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W16,0-11 mois
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y2,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y2,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois
BFA,Burkina Faso,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 mois
BFA,Burkina Faso,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
BGD,Bangladesh,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,<1 year children
BGD,Bangladesh,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,<1 year children
BGD,Bangladesh,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,<1 year children
BGD,Bangladesh,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,<1 year children
BGD,Bangladesh,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,PW,General/routine,NATIONAL,W6,Fractional dose
BGD,Bangladesh,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),3.0,PW,General/routine,NATIONAL,W14,Fractional dose
BGD,Bangladesh,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,PW,General/routine,NATIONAL,W38,<1 year children;  15-18m children
BGD,Bangladesh,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,PW,General/routine,NATIONAL,M15,<1 year children;  15-18m children
BGD,Bangladesh,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,W6,<1 year children
BGD,Bangladesh,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W10,<1 year children
BGD,Bangladesh,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W14,<1 year children
BGD,Bangladesh,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,<1 year children
BGD,Bangladesh,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,<1 year children
BGD,Bangladesh,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,<1 year children
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15-Y49,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M59,6-59 months children
BGR,Bulgaria,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,6-59 months children
BGR,Bulgaria,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,2.0,PW,General/routine,NATIONAL,M7,6-59 months children
BGR,Bulgaria,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,3.0,PW,General/routine,NATIONAL,Y7,6-59 months children
BGR,Bulgaria,EURO,2023,CCHF,CCHF (Crimean-Congo Hemorrhagic Fever) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y7,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M16,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Health facility staff in endemic regions
BGR,Bulgaria,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory.
BGR,Bulgaria,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M1,Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory.
BGR,Bulgaria,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory.
BGR,Bulgaria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y13,9 valent vaccine administered; females only aged 10-13 years in line with National program for primary prophylaxis of cervical cancer 2021-2024
BGR,Bulgaria,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,9 valent vaccine administered; females only aged 10-13 years in line with National program for primary prophylaxis of cervical cancer 2021-2024
BGR,Bulgaria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years
BGR,Bulgaria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
BGR,Bulgaria,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BGR,Bulgaria,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BGR,Bulgaria,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
BGR,Bulgaria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13,Children with chronic conditions
BGR,Bulgaria,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y12,Children with chronic conditions
BGR,Bulgaria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
BGR,Bulgaria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
BGR,Bulgaria,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
BGR,Bulgaria,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,As post-exposure prophylaxis
BGR,Bulgaria,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10-W24,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10-W24,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W20-W32,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y35,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y45,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y55,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y65,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y17,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BGR,Bulgaria,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y12,1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for control and treatment of rotavirus infections 2017-2021
BHR,Bahrain,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Infants born to parents (or other household close contact) originally from TB endemic areas and with current smears positive of pulmonary TB
BHR,Bahrain,EMRO,2023,CHOLERA,Cholera vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Given in certain emergency situations for relief workers (military workers travelling to at risk countries)
BHR,Bahrain,EMRO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,B,Given in certain emergency situations for relief workers (military workers travelling to at risk countries)
BHR,Bahrain,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Routine childhood vaccine given at age of 2 and 4 months
BHR,Bahrain,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Routine childhood vaccine given at age of 2 and 4 months
BHR,Bahrain,EMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Routine childhood vaccine  given to hildren at age of 4-5 years (preschool entry)
BHR,Bahrain,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Routine childhood vaccine given at age of 6 months and at the age of 18 months
BHR,Bahrain,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Routine childhood vaccine given at age of 6 months and at the age of 18 months
BHR,Bahrain,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"High risk groups, certain occupations at risk, travellers"
BHR,Bahrain,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M18,"High risk groups, certain occupations at risk, travellers"
BHR,Bahrain,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y12,Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,Y13,Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M15,and completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,Y2,and completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y2,"High risk groups, certain occupations at risk including HCW, college students"
BHR,Bahrain,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,"High risk groups, certain occupations at risk including HCW, college students"
BHR,Bahrain,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"High risk groups, certain occupations at risk including HCW, college students"
BHR,Bahrain,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Given as single dose for >5 years children with sickle cell disease, anatomical and/or surgical asplenia, post bone marrow transplant, certain cancer after finishing treatment"
BHR,Bahrain,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,"Started administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it."
BHR,Bahrain,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,"Started administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it."
BHR,Bahrain,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,"Started administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it."
BHR,Bahrain,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y50,Health and care workers
BHR,Bahrain,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y50,Pregnant women
BHR,Bahrain,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHR,Bahrain,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y19,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHR,Bahrain,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,<=Y9,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHR,Bahrain,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<=Y9,Children with chronic conditions
BHR,Bahrain,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Immunocompromised and their households
BHR,Bahrain,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Immunocompromised and their households
BHR,Bahrain,EMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Immunocompromised and their households
BHR,Bahrain,EMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Immunocompromised and their households
BHR,Bahrain,EMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Immunocompromised and their households
BHR,Bahrain,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2,Routine childhood vaccine.
BHR,Bahrain,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,Y2,"Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak"
BHR,Bahrain,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,"Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak"
BHR,Bahrain,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y2,"Given to high risk groups, HCWs and to travelers to Holly places, meningitis belt countries and countries reporting outbreak"
BHR,Bahrain,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,"Routine childhood vaccine, given at the age of 12 and 18 months."
BHR,Bahrain,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,"Routine childhood vaccine, given at the age of 12 and 18 months."
BHR,Bahrain,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M18,"Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers."
BHR,Bahrain,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers."
BHR,Bahrain,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,M18,"Given for non-immune women at reproductive age group discovered during premarital counselling, postnatally for non-immune women discovered during antenatal screening, those discovered during preschool screening (without 2 valid MMR doses), if cases identified in a residency blocks, travellers to endemic countries and Hajj Pilgrims, healthcare workers."
BHR,Bahrain,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M4,Routine childhood vaccine and also provided to travellers to polio endemic countries
BHR,Bahrain,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M6,Routine childhood vaccine and also provided to travellers to polio endemic countries
BHR,Bahrain,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,M18,Routine childhood vaccine and also provided to travellers to polio endemic countries
BHR,Bahrain,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,Y5,Routine childhood vaccine and also provided to travellers to polio endemic countries
BHR,Bahrain,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,Y5,Travellers to polio endemic countries
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M15,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y50,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years."
BHR,Bahrain,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years"
BHR,Bahrain,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years"
BHR,Bahrain,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Routine childhood vaccine
BHR,Bahrain,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Routine childhood vaccine
BHR,Bahrain,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,RISKGROUPS,General/routine,NATIONAL,>=Y7,"The vaccine is administered to defaulters children > 7 years of age, if they miss any of the routine doses of the TD containing vaccine."
BHR,Bahrain,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y7,"Pregnant women, in case of injury, certain occupations at risk and others at risk of exposure"
BHR,Bahrain,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,"Pregnant women, in case of injury, certain occupations at risk and others at risk of exposure"
BHR,Bahrain,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,>Y65,Others at-risk persons
BHR,Bahrain,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13,Students at schools
BHR,Bahrain,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13,Older individuals >65 years
BHR,Bahrain,EMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Travellers, certain at risk groups"
BHR,Bahrain,EMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y2,"Travellers, certain at risk groups"
BHR,Bahrain,EMRO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,Y1,Routine childhood vaccine given at one year and three years of age.
BHR,Bahrain,EMRO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y3,Routine childhood vaccine given at one year and three years of age.
BHR,Bahrain,EMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,Y3,"Given to high risk groups including HCW at direct patient care, household of oncology patient and others"
BHR,Bahrain,EMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y3,"Given to high risk groups including HCW at direct patient care, household of oncology patient and others"
BHR,Bahrain,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y3,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,DTWPHIB,DTwP-Hib (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Travellers to YF endemic areas
BHS,Bahamas,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BHS,Bahamas,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Travellers
BHS,Bahamas,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BHS,Bahamas,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Travellers
BHS,Bahamas,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Travellers
BHS,Bahamas,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Travellers
BHS,Bahamas,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M5,Travellers
BHS,Bahamas,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y12,"Females and males, children aged 9-12 years"
BHS,Bahamas,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females and males, children aged 9-12 years"
BHS,Bahamas,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
BHS,Bahamas,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
BHS,Bahamas,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
BHS,Bahamas,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHS,Bahamas,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHS,Bahamas,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BHS,Bahamas,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
BHS,Bahamas,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
BHS,Bahamas,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
BHS,Bahamas,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y16,1st contact at approximately age 16 years: students attending international colleges/universities
BHS,Bahamas,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,1st contact at approximately age 16 years: students attending international colleges/universities
BHS,Bahamas,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15,1st contact at approximately age 16 years: students attending international colleges/universities
BHS,Bahamas,AMRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,HW,Health workers,NATIONAL,M15,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M15,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15,"High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox"
BHS,Bahamas,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
BHS,Bahamas,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>Y10,Every 10 years
BHS,Bahamas,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y12,and at 1st contact for antenatal women
BHS,Bahamas,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y12,1st contact for antenatal women
BHS,Bahamas,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,1st contact for antenatal women
BHS,Bahamas,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y4-Y5,1st contact for antenatal women
BHS,Bahamas,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M3-M4,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M4-M6,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18-Y2,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y7,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y5-Y7,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y5-Y7,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y7,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M1,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y9-Y14,"Clinical indications, health and care workers, risk groups (for example: beauticians, tattoo artist … )"
BIH,Bosnia and Herzegovina,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y9-Y14,Olders persons
BIH,Bosnia and Herzegovina,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y9-Y14,Health and care workers
BIH,Bosnia and Herzegovina,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y9-Y14,Pregnant women
BIH,Bosnia and Herzegovina,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y14,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BIH,Bosnia and Herzegovina,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y14,Children with chronic conditions
BIH,Bosnia and Herzegovina,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y9-Y14,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y6,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,Y1,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,Y1,Travellers
BIH,Bosnia and Herzegovina,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,Clinical indications
BIH,Bosnia and Herzegovina,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y18,Clinical indications
BIH,Bosnia and Herzegovina,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14-Y18,Travellers
BLR,Belarus,EURO,2023,ANTHRAX,Anthrax vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14-Y18,эпидемические показания
BLR,Belarus,EURO,2023,AP,aP (acellular pertussis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2-M18,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,D3-D5,Для первичной щадящей иммунизации
BLR,Belarus,EURO,2023,D_S,Diphtheria vaccine for older children and adults,1.0,RISKGROUPS,General/routine,NATIONAL,Y11,Для первичной щадящей иммунизации
BLR,Belarus,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Применяется также для вакцинации детей в возрасте 6 лет на ряду с АДС-М
BLR,Belarus,EURO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2-M18,"Применяется у детей в возрасте М2-М18, имеющих медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Применяется у детей в возрасте М2-М18, имеющих медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,"дети в 2, 3, 4 месяца жизни с использованием комбинированной вакцины"
BLR,Belarus,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,"дети в 2, 3, 4 месяца жизни с использованием комбинированной вакцины"
BLR,Belarus,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,"дети в 2, 3, 4 месяца жизни с использованием комбинированной вакцины"
BLR,Belarus,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,эпидемические показания-контакт
BLR,Belarus,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,эпидемические показания-контакт
BLR,Belarus,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,эпидемические показания
BLR,Belarus,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,новорожденные в первые 12 часов жизни (МОНОВАКЦИНА)
BLR,Belarus,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y4,"Дети, ранее не получившие профилактические прививки против гемофильной инфекции, до достижения ими возраста 5 лет в соответствии с инструкцией по медицинскому применению, прилагаемой к иммунобиологическому лекарственному средству, и имеющие одно из следующих заболеваний или состояний: хронический гепатит; цирроз печени; хронические заболевания почек, сердца и легких; иммунодефицитные состояния; муковисцидоз"
BLR,Belarus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
BLR,Belarus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
BLR,Belarus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
BLR,Belarus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLR,Belarus,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y3,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLR,Belarus,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y3,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLR,Belarus,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y3,Children with chronic conditions
BLR,Belarus,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
BLR,Belarus,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
BLR,Belarus,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
BLR,Belarus,EURO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y7,Children with chronic conditions
BLR,Belarus,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Children with chronic conditions
BLR,Belarus,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
BLR,Belarus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,эпидемические показания
BLR,Belarus,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,эпидемические показания
BLR,Belarus,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,эпидемические показания
BLR,Belarus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,эпидемические показания
BLR,Belarus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_F,General/routine,NATIONAL,Y16,эпидемические показания
BLR,Belarus,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,эпидемические показания
BLR,Belarus,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,эпидемические показания
BLR,Belarus,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,эпидемические показания
BLZ,Belize,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Children below age 1 year
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",6.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Children 18 months and 48 months
BLZ,Belize,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Children 18 months and 48 months
BLZ,Belize,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Children 2 to 6 months
BLZ,Belize,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Children 2 to 6 months
BLZ,Belize,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Children 2 to 6 months
BLZ,Belize,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M6,Health Care and other front line workers
BLZ,Belize,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Given to adults on request  or without documentation of Hep B as a child
BLZ,Belize,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,new borns
BLZ,Belize,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Only one dose is administered since May 2023, to school children in Std 4 class. males and females 9-14 years. School based program but also administered in clinic settings as necessary"
BLZ,Belize,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Only one dose is administered since May 2023, to school children in Std 4 class. males and females 9-14 years. School based program but also administered in clinic settings as necessary"
BLZ,Belize,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
BLZ,Belize,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
BLZ,Belize,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLZ,Belize,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLZ,Belize,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12-M23,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"and at M2,  M4, M6, M18, Y4, Y12 for HIV exposed infants and"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"and at M2,  M4, M6, M18, Y4, Y12 for HIV exposed infants and"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023,IPV,IPV (Inactivated polio vaccine),6.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children 12 and 18 months
BLZ,Belize,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children 12 and 18 months
BLZ,Belize,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Children 6 months, 18 months and 4 years"
BLZ,Belize,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,"Children 6 months, 18 months and 4 years"
BLZ,Belize,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,"Children 6 months, 18 months and 4 years"
BLZ,Belize,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"2M, 4M, 6M. Vaccinated in campaignstarted in December 2023"
BLZ,Belize,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"2M, 4M, 6M. Vaccinated in campaignstarted in December 2023"
BLZ,Belize,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"2M, 4M, 6M. Vaccinated in campaignstarted in December 2023"
BLZ,Belize,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,Children in Std 6 (age 12) given a booster dose
BLZ,Belize,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y12,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,Y12,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,Pregnant without proof of previous vaccination are given 2 doses
BLZ,Belize,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M36,Travellers to countries endemic to YF
BMU,Bermuda,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,On request for residents from endemic areas
BMU,Bermuda,AMRO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,CHOLERA,Cholera vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+W2,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Travellers
BMU,Bermuda,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Travellers
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M6,6/12 Month old infants
BMU,Bermuda,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M7,6/12 Month old infants
BMU,Bermuda,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12,6/12 Month old infants
BMU,Bermuda,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,High risk adults for revaccination
BMU,Bermuda,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"females and males; x2 doses for <15 years, x3 doses for >15 years, and also available for other adults upon request"
BMU,Bermuda,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,"females and males; x2 doses for <15 years, x3 doses for >15 years, and also available for other adults upon request"
BMU,Bermuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
BMU,Bermuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
BMU,Bermuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
BMU,Bermuda,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
BMU,Bermuda,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y18,"Adults with chronic conditions, residents living in long-term care facilities"
BMU,Bermuda,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y18,Children with chronic conditions
BMU,Bermuda,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Unvaccinated travellers to high risk areas
BMU,Bermuda,AMRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to high-risk areas
BMU,Bermuda,AMRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D28,Travellers to high-risk areas
BMU,Bermuda,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M15,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y6,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,TRAVELLERS,General/routine,NATIONAL,M18,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,High risk adults
BMU,Bermuda,AMRO,2023,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D7,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y18,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact pregnancy
BMU,Bermuda,AMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y3,Travellers
BMU,Bermuda,AMRO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M24,Travellers
BMU,Bermuda,AMRO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y6,Travellers
BMU,Bermuda,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y50,on referral
BMU,Bermuda,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,on referral
BOL,Bolivia (Plurinational State of),AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18-M23,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"A niñas de 10 años, con dosis única"
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"A niñas de 10 años, con dosis única"
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y60,Health and care workers
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y60,Pregnant women
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,"Adults with chronic conditions, other groups"
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,<Y1,"Adults with chronic conditions, other groups"
BOL,Bolivia (Plurinational State of),AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Adults with chronic conditions, other groups"
BOL,Bolivia (Plurinational State of),AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,La segunda dosis de SRP se incluyo en el esquema nacional en la gestión 2018
BOL,Bolivia (Plurinational State of),AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18-M23,La segunda dosis de SRP se incluyo en el esquema nacional en la gestión 2018
BOL,Bolivia (Plurinational State of),AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18-M23,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 1 año
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y7-Y49,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,Menores de 5 Años
BOL,Bolivia (Plurinational State of),AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M12-M23,De 1 año
BRA,Brazil,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Crianças menores de 5 anos de idade e contatos de portadores de hanseníase
BRA,Brazil,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Crianças menores de 5 anos de idade e contatos de portadores de hanseníase
BRA,Brazil,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19,special population; only in reference centers for special immunobiologicals
BRA,Brazil,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,General/routine,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,General/routine,NATIONAL,>=Y7,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,from 15 months to 4 years; 11 months and 29 days prior vaccination history
BRA,Brazil,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19,special population; only in reference centers for special immunobiologicals
BRA,Brazil,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y26,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
BRA,Brazil,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
BRA,Brazil,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Residents living in long-term care facilities, other groups"
BRA,Brazil,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y6,"Residents living in long-term care facilities, other groups"
BRA,Brazil,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Residents living in long-term care facilities, other groups"
BRA,Brazil,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Residents living in long-term care facilities, other groups"
BRA,Brazil,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Residents living in long-term care facilities, other groups"
BRA,Brazil,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M9,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,Adults,NATIONAL,M12,offered to people up to 49 years
BRA,Brazil,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M12,offered to people up to 49 years
BRA,Brazil,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,ADULTS,General/routine,NATIONAL,M15,offered to people up to 49 years
BRA,Brazil,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,M15,offered to people up to 49 years
BRA,Brazil,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,ADULTS,General/routine,NATIONAL,Y4,offered to people up to 49 years
BRA,Brazil,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,offered to people up to 49 years
BRA,Brazil,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,offered to people up to 49 years
BRA,Brazil,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,offered to people up to 49 years
BRA,Brazil,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,offered to people up to 49 years
BRA,Brazil,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,>=Y7,offered to people up to 49 years
BRA,Brazil,AMRO,2023,VARICELLA,Varicella vaccine,1.0,ADULTS,General/routine,NATIONAL,Y4,offered to people up to 49 years
BRA,Brazil,AMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,Y4,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,HW,General/routine,NATIONAL,M6-M11,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,HW,General/routine,NATIONAL,M12-M18,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,3.0,HW,General/routine,NATIONAL,M19-M25,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,4.0,HW,General/routine,NATIONAL,M26-M32,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,5.0,HW,General/routine,NATIONAL,M33-M39,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,VITAMINA,Vitamin A supplements,6.0,HW,General/routine,NATIONAL,M40-M46,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,HW,General/routine,NATIONAL,M9,Unvaccinated health professionals
BRA,Brazil,AMRO,2023,YF,YF (Yellow fever) vaccine,2.0,HW,General/routine,NATIONAL,Y4,Unvaccinated health professionals
BRB,Barbados,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,Infants of parents that travel to countries with a high burden of tuberculosis
BRB,Barbados,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,CATCHUP_C,Catch-up children,NATIONAL,Y5-Y7,Children who missed their DTP at Y4.5
BRB,Barbados,AMRO,2023,DTAP,DTaP (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children who have a history of seizures
BRB,Barbados,AMRO,2023,DTAP,DTaP (acellular) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4.5,Children who have a history of seizures
BRB,Barbados,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4.5,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,As per request. Travellers and those on humanitarian missions.
BRB,Barbados,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,As per request. Travellers and those on humanitarian missions.
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y11,"Females and males; class 4's (Y10-Y11) 1st dose Form 1's (Y11), 1 dose administration approval was granted in November 2022"
BRB,Barbados,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Females and males; class 4's (Y10-Y11) 1st dose Form 1's (Y11), 1 dose administration approval was granted in November 2022"
BRB,Barbados,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
BRB,Barbados,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
BRB,Barbados,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BRB,Barbados,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y1.5,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4.5,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y11,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10-Y11,Children with chronic conditions: On referral by Pediatricians only
BRB,Barbados,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y10-Y11,Pregnant women where necessary (if they have not had a booster in a 10 year period). This is usually administered in the 2nd trimester.
BRB,Barbados,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,Pregnant women where necessary (if they have not had a booster in a 10 year period). This is usually administered in the 2nd trimester.
BRB,Barbados,AMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCW
BRB,Barbados,AMRO,2023,VARICELLA,Varicella vaccine,2.0,HW,Health workers,NATIONAL,+W6,HCW
BRB,Barbados,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y1,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,females; in school year 7
BRN,Brunei Darussalam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females; in school year 7
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=60 years old
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,M19-24 - dose 2
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,M18 - dose 1
BRN,Brunei Darussalam,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
BRN,Brunei Darussalam,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M6,travellers (Hajj pilgrimage)
BRN,Brunei Darussalam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,travellers (Hajj pilgrimage)
BRN,Brunei Darussalam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,travellers (Hajj pilgrimage)
BRN,Brunei Darussalam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"2+1 dose to preterm babies, children with chronic medical conditions at the tertiary hospital (Paediatric department)"
BRN,Brunei Darussalam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,M18,primigravidas at 28wks + 32wks pregnant
BRN,Brunei Darussalam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,M18,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_F,General/routine,NATIONAL,M24,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_F,General/routine,NATIONAL,W6,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_F,General/routine,NATIONAL,W10,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_F,General/routine,NATIONAL,W14,primigravidas at 28wks + 32wks pregnant
BTN,Bhutan,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_F,General/routine,NATIONAL,B,At birth within 24 hours
BTN,Bhutan,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
BTN,Bhutan,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
BTN,Bhutan,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
BTN,Bhutan,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
BTN,Bhutan,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
BTN,Bhutan,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BTN,Bhutan,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M24,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
BTN,Bhutan,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M24,Children with chronic conditions
BTN,Bhutan,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
BTN,Bhutan,SEARO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W32,Children with chronic conditions
BTN,Bhutan,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
BTN,Bhutan,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M24,Children with chronic conditions
BTN,Bhutan,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Children with chronic conditions
BTN,Bhutan,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
BTN,Bhutan,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W10,Children with chronic conditions
BTN,Bhutan,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
BTN,Bhutan,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,from January 2019
BTN,Bhutan,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,from January 2019
BTN,Bhutan,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M9,from January 2019
BTN,Bhutan,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,from January 2019
BTN,Bhutan,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,from January 2019
BTN,Bhutan,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,PW,General/routine,NATIONAL,M18,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,M2,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,M3,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,M4,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y13,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M3,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M4,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M18,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,FEMALE,General/routine,NATIONAL,Y7,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M4,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M4,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y13,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,+W4,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,1st contact,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,as needed for special persons (i.e. travellers)
BWA,Botswana,AFRO,2023,YF,YF (Yellow fever) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y10,as needed for special persons (i.e. travellers)
CAF,Central African Republic,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Naissances vivantes
CAF,Central African Republic,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Survivants
CAF,Central African Republic,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Survivants
CAF,Central African Republic,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Survivants
CAF,Central African Republic,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,Survivants
CAF,Central African Republic,AFRO,2023,MEASLES,Measles vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,Survivants
CAF,Central African Republic,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,Survivants
CAF,Central African Republic,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,Survivants
CAF,Central African Republic,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,Survivants
CAF,Central African Republic,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,Survivants
CAF,Central African Republic,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,Survivants
CAF,Central African Republic,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Survivants
CAF,Central African Republic,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Survivants
CAF,Central African Republic,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Survivants
CAF,Central African Republic,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Survivants
CAF,Central African Republic,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,Survivants
CAN,Canada,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,SUBNATIONAL,M1,Given in: NT and NU
CAN,Canada,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,PW,General/routine,SUBNATIONAL,M2,"Given in provinces/territories: x3 doses at M2, M4, M6 in BC, AB, PE, YT; x2 doses at M2, M4 in QC"
CAN,Canada,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,PW,General/routine,SUBNATIONAL,M4,"Given in provinces/territories: x3 doses at M2, M4, M6 in BC, AB, PE, YT; x2 doses at M2, M4 in QC"
CAN,Canada,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,PW,General/routine,SUBNATIONAL,M6,"Given in provinces/territories: x3 doses at M2, M4, M6 in BC, AB, PE, YT; x2 doses at M2, M4 in QC"
CAN,Canada,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,"Given in provinces/territories: x4 doses at M2, M4, M6, M18 in SK, MB, ON, NB, NS, NL, NT, NU; x1 dose at M18 in BC, AB, PE, YT; x1 dose at M12 in QC"
CAN,Canada,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,"Given in provinces/territories: x4 doses at M2, M4, M6, M18 in SK, MB, ON, NB, NS, NL, NT, NU; x1 dose at M18 in BC, AB, PE, YT; x1 dose at M12 in QC"
CAN,Canada,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6-M12,"Given in provinces/territories: x4 doses at M2, M4, M6, M18 in SK, MB, ON, NB, NS, NL, NT, NU; x1 dose at M18 in BC, AB, PE, YT; x1 dose at M12 in QC"
CAN,Canada,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Given in provinces/territories: x4 doses at M2, M4, M6, M18 in SK, MB, ON, NB, NS, NL, NT, NU; x1 dose at M18 in BC, AB, PE, YT; x1 dose at M12 in QC"
CAN,Canada,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,M18,"Given in province: QC at M18, catch-up program in 3rd year secondary school in QC, and temporary catch-up schedule for children in the fourth year of primary school (hepatitis A only)"
CAN,Canada,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,CATCHUP_C,General/routine,SUBNATIONAL,M18,"Given in province: QC at M18, catch-up program in 3rd year secondary school in QC, and temporary catch-up schedule for children in the fourth year of primary school (hepatitis A only)"
CAN,Canada,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,M18,"Given in province: QC at M18, catch-up program in 3rd year secondary school in QC, and temporary catch-up schedule for children in the fourth year of primary school (hepatitis A only)"
CAN,Canada,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,M18,x3 doses in grade 6 in AB (catch up program)
CAN,Canada,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,CATCHUP_C,General/routine,SUBNATIONAL,M1-Y12,"Given in province/territories: at birth, M2, M6 in NB; at birth, M1, M6 in NT; at birth, M1, M9 in NU. x3 doses in grade 6 in AB (catch up program); x2 doses in grade 6 in SK, MB, NL; x2 doses in grade 7 in ON, NS"
CAN,Canada,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,CATCHUP_C,General/routine,SUBNATIONAL,M6-M9,"Given in province/territories: at birth, M2, M6 in NB; at birth, M1, M6 in NT; at birth, M1, M9 in NU. x3 doses in grade 6 in AB (catch up program); x2 doses in grade 6 in SK, MB, NL; x2 doses in grade 7 in ON, NS"
CAN,Canada,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,General/routine,SUBNATIONAL,B-Y12,"Given in province/territories: at birth, M2, M6 in NB; at birth, M1, M6 in NT; at birth, M1, M9 in NU. x3 doses in grade 6 in AB (catch up program); x2 doses in grade 6 in SK, MB, NL; x2 doses in grade 7 in ON, NS"
CAN,Canada,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,CATCHUP_C,Catch-up children,SUBNATIONAL,B-Y12,"females and males; x2 in gr.6 in BC, AB, SK, MB, PE, NL, YT, NU; x2 in gr.7 in NS, NB; ON; 1x in 4th yr primary school + 1x in 3rd yr secondary school in QC and catch-up in 3rd year secondary school in QC; x2 9-14yrs, x3 15+yrs in NT"
CAN,Canada,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y13,"females and males; 2nd dose 6 months after the 1st dose; x2 in gr.6 in BC, AB, SK, MB, PE, NL, YT, NU; x2 in gr.7 in NS, NB; ON; 1x in 4th yr primary school + 1x in 3rd yr secondary school in QC and catch-up in 3rd year secondary school in QC; x2 9-14yrs, x3 15+yrs in NT"
CAN,Canada,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y16,"females and males; 2nd dose 6 months after the 1st dose; x2 in gr.6 in BC, AB, SK, MB, PE, NL, YT, NU; x2 in gr.7 in NS, NB; ON; 1x in 4th yr primary school + 1x in 3rd yr secondary school in QC and catch-up in 3rd year secondary school in QC; x2 9-14yrs, x3 15+yrs in NT"
CAN,Canada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >=Y65
CAN,Canada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
CAN,Canada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,Pregnant women
CAN,Canada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
CAN,Canada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M6-Y4,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
CAN,Canada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y17,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
CAN,Canada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y17,Children with chronic conditions
CAN,Canada,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,Y9-Y17,"Given in provinces/territories: x1 at grade 9 in BC, AB, NB, PE, YT and NU; x1 at grade 6 in SK, MB; x1 at grade 7 in ON, NS; x1 in grade 4 in NL; x1 in grade 12 in NT; and x1 3rd year of secondary school in QC"
CAN,Canada,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,Y9-Y17,catch-up in 3rd year secondary school in QC
CAN,Canada,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,CATCHUP_C,General/routine,SUBNATIONAL,M12,"Given in provinces/territories: x2 doses at M2, M12 in BC, YT, NT; x2 doses at M4, M12 in AB; x1 dose at M12 in SK, MB, ON, NB, NS, PE, NL, NU; x1 dose at M18 in QC; and catch-up in 3rd year secondary school in QC"
CAN,Canada,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2-M18,"Given in provinces/territories: x2 doses at M2, M12 in BC, YT, NT; x2 doses at M4, M12 in AB; x1 dose at M12 in SK, MB, ON, NB, NS, PE, NL, NU; x1 dose at M18 in QC; and catch-up in 3rd year secondary school in QC"
CAN,Canada,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,General/routine,SUBNATIONAL,M12,"Given in provinces/territory: BC, ON, YT"
CAN,Canada,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,M12,catch-up in 3rd year secondary school in QC
CAN,Canada,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,CATCHUP_C,General/routine,SUBNATIONAL,M12,"Given in provinces/territories: x2 - M12, Y4-Y6 in MB; x2 - M12, M18 in  AB, SK, QC,  NB, NS,  PE, NL, NT, NU; x1 - Y4-Y6 in BC, ON, YT (2nd dose); and catch-up in 3rd year secondary school in QC"
CAN,Canada,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,CATCHUP_C,General/routine,NATIONAL,M18-Y6,"Given in provinces/territories: x2 - M12, Y4-Y6 in MB; x2 - M12, M18 in  AB, SK, QC,  NB, NS,  PE, NL, NT, NU; x1 - Y4-Y6 in BC, ON, YT (2nd dose); and catch-up in 3rd year secondary school in QC"
CAN,Canada,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,General/routine,SUBNATIONAL,M2,Province of Quebec
CAN,Canada,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,CATCHUP_C,General/routine,SUBNATIONAL,M4,Province of Quebec
CAN,Canada,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2-M12,"PCV13 given in provinces/territories: x3 at M2, M4, M12 in BC, AB, SK, MB, ON, NB, NS, PE, NL, YT, PCV13 given in QC x1 at M12; PCV13 given in NT x4 at M2 M4 M6 M18 and in NU x4 at M2 M4 M6 M15"
CAN,Canada,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"PCV13 given in provinces/territories: x3 at M2, M4, M12 in BC, AB, SK, MB, ON, NB, NS, PE, NL, YT, PCV13 given in QC x1 at M12; PCV13 given in NT x4 at M2 M4 M6 M18 and in NU x4 at M2 M4 M6 M15"
CAN,Canada,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M6-M12,"PCV13 given in provinces/territories: x3 at M2, M4, M12 in BC, AB, SK, MB, ON, NB, NS, PE, NL, YT, PCV13 given in QC x1 at M12; PCV13 given in NT x4 at M2 M4 M6 M18 and in NU x4 at M2 M4 M6 M15"
CAN,Canada,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,CATCHUP_C,General/routine,NATIONAL,M15-M18,"PCV13 given in provinces/territories: x3 at M2, M4, M12 in BC, AB, SK, MB, ON, NB, NS, PE, NL, YT, PCV13 given in QC x1 at M12; PCV13 given in NT x4 at M2 M4 M6 M18 and in NU x4 at M2 M4 M6 M15"
CAN,Canada,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,"Schedule information was collected for healthy, previously immunized adults. Given as one dose in all jurisdictions at 65yrs+, except NU. In NU, one dose given to those 50+. In YK, given to all those 65+ and all residents of extended or intermediate care facilities and high-risk individuals."
CAN,Canada,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,General/routine,SUBNATIONAL,Y2-Y3,Given in territory: NU between Y2-Y3
CAN,Canada,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y2-Y3,"Schedule information was collected for healthy, previously immunized adults. Given as one dose in all jurisdictions at 65yrs+, except NU. In NU, one dose given to those 50+. In YK, given to all those 65+ and all residents of extended or intermediate care facilities and high-risk individuals."
CAN,Canada,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M2,"x2 doses at M2, M4 in BC, AB, MB,ON,QC, NL"
CAN,Canada,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M4,"x2 doses at M2, M4 in BC, AB, MB,ON,QC, NL"
CAN,Canada,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M2,"Given in provinces/territories: x3 doses at M2, M4, M6 in  SK, NB, NS, PE, YT, NT, NU;"
CAN,Canada,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M4,"Given in provinces/territories: x3 doses at M2, M4, M6 in  SK, NB, NS, PE, YT, NT, NU;"
CAN,Canada,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,SUBNATIONAL,M6,"Given in provinces/territories: x3 doses at M2, M4, M6 in  SK, NB, NS, PE, YT, NT, NU;"
CAN,Canada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Schedule information was collected for healthy, previously immunized adults. Given in provinces/territories every 10 yr in BC, SK, MB, ON, NB, NS, YT, NU; x1 in at 50 yrs in QC"
CAN,Canada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+Y10,"Schedule information was collected for healthy, previously immunized adults. Given in provinces/territories every 10 yr in BC, SK, MB, ON, NB, NS, YT, NU; x1 in at 50 yrs in QC"
CAN,Canada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,SUBNATIONAL,Y15,Given in 3rd year of high school in QC
CAN,Canada,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,SUBNATIONAL,+Y10,"Schedule information was collected for healthy, previously immunized adults. Given with each pregnancy in BC and QC; Given every 10 years and each pregnancy in AB, PE, NL, and NT; One booster dose per adult lifetime and each pregnancy in SK, MB, ON, NB, NS, YT, and NU."
CAN,Canada,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Schedule information was collected for healthy, previously immunized adults. Given with each pregnancy in BC and QC; Given every 10 years and each pregnancy in AB, PE, NL, and NT; One booster dose per adult lifetime and each pregnancy in SK, MB, ON, NB, NS, YT, and NU."
CAN,Canada,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,B_ADO_W,General/routine,SUBNATIONAL,Y11-Y16,"Given in provinces/territories: x1 in gr.9 in BC, AB, PE, NL, YT; x1 in gr.8 in SK; x1 in gr.7 in NB, NS, NT; x1 gr.6 in NU; x1 in gr.8 or 9 in MB; x1 at Y14-Y16 in ON"
CAN,Canada,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11-Y16,"Schedule information was collected for healthy, previously immunized adults. Given with each pregnancy in BC and QC; Given every 10 years and each pregnancy in AB, PE, NL, and NT; One booster dose per adult lifetime and each pregnancy in SK, MB, ON, NB, NS, YT, and NU."
CAN,Canada,AMRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,Y11-Y16,QC catch-up in 3rd year secondary school
CAN,Canada,AMRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,"Given in provinces/territories: between Y4-Y6 in BC, SK, MB, ON, QC, NS, NL, NT, YT, NU (DTaPHibIPV sub in NL, NT if shortage); between Y4-Y5 in PE; at Y4 in AB, NB; and in province: QC catch-up in 3rd year secondary school"
CAN,Canada,AMRO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,Catch-up children,SUBNATIONAL,Y4-Y6,"Given in: M12 in BC, YT; M15 in ON; grade 6 in NU (catch-up program); between Y4-Y6 in QC (catch-up program)"
CAN,Canada,AMRO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,General/routine,SUBNATIONAL,M12-M15,"Given in: M12 in BC, YT; M15 in ON; grade 6 in NU (catch-up program); between Y4-Y6 in QC (catch-up program)"
CAN,Canada,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,>=Y60,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CAN,Canada,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,>=Y60,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y7,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y11-Y15,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,+M6,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,if mother is HBA1c-pos
CHE,Switzerland,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,Females and males
CHE,Switzerland,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
CHE,Switzerland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Females and males
CHE,Switzerland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
CHE,Switzerland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
CHE,Switzerland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities"
CHE,Switzerland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
CHE,Switzerland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M24,Children with chronic conditions
CHE,Switzerland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y11-Y15,Children with chronic conditions
CHE,Switzerland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
CHE,Switzerland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
CHE,Switzerland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
CHE,Switzerland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
CHE,Switzerland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
CHE,Switzerland,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M10,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y6,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M10,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y45,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y65,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11-Y15,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M9,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M12,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y14,Vaccination only recommended if no previous natural infection
CHE,Switzerland,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y14,Vaccination only recommended if no previous natural infection
CHE,Switzerland,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y11-Y14,Travellers
CHE,Switzerland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,La vacunación se inició en abril de 2019
CHL,Chile,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Se administra a niñas y niños de:  4° básico (9 años); niñas  5° básico (10 años) En niñas y niños desde los 9 a los 13 años el intervalo es de 12 meses y desde los 14 años en adelantes el esquema es 0,2,6 meses. El año 2020 los niños que iniciaron su esquema el 2019 completaran con 2° dosis cuando cursen 5° básico(10 años)"
CHL,Chile,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y10,"Se administra a niñas y niños de:  4° básico (9 años); niñas  5° básico (10 años) En niñas y niños desde los 9 a los 13 años el intervalo es de 12 meses y desde los 14 años en adelantes el esquema es 0,2,6 meses. El año 2020 los niños que iniciaron su esquema el 2019 completaran con 2° dosis cuando cursen 5° básico(10 años)"
CHL,Chile,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Se administra a niñas y niños de:  4° básico (9 años); niñas  5° básico (10 años) En niñas y niños desde los 9 a los 13 años el intervalo es de 12 meses y desde los 14 años en adelantes el esquema es 0,2,6 meses. El año 2020 los niños que iniciaron su esquema el 2019 completaran con 2° dosis cuando cursen 5° básico(10 años)"
CHL,Chile,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
CHL,Chile,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
CHL,Chile,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Other groups
CHL,Chile,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,Other groups
CHL,Chile,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y10,Other groups
CHL,Chile,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Other groups
CHL,Chile,AMRO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M36,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Niñas y niños de 2 y 4 meses. Se comienza a aplicar en julio de 2023.
CHL,Chile,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Prematuros: adicional al esquema nacional de niños, solo a prematuros se administra una tercera dosis a los 6 meses"
CHL,Chile,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Prematuros: adicional al esquema nacional de niños, solo a prematuros se administra una tercera dosis a los 6 meses"
CHL,Chile,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,"Prematuros: adicional al esquema nacional de niños, solo a prematuros se administra una tercera dosis a los 6 meses"
CHL,Chile,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13,"Prematuros: adicional al esquema nacional de niños, solo a prematuros se administra una tercera dosis a los 6 meses"
CHL,Chile,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y13,Embarazadas - Se administra en la SG28
CHL,Chile,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M18,se incorpora en enero del año 2022
CHL,Chile,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,M36,se incorpora en enero del año 2022
CHL,Chile,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,SUBNATIONAL,M18,Solo en Isla de Pascua
CHN,China,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Solo en Isla de Pascua
CHN,China,WPRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Solo en Isla de Pascua
CHN,China,WPRO,2023,DTAP,DTaP (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M3,Solo en Isla de Pascua
CHN,China,WPRO,2023,DTAP,DTaP (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Solo en Isla de Pascua
CHN,China,WPRO,2023,DTAP,DTaP (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M5,Solo en Isla de Pascua
CHN,China,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Solo en Isla de Pascua
CHN,China,WPRO,2023,HEPA_INACTD,Hepatitis A inactivted,1.0,B_2YL_W,General/routine,SUBNATIONAL,M18,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,HEPA_INACTD,Hepatitis A inactivted,2.0,B_2YL_W,General/routine,SUBNATIONAL,Y2,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,HEPA_LIVEATD,Hepatitis A live attenuated,1.0,B_2YL_W,General/routine,NATIONAL,M18,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M1,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,M2,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,M3,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,B_2YL_W,General/routine,SUBNATIONAL,M8,"Hepatitis A live attenuated at M18, Hepatitis A inactivated at M18 and Y2"
CHN,China,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,B_2YL_W,General/routine,SUBNATIONAL,M8,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,3.0,B_2YL_W,General/routine,SUBNATIONAL,Y2,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,4.0,B_2YL_W,General/routine,SUBNATIONAL,Y6,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M8,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,Y2,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M6,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MEN_A_PS,Meningococcal A polysaccharide vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M9,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,B_2YL_W,General/routine,NATIONAL,Y3,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,2.0,B_2YL_W,General/routine,NATIONAL,Y6,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,B_2YL_W,General/routine,NATIONAL,M8,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,B_2YL_W,General/routine,NATIONAL,M18,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,M4,2nd dose is administered +7-10 days after the 1st dose
CHN,China,WPRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,Y4,2nd dose is administered +7-10 days after the 1st dose
CIV,Côte d'Ivoire,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,naissances vivantes
CIV,Côte d'Ivoire,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,dans les 24h qui suivent la naissance
CIV,Côte d'Ivoire,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,filles de 9 ans; le vaccin HPV chez les jeunes filles de 9 ans s'administre en une seule dose depuis septembre 2023 en cote D'ivoire
CIV,Côte d'Ivoire,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,filles de 9 ans; le vaccin HPV chez les jeunes filles de 9 ans s'administre en une seule dose depuis septembre 2023 en cote D'ivoire
CIV,Côte d'Ivoire,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
CIV,Côte d'Ivoire,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
CIV,Côte d'Ivoire,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,HW,General/routine,NATIONAL,W6,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,HW,General/routine,NATIONAL,W14,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,HW,General/routine,NATIONAL,M9,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,HW,General/routine,NATIONAL,M9,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,HW,General/routine,NATIONAL,M15,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,HW,General/routine,NATIONAL,B,"naissances vivantes, nourrissons survivants"
CIV,Côte d'Ivoire,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,HW,General/routine,NATIONAL,W6,"naissances vivantes, nourrissons survivants"
CIV,Côte d'Ivoire,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,HW,General/routine,NATIONAL,W10,"naissances vivantes, nourrissons survivants"
CIV,Côte d'Ivoire,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,HW,General/routine,NATIONAL,W14,"naissances vivantes, nourrissons survivants"
CIV,Côte d'Ivoire,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,HW,General/routine,NATIONAL,W6,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,HW,General/routine,NATIONAL,W10,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,HW,General/routine,NATIONAL,W14,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,HW,General/routine,NATIONAL,W6,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,HW,General/routine,NATIONAL,W10,nourrissons survivants
CIV,Côte d'Ivoire,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,SUBNATIONAL,M6,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,SUBNATIONAL,M12,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,SUBNATIONAL,M18,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,SUBNATIONAL,M24,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,SUBNATIONAL,M30,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,SUBNATIONAL,M36,6-59 mois; la vitamine A s'administre tous les 6 mois de 6 à 59 mois; la vitamine A est administrée en routine dans 41 districts sanitaires
CIV,Côte d'Ivoire,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,nourrissons survivants
CMR,Cameroon,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,naissances vivantes
CMR,Cameroon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
CMR,Cameroon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
CMR,Cameroon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
CMR,Cameroon,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Filles et Garçons de 9 ans; Depuis 2023, le vaccin contre le HPV est administré en dose unique et désormais administré aux filles et aux garçons"
CMR,Cameroon,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,BOTH,General/routine,NATIONAL,W14,0-11 mois
CMR,Cameroon,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,BOTH,General/routine,NATIONAL,M9,0-11 mois
CMR,Cameroon,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,BOTH,General/routine,NATIONAL,M15,9-15 mois
CMR,Cameroon,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,BOTH,General/routine,NATIONAL,M9,9-15 mois
CMR,Cameroon,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,BOTH,General/routine,NATIONAL,B,0-11 mois
CMR,Cameroon,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,BOTH,General/routine,NATIONAL,W6,0-11 mois
CMR,Cameroon,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,BOTH,General/routine,NATIONAL,W10,0-11 mois
CMR,Cameroon,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,BOTH,General/routine,NATIONAL,W14,0-11 mois
CMR,Cameroon,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,BOTH,General/routine,NATIONAL,W6,0-11 mois
CMR,Cameroon,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,BOTH,General/routine,NATIONAL,W10,0-11 mois
CMR,Cameroon,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,BOTH,General/routine,NATIONAL,W14,0-11 mois
CMR,Cameroon,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,BOTH,General/routine,NATIONAL,W6,"0-11 mois; Depuis 2023, nous sommes passés de deux doses administrées à trois doses"
CMR,Cameroon,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,BOTH,General/routine,NATIONAL,W10,"0-11 mois; Depuis 2023, nous sommes passés de deux doses administrées à trois doses"
CMR,Cameroon,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,BOTH,General/routine,NATIONAL,W14,"0-11 mois; Depuis 2023, nous sommes passés de deux doses administrées à trois doses"
CMR,Cameroon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+M12,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+M12,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 mois; FPPI
CMR,Cameroon,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,Pregnant women,NATIONAL,M36,FPPI
CMR,Cameroon,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,W14,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,PW,General/routine,NATIONAL,M9,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,MEASLES,Measles vaccine,1.0,PW,General/routine,NATIONAL,M9,9-23 mois
COD,Democratic Republic of the Congo,AFRO,2023,MEASLES,Measles vaccine,2.0,PW,General/routine,NATIONAL,M15,9-23 mois
COD,Democratic Republic of the Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,B,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W6,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W10,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,W14,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
COD,Democratic Republic of the Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 mois
COD,Democratic Republic of the Congo,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,9-11 mois
COG,Congo,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 mois
COG,Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W8,0-11 mois
COG,Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W12,0-11 mois
COG,Congo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W16,0-11 mois
COG,Congo,AFRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,PW,General/routine,NATIONAL,W16,0-11 mois
COG,Congo,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,PW,General/routine,NATIONAL,W36,9-18 mois
COG,Congo,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,PW,General/routine,NATIONAL,W60,9-18 mois
COG,Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,B,0-11 mois
COG,Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W8,0-11 mois
COG,Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W12,0-11 mois
COG,Congo,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,W16,0-11 mois
COG,Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W8,0-11 mois
COG,Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W12,0-11 mois
COG,Congo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W16,0-11 mois
COG,Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,PW,General/routine,NATIONAL,W8,0-11 mois
COG,Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,PW,General/routine,NATIONAL,W12,0-11 mois
COG,Congo,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,PW,General/routine,NATIONAL,W16,0-11 mois
COG,Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,W36,9-11 mois
COG,Congo,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,W60,9-11 mois
COG,Congo,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,W36,9-11 mois
COK,Cook Islands,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,9-11 mois
COK,Cook Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,9-11 mois
COK,Cook Islands,WPRO,2023,DTAPHIBHEPB,DTaP-Hib-HepB (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,9-11 mois
COK,Cook Islands,WPRO,2023,DTAPHIBHEPB,DTaP-Hib-HepB (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3,9-11 mois
COK,Cook Islands,WPRO,2023,DTAPHIBHEPB,DTaP-Hib-HepB (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M5,9-11 mois
COK,Cook Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,9-11 mois
COK,Cook Islands,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M5,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M12,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,M18,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M18,Booster for healthcare workers and frontliners
COK,Cook Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M12,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M5,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M8,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,During measles outbreak at M6-M12
COK,Cook Islands,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y11,During measles outbreak at M6-M12
COL,Colombia,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,"Recién nacidos y hasta 11 meses, 29 días"
COL,Colombia,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,A5,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,Y1,Niños de un año de edad
COL,Colombia,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y17,"La vacuna es aplicada solo a mujeres que cumplan los 9 años a 17 años, con dos dosis de vacuna. El periodo de aplicación de las dosis de la vacuna es 0 meses y la segunda dosis a los seis meses. El 1 d eoctubre de 2023, se cambia el esquema de dos dosis de vacuna a una dosis y se incluye a niños de 9 años de edad"
COL,Colombia,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"La vacuna es aplicada solo a mujeres que cumplan los 9 años a 17 años, con dos dosis de vacuna. El periodo de aplicación de las dosis de la vacuna es 0 meses y la segunda dosis a los seis meses. El 1 d eoctubre de 2023, se cambia el esquema de dos dosis de vacuna a una dosis y se incluye a niños de 9 años de edad"
COL,Colombia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"La vacuna es aplicada solo a mujeres que cumplan los 9 años a 17 años, con dos dosis de vacuna. El periodo de aplicación de las dosis de la vacuna es 0 meses y la segunda dosis a los seis meses. El 1 d eoctubre de 2023, se cambia el esquema de dos dosis de vacuna a una dosis y se incluye a niños de 9 años de edad"
COL,Colombia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
COL,Colombia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
COL,Colombia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities"
COL,Colombia,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,"Adults with chronic conditions, residents living in long-term care facilities"
COL,Colombia,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,"Adults with chronic conditions, residents living in long-term care facilities"
COL,Colombia,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M11,Children with chronic conditions
COL,Colombia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
COL,Colombia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
COL,Colombia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
COL,Colombia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
COL,Colombia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
COL,Colombia,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Solamente es utilizada en casos de brote y con un esquema así:  niños de 7-23 m con dos dosis, , niños de 2 años hasta la edad de 59 años en brotes una dosis"
COL,Colombia,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Solamente es utilizada en casos de brote y con un esquema así:  niños de 7-23 m con dos dosis, , niños de 2 años hasta la edad de 59 años en brotes una dosis"
COL,Colombia,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Solamente es utilizada en casos de brote y con un esquema así:  niños de 7-23 m con dos dosis, , niños de 2 años hasta la edad de 59 años en brotes una dosis"
COL,Colombia,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Solamente es utilizada en casos de brote y con un esquema así:  niños de 7-23 m con dos dosis, , niños de 2 años hasta la edad de 59 años en brotes una dosis"
COL,Colombia,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,"Solamente es utilizada en casos de brote y con un esquema así:  niños de 7-23 m con dos dosis, , niños de 2 años hasta la edad de 59 años en brotes una dosis"
COL,Colombia,AMRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Se realizo la aplicacion de esta vacuna en un estudio Clinico que se dividio en Inmediato y tardio de fabricante. Se aplico a poblacion de 18 anos con vulnerabilidad.
COL,Colombia,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y59,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,PCV13 en niños y niñas nacidos a partir del primero de mayo del 2022
COL,Colombia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,PCV13 en niños y niñas nacidos a partir del primero de mayo del 2022
COL,Colombia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,PCV13 en niños y niñas nacidos a partir del primero de mayo del 2022
COL,Colombia,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"En pre-exposición 3 dosis (día 0, 7, 28). Post-exposición 5 dosis (0, 3, 7, 14, 30)"
COL,Colombia,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"En pre-exposición 3 dosis (día 0, 7, 28). Post-exposición 5 dosis (0, 3, 7, 14, 30)"
COL,Colombia,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"En pre-exposición 3 dosis (día 0, 7, 28). Post-exposición 5 dosis (0, 3, 7, 14, 30)"
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,HW,Health workers,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,HW,Health workers,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,+M6,"Se aplica en población desde los 7 años de edad que tienen contraindicación para recibir DPT con el mismo esquema y en mujeres embarazadas desde la semana 26 de gestación, así como en niños que presentaron reacción a la Pentavalente"
COL,Colombia,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,"Se aplica en población desde los 7 años de edad que tienen contraindicación para recibir DPT con el mismo esquema y en mujeres embarazadas desde la semana 26 de gestación, así como en niños que presentaron reacción a la Pentavalente"
COL,Colombia,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Se aplica en población desde los 7 años de edad que tienen contraindicación para recibir DPT con el mismo esquema y en mujeres embarazadas desde la semana 26 de gestación, así como en niños que presentaron reacción a la Pentavalente"
COL,Colombia,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5,"Se aplica en población desde los 7 años de edad que tienen contraindicación para recibir DPT con el mismo esquema y en mujeres embarazadas desde la semana 26 de gestación, así como en niños que presentaron reacción a la Pentavalente"
COL,Colombia,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12-M18,"La dosis de fiebre amarilla, en el país tiene dos grupos poblacionales a los que se vacunan: 12 meses en zonas endémicas y 18 meses en zonas no endémicas"
COM,Comoros,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,0- J28
COM,Comoros,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,0-11 mois
COM,Comoros,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,0-11 mois
COM,Comoros,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,0-11 mois
COM,Comoros,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,0-11 mois
COM,Comoros,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,9-23 mois
COM,Comoros,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,9-23 mois
COM,Comoros,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,0-11 mois
COM,Comoros,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,0-11 mois
COM,Comoros,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W10,0-11 mois
COM,Comoros,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,W14,0-11 mois
COM,Comoros,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
COM,Comoros,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
COM,Comoros,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
COM,Comoros,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COM,Comoros,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 mois
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 mois
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 mois
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 mois
COM,Comoros,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 mois
CPV,Cabo Verde,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,naissance vivants
CPV,Cabo Verde,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,M2,Enfants
CPV,Cabo Verde,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,M4,Enfants
CPV,Cabo Verde,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,M6,Enfants
CPV,Cabo Verde,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Enfants
CPV,Cabo Verde,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Naissance vivants
CPV,Cabo Verde,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M2,Naissance vivants
CPV,Cabo Verde,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,Naissance vivants
CPV,Cabo Verde,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M6,Naissance vivants
CPV,Cabo Verde,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,5.0,B_2YL_W,General/routine,NATIONAL,M18,Naissance vivants
CPV,Cabo Verde,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"Filles de 10 ans, premier contact"
CPV,Cabo Verde,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,Enfants
CPV,Cabo Verde,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,Enfants
CPV,Cabo Verde,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M9,Enfants
CPV,Cabo Verde,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,M15,Enfants
CPV,Cabo Verde,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,Naissance vivants et enfants
CPV,Cabo Verde,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M2,Naissance vivants et enfants
CPV,Cabo Verde,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M4,Naissance vivants et enfants
CPV,Cabo Verde,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M6,Naissance vivants et enfants
CPV,Cabo Verde,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,FEMALE,General/routine,NATIONAL,M18,Naissance vivants et enfants
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M12,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M2,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Se aplica desde el 2019 a todas las niñas de 10 años
CRI,Costa Rica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Se aplica desde el 2019 a todas las niñas de 10 años
CRI,Costa Rica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y58,Se aplica desde el 2019 a todas las niñas de 10 años
CRI,Costa Rica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y58,Health and care workers
CRI,Costa Rica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y58,Pregnant women
CRI,Costa Rica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y58,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y6,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M15,Residents living in long-term care facilities
CRI,Costa Rica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,HW,Health workers,NATIONAL,M15,También se aplica a personal de salud
CRI,Costa Rica,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,1 dosis única a todo adulto de 60 años o más
CRI,Costa Rica,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,desde fe.2019
CRI,Costa Rica,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,desde fe.2019
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y20,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y10,"Se aplica una dosis de Tdap en cada embarazo después de la semana 20, en funcionarios de salud en contacto con neonatos de la CCSS"
CRI,Costa Rica,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y10,"Se aplica una dosis de Tdap en cada embarazo después de la semana 20, en funcionarios de salud en contacto con neonatos de la CCSS"
CRI,Costa Rica,AMRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Se aplica una dosis de refuerzo de Tetravalente a los 4 años de edad
CRI,Costa Rica,AMRO,2023,VARICELLA,Varicella vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M15,Se aplica una dosis de refuerzo de Tetravalente a los 4 años de edad
CUB,Cuba,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Se aplica una dosis de refuerzo de Tetravalente a los 4 años de edad
CUB,Cuba,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Se aplica una dosis de refuerzo de Tetravalente a los 4 años de edad
CUB,Cuba,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,M18,Older persons
CUB,Cuba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,M18,Health and care workers
CUB,Cuba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,M18,Pregnant women
CUB,Cuba,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Adults with chronic conditions
CUB,Cuba,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y2,Adults with chronic conditions
CUB,Cuba,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y5,Adults with chronic conditions
CUB,Cuba,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y5,Children with chronic conditions
CUB,Cuba,AMRO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,RISKGROUPS,General/routine,NATIONAL,M4,dosis fraccionada
CUB,Cuba,AMRO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),2.0,RISKGROUPS,General/routine,NATIONAL,M8,dosis fraccionada
CUB,Cuba,AMRO,2023,LEPTOSPIROSIS,Leptospirosis,1.0,RISKGROUPS,Risk group(s),NATIONAL,M8,Grupo de riesgos
CUB,Cuba,AMRO,2023,MEN_BC,Meningococcal BC vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Grupo de riesgos
CUB,Cuba,AMRO,2023,MEN_BC,Meningococcal BC vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Grupo de riesgos
CUB,Cuba,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Grupo de riesgos
CUB,Cuba,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Grupo de riesgos
CUB,Cuba,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,<Y1,Grupo de riesgos
CUB,Cuba,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,Y1,Grupo de riesgos
CUB,Cuba,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,Y2,Grupo de riesgos
CUB,Cuba,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y9,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,Y35,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,Y45,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,Y45,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,Y65,Grupo de riesgos
CUB,Cuba,AMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y14,Grupo de riesgos
CUB,Cuba,AMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,ADULTS,General/routine,NATIONAL,Y10,Grupo de riesgos
CUB,Cuba,AMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,2.0,ADULTS,General/routine,NATIONAL,Y13,Grupo de riesgos
CUB,Cuba,AMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,3.0,ADULTS,General/routine,NATIONAL,Y16,Grupo de riesgos
CUB,Cuba,AMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,Grupo de riesgos
CUW,Curaçao,AMRO,2019,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Grupo de riesgos
CUW,Curaçao,AMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3.5,Grupo de riesgos
CUW,Curaçao,AMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,Grupo de riesgos
CUW,Curaçao,AMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M5.5,Grupo de riesgos
CUW,Curaçao,AMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Grupo de riesgos
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,healthcare workers
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,healthcare workers
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,healthcare workers
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,at risk persons
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,at risk persons
CUW,Curaçao,AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,at risk persons
CUW,Curaçao,AMRO,2019,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,at risk persons
CUW,Curaçao,AMRO,2019,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,M2,at risk persons
CUW,Curaçao,AMRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M12,at risk persons
CUW,Curaçao,AMRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,General/routine,NATIONAL,M15,at risk persons
CUW,Curaçao,AMRO,2019,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,M15,at risk persons
CUW,Curaçao,AMRO,2019,OPV,OPV (Oral polio vaccine),5.0,ADULTS,General/routine,NATIONAL,Y4,at risk persons
CUW,Curaçao,AMRO,2019,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M3.5,at risk persons
CUW,Curaçao,AMRO,2019,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M5.5,at risk persons
CUW,Curaçao,AMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3.5,at risk persons
CUW,Curaçao,AMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,at risk persons
CUW,Curaçao,AMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M5.5,at risk persons
CUW,Curaçao,AMRO,2019,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,at risk persons
CUW,Curaçao,AMRO,2019,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,2nd booster Y4-6
CYM,Cayman Islands,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,International travelers (including students going to college)
CYM,Cayman Islands,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,International travelers (including students going to college)
CYM,Cayman Islands,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",2.0,TRAVELLERS,Travellers,NATIONAL,+M1,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",3.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M12,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M18,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M12,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M18,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,birth dose administered at birth to 48 hours
CYM,Cayman Islands,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W6,birth dose administered at birth to 48 hours
CYM,Cayman Islands,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M9,birth dose administered at birth to 48 hours
CYM,Cayman Islands,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y12,Females
CYM,Cayman Islands,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
CYM,Cayman Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
CYM,Cayman Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
CYM,Cayman Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
CYM,Cayman Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
CYM,Cayman Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
CYM,Cayman Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
CYM,Cayman Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
CYM,Cayman Islands,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,International travelers as booster dose
CYM,Cayman Islands,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M12,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Single dose unimmunized adults (65 yrs and older & immunocompromised individuals) & single dose for Immunocompromised individuals who did not receive the Pneumococcal vaccine.
CYM,Cayman Islands,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Single dose unimmunized adults (65 yrs and older & immunocompromised individuals) & single dose for Immunocompromised individuals who did not receive the Pneumococcal vaccine.
CYM,Cayman Islands,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Single dose unimmunized adults (65 yrs and older & immunocompromised individuals) & single dose for Immunocompromised individuals who did not receive the Pneumococcal vaccine.
CYM,Cayman Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,M4,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W6,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y16,Yr 10 & 11 High Schools
CYM,Cayman Islands,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14-Y16,"Pregnant women W27-W36 gestation, unique dose each pregnancy"
CYM,Cayman Islands,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,"Pregnant women W27-W36 gestation, unique dose each pregnancy"
CYM,Cayman Islands,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y3-Y4,2nd dose is at Y3 or Y4
CYM,Cayman Islands,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,unimmunized international travelers single dose
CYM,Cayman Islands,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2-M6,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2-M6,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Adults age 60 and older and other risk adults
CYP,Cyprus,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2-M3,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4-M5,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6-M8,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18-M20,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Persons with continuous contact with a contagious form of TB
CYP,Cyprus,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y6,Special indications
CYP,Cyprus,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M24,Special indications
CYP,Cyprus,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M30,Special indications
CYP,Cyprus,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M30,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2-M3,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4-M5,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6-M8,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2-M3,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4-M5,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6-M8,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18-M20,Recommended for all people if not being vaccinated in childhood
CYP,Cyprus,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,Both females and males
CYP,Cyprus,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Both females and males
CYP,Cyprus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,Both females and males
CYP,Cyprus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
CYP,Cyprus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,All pregnant women the first trimester
CYP,Cyprus,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
CYP,Cyprus,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y15,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
CYP,Cyprus,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y15,Children with chronic conditions
CYP,Cyprus,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,M6-Y15,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12-M15,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y6,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12-M15,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12-M15,Booster dose for travellers where recommended
CYP,Cyprus,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,high-risk groups
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,+Y10,Single dose in adults and for women in every pregnancy
CYP,Cyprus,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Single dose in adults and for women in every pregnancy
CYP,Cyprus,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11-Y12,Single dose in adults and for women in every pregnancy
CYP,Cyprus,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y11-Y12,Travellers when indicated
CYP,Cyprus,EURO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12-M15,Travellers when indicated
CYP,Cyprus,EURO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y6,Travellers when indicated
CYP,Cyprus,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y4-Y6,Travellers to endemic areas
CZE,Czechia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M3,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M5,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M11,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administrated to newborns of HBsAg positive mothers
CZE,Czechia,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
CZE,Czechia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
CZE,Czechia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities"
CZE,Czechia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
CZE,Czechia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13,Children with chronic conditions
CZE,Czechia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
CZE,Czechia,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y10,Children with chronic conditions
CZE,Czechia,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y10,Regular booster vaccination every 10-15 years in adult population
CZE,Czechia,EURO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,Y25,"Regular booster vaccination every 10-15 years in adult population, therefore 6th dose is in Y25"
DEU,Germany,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M11,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,M3,"1) People with sexual behaviours with increased risk of exposure; for example, men who have sex with men (MSM) 2) People who frequently receive blood components, e. g., injecting drug users, haemophiliacs, or people with liver disease/general conditions affecting the liver. 3) Residents of psychiatric institutions or comparable welfare facilities for people with behavioural disorders or cerebral damage. 4) People who are at increased risk of occupational exposure, including trainees, interns, students and volunteers with comparable exposure risk, for example: healthcare workers (including medical and rescue services, kitchen, laboratory, technical; and cleaning services, psychiatric and welfare institutions); people in contact with sewage e. g. sewer system and wastewater workers; employment (including kitchen and cleaning) in children’s day care centres, children’s homes, sheltered employment facilities, refugee shelters, and the like."
DEU,Germany,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"1) People with sexual behaviours with increased risk of exposure; for example, men who have sex with men (MSM) 2) People who frequently receive blood components, e. g., injecting drug users, haemophiliacs, or people with liver disease/general conditions affecting the liver. 3) Residents of psychiatric institutions or comparable welfare facilities for people with behavioural disorders or cerebral damage. 4) People who are at increased risk of occupational exposure, including trainees, interns, students and volunteers with comparable exposure risk, for example: healthcare workers (including medical and rescue services, kitchen, laboratory, technical; and cleaning services, psychiatric and welfare institutions); people in contact with sewage e. g. sewer system and wastewater workers; employment (including kitchen and cleaning) in children’s day care centres, children’s homes, sheltered employment facilities, refugee shelters, and the like."
DEU,Germany,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"1) People with sexual behaviours with increased risk of exposure; for example, men who have sex with men (MSM) 2) People who frequently receive blood components, e. g., injecting drug users, haemophiliacs, or people with liver disease/general conditions affecting the liver. 3) Residents of psychiatric institutions or comparable welfare facilities for people with behavioural disorders or cerebral damage. 4) People who are at increased risk of occupational exposure, including trainees, interns, students and volunteers with comparable exposure risk, for example: healthcare workers (including medical and rescue services, kitchen, laboratory, technical; and cleaning services, psychiatric and welfare institutions); people in contact with sewage e. g. sewer system and wastewater workers; employment (including kitchen and cleaning) in children’s day care centres, children’s homes, sheltered employment facilities, refugee shelters, and the like."
DEU,Germany,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M3,"1) People at risk of severe hepatitis B because of an existing or expected immunodeficiency or immunosuppression, or other pre-existing diseases, for example: HIV-positive or hepatitis C-positive individuals, and patients on haemodialysis. 2) People at increased risk of non-occupational exposure, for example: people in contact with HBsAg carriers in the family or flat share, people at high risk of acquiring hepatitis B through sexual contact, injecting drug users, prison inmates, and psychiatric inpatients. 3) People at increased risk of occupational exposure, including trainees, interns, students and volunteers with comparable exposure risk, for example: healthcare personnel (including laboratory personnel and cleaning personnel), medical and rescue services, occupational first aid providers, police officers, and personnel at facilities with large numbers of hepatitis B-virus (HBV)-infected people (for example, correctional facilities, shelters for refugees, immigrants or asylum."
DEU,Germany,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"1) People at risk of severe hepatitis B because of an existing or expected immunodeficiency or immunosuppression, or other pre-existing diseases, for example: HIV-positive or hepatitis C-positive individuals, and patients on haemodialysis. 2) People at increased risk of non-occupational exposure, for example: people in contact with HBsAg carriers in the family or flat share, people at high risk of acquiring hepatitis B through sexual contact, injecting drug users, prison inmates, and psychiatric inpatients. 3) People at increased risk of occupational exposure, including trainees, interns, students and volunteers with comparable exposure risk, for example: healthcare personnel (including laboratory personnel and cleaning personnel), medical and rescue services, occupational first aid providers, police officers, and personnel at facilities with large numbers of hepatitis B-virus (HBV)-infected people (for example, correctional facilities, shelters for refugees, immigrants or asylum."
DEU,Germany,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"1) Newborns of seropositive women within 12 hours postpartum, together with Hepatitis B immunoglobulin 2) Newborns of mothers whose HBsAg status is unknown and in whom serological testing is not possible before or immediately after delivery. 3) People at risk of severe hepatitis B because of an existing or expected immunodeficiency or immunosuppression, or other pre-existing diseases, for example: HIV-positive or hepatitis C-positive individuals, and patients on haemodialysis. 4) People at increased risk of non-occupational exposure, for example: people in contact with HBsAg carriers in the family or flat share, people at high risk of acquiring hepatitis B through sexual contact, injecting drug users, prison inmates, and psychiatric inpatients."
DEU,Germany,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,People with anatomical or functional asplenia (e. g. sickle cell anaemia).
DEU,Germany,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
DEU,Germany,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
DEU,Germany,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
DEU,Germany,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions
DEU,Germany,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"People with congenital or acquired immunodeficiencies, especially those with complement/properdin deficiencies; receiving complement C5-inhibitor therapy with e. g. Eculizumab or Ravulizumab; with hypogammaglobulinaemia; with anatomic or functional asplenia (e. g. sickle cell anaemia)."
DEU,Germany,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"People with congenital or acquired immunodeficiencies, especially those with complement/properdin deficiencies; receiving complement C5-inhibitor therapy with e. g. Eculizumab or Ravulizumab; with hypogammaglobulinaemia; with anatomic or functional asplenia (e. g. sickle cell anaemia)."
DEU,Germany,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M12,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,Adults,NATIONAL,M12,"1) One MMR dose for all adults born after 1970 with unclear vaccination status, who have not been vaccinated, or who received only one vaccination during childhood. 2) Two MMR doses for individuals born after 1970 in the following fields of professional activity (including trainees, interns, students and volunteers): Medical facilities including facilities of other human medical health care professions; occupation with contact to potentially infectious material; care facilities for mostly elderly people; community facilities e. g. day care facility for children or pupils; institutions housing immigrants, refugees and asylum seekers; technical and vocational colleges, universities. 3) Two MMR doses for women of childbearing age who are non-immunised or with an unclear vaccination status. 4) One MMR dose for women of childbearing age only vaccinated once. 5) Mothers with a seronegative rubella test in pregnancy should be given 2 MMR doses postpartum, 4 weeks apart."
DEU,Germany,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,General/routine,NATIONAL,M11,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M11,"1) One MMR dose for all adults born after 1970 with unclear vaccination status, who have not been vaccinated, or who received only one vaccination during childhood. 2) Two MMR doses for individuals born after 1970 in the following fields of professional activity (including trainees, interns, students and volunteers): Medical facilities including facilities of other human medical health care professions; occupation with contact to potentially infectious material; care facilities for mostly elderly people; community facilities e. g. day care facility for children or pupils; institutions housing immigrants, refugees and asylum seekers; technical and vocational colleges, universities. 3) Two MMR doses for women of childbearing age who are non-immunised or with an unclear vaccination status. 4) One MMR dose for women of childbearing age only vaccinated once. 5) Mothers with a seronegative rubella test in pregnancy should be given 2 MMR doses postpartum, 4 weeks apart."
DEU,Germany,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,"1) One MMR dose for all adults born after 1970 with unclear vaccination status, who have not been vaccinated, or who received only one vaccination during childhood. 2) Two MMR doses for individuals born after 1970 in the following fields of professional activity (including trainees, interns, students and volunteers): Medical facilities including facilities of other human medical health care professions; occupation with contact to potentially infectious material; care facilities for mostly elderly people; community facilities e. g. day care facility for children or pupils; institutions housing immigrants, refugees and asylum seekers; technical and vocational colleges, universities. 3) Two MMR doses for women of childbearing age who are non-immunised or with an unclear vaccination status. 4) One MMR dose for women of childbearing age only vaccinated once. 5) Mothers with a seronegative rubella test in pregnancy should be given 2 MMR doses postpartum, 4 weeks apart."
DEU,Germany,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,CATCHUP_C,General/routine,NATIONAL,M15,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Two doses for men who have sex with men (MSM) and are >= 18 years of age and frequently change sexual partners (for people who have been vaccinated against smallpox in the past, a single vaccine dose is sufficient)."
DEU,Germany,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Two doses for men who have sex with men (MSM) and are >= 18 years of age and frequently change sexual partners (for people who have been vaccinated against smallpox in the past, a single vaccine dose is sufficient)."
DEU,Germany,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,"Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis."
DEU,Germany,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M11,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M11,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age. Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis."
DEU,Germany,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"1) One dose of PCV20 for all people aged >= 60 years. 2) One dose of PCV20 for adults >= 18 years at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 3) Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 4) One dose of PCV20 for people performing professional activities such as welding or separating metals leading to exposure to metal smoke, including metal-oxidic welding smoke."
DEU,Germany,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"1) One dose of PCV20 for all people aged >= 60 years. 2) One dose of PCV20 for adults >= 18 years at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 3) Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 4) One dose of PCV20 for people performing professional activities such as welding or separating metals leading to exposure to metal smoke, including metal-oxidic welding smoke."
DEU,Germany,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,"1) One dose of PCV20 for all people aged >= 60 years. 2) One dose of PCV20 for adults >= 18 years at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 3) Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 4) One dose of PCV20 for people performing professional activities such as welding or separating metals leading to exposure to metal smoke, including metal-oxidic welding smoke."
DEU,Germany,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,W12-W32,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M3,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W6,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,W12-W32,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M3,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M4,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W6,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,W6,"1) People exposed to ticks in TBE risk areas (for maps, see https://www.rki.de/DE/Content/InfAZ/F/FSME/Karte_Tab.html). 2) People at risk of TBE through their profession (exposed laboratory personnel as well as those in risk areas, including forest workers and those exposed during farming)."
DEU,Germany,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,W6,"1) People exposed to ticks in TBE risk areas (for maps, see https://www.rki.de/DE/Content/InfAZ/F/FSME/Karte_Tab.html). 2) People at risk of TBE through their profession (exposed laboratory personnel as well as those in risk areas, including forest workers and those exposed during farming)."
DEU,Germany,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,W6,"1) People exposed to ticks in TBE risk areas (for maps, see https://www.rki.de/DE/Content/InfAZ/F/FSME/Karte_Tab.html). 2) People at risk of TBE through their profession (exposed laboratory personnel as well as those in risk areas, including forest workers and those exposed during farming)."
DEU,Germany,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,W6,"1) People exposed to ticks in TBE risk areas (for maps, see https://www.rki.de/DE/Content/InfAZ/F/FSME/Karte_Tab.html). 2) People at risk of TBE through their profession (exposed laboratory personnel as well as those in risk areas, including forest workers and those exposed during farming)."
DEU,Germany,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,"1) Td booster vaccination every 10 years. 2) Next due Td vaccination requires one dose as a Tdap or, in the case of a respective indication, as a Tdap-IPV combination vaccination."
DEU,Germany,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,"1) One dose of Tdap for all adults instead of next Td booster. 2) One dose of Tdap for pregnant women at the beginning of the 3rd trimester (from the 28th week of pregnancy). In case of an increased probability for premature birth, vaccination should be administered during the 2nd trimester. This vaccination should be administered in every pregnancy, regardless of the interval to previously administered pertussis vaccinations."
DEU,Germany,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y8,Catch-up is recommended up until and including 8 years of age
DEU,Germany,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,Catch-up is recommended up until and including 8 years of age
DEU,Germany,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y5-Y6,"1) One dose of Tdap for all adults instead of next Td booster. 2) One dose of Tdap for pregnant women at the beginning of the 3rd trimester (from the 28th week of pregnancy). In case of an increased probability for premature birth, vaccination should be administered during the 2nd trimester. This vaccination should be administered in every pregnancy, regardless of the interval to previously administered pertussis vaccinations."
DEU,Germany,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y9-Y16,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M11,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,M11,"1) Two doses of varicella vaccine for seronegative women who wish to conceive, seronegative patients before planned immunosuppressive therapy or organ transplantation, susceptible patients with severe neurodermatitis, susceptible people in close contact with the two previous groups. 2) Seronegative personnel (including trainees, interns, students and volunteers) in the following fields of professional activity: Medical facilities including facilities of other human medical health care professions; activities involving contact with potentially infectious material; care facilities for mostly elderly people; community facilities e. g. day care facility for children or pupils; institutions housing immigrants, refugees and asylum seekers."
DEU,Germany,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,"1) Two doses of varicella vaccine for seronegative women who wish to conceive, seronegative patients before planned immunosuppressive therapy or organ transplantation, susceptible patients with severe neurodermatitis, susceptible people in close contact with the two previous groups. 2) Seronegative personnel (including trainees, interns, students and volunteers) in the following fields of professional activity: Medical facilities including facilities of other human medical health care professions; activities involving contact with potentially infectious material; care facilities for mostly elderly people; community facilities e. g. day care facility for children or pupils; institutions housing immigrants, refugees and asylum seekers."
DEU,Germany,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DEU,Germany,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,>=Y60,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DEU,Germany,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W14,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,MEASLES,Measles vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,MEASLES,Measles vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M15,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,W6,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,W10,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,W14,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,B_2YL_W,General/routine,NATIONAL,M15,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,B,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes
DJI,Djibouti,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes
DJI,Djibouti,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes
DJI,Djibouti,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
DJI,Djibouti,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
DJI,Djibouti,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,Femmes enceintes
DJI,Djibouti,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M15,Femmes enceintes
DMA,Dominica,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B-Y1,Births of previous year
DMA,Dominica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y3,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,Children 18M and 3 years
DMA,Dominica,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,B_CHILD_F,General/routine,NATIONAL,Y3,Children 18M and 3 years
DMA,Dominica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_F,General/routine,NATIONAL,M2,Births of previous year
DMA,Dominica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_F,General/routine,NATIONAL,M4,Births of previous year
DMA,Dominica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_F,General/routine,NATIONAL,M6,Births of previous year
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M6,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,All new borns
DMA,Dominica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,Introduced in October 2019; females and males; and a 3rd dose given if older than 15 years
DMA,Dominica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older adults 65 years and older
DMA,Dominica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
DMA,Dominica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
DMA,Dominica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
DMA,Dominica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M35,"Adults with chronic conditions, residents living in long-term care facilities"
DMA,Dominica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y3,"Adults with chronic conditions, residents living in long-term care facilities"
DMA,Dominica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y3,Children with chronic conditions
DMA,Dominica,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,0-12 months cohort
DMA,Dominica,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,0-12 months cohort
DMA,Dominica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children under 2 years
DMA,Dominica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children under 2 years
DMA,Dominica,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Population 6 months to 12 years
DMA,Dominica,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Population 6 months to 12 years
DMA,Dominica,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y3,Population 6 months to 12 years
DMA,Dominica,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y12,Population 6 months to 12 years
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M5,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+W4-W6,"all other persons if not covered dose one, +W4-W6, and +M6"
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"all other persons if not covered dose one, +W4-W6, and +M6"
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10-Y12,"Students moving on to high school in grade 6; and all other persons if not covered dose one, +W4-W6, and +M6"
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,1st contact,"all other persons if not covered dose one, +W4-W6, and +M6"
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M5,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to endemic countries
DNK,Denmark,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Travellers to endemic countries
DNK,Denmark,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,Travellers to endemic countries
DNK,Denmark,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12,Travellers to endemic countries
DNK,Denmark,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Travellers to endemic countries
DNK,Denmark,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y18,free vaccination up to the age of 18
DNK,Denmark,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,"Females only up until August 2019; from September 2019 programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18)."
DNK,Denmark,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y14,"Females only up until August 2019; from September 2019 programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18)."
DNK,Denmark,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y65-Y84,"Females only up until August 2019; from September 2019 programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18)."
DNK,Denmark,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y65-Y84,Health and care workers
DNK,Denmark,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y65-Y84,Pregnant women in second and third trimester
DNK,Denmark,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y65-Y84,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
DNK,Denmark,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y6,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
DNK,Denmark,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y6,Children with chronic conditions
DNK,Denmark,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4,Children with chronic conditions
DNK,Denmark,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
DNK,Denmark,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Recommended for all non-immune adults. Free of charge from April 1, 2018. Women of childbearing age not immune to Rubella demonstrated by antibody measurement. Given in the form of a single MFR."
DNK,Denmark,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups not for free but a smaller co-payment
DNK,Denmark,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,specific risk groups
DNK,Denmark,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Risk groups. If PCV13 is administrated 1st, 1st dose of PPV is at an interval of 8 weeks. A temporary vacination offer for everyone over 65 in the period of April 2020 until 31.12.2022. In 2023 it has become a recommended vaccine for certain risk groups but with a smaller co-payment"
DNK,Denmark,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y6,"Risk groups. If PCV13 is administrated 1st, 1st dose of PPV is at an interval of 8 weeks. A temporary vacination offer for everyone over 65 in the period of April 2020 until 31.12.2022. In 2023 it has become a recommended vaccine for certain risk groups but with a smaller co-payment"
DNK,Denmark,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,+Y6,Introduced from November 2019 for pregnant women in their 2nd or 3rd trimester (temporary free vaccination offer against epidemic to be in effect until 31.3.2023). From 1.1 2024 it has been a permanent offer.
DOM,Dominican Republic,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Introduced from November 2019 for pregnant women in their 2nd or 3rd trimester (temporary free vaccination offer against epidemic to be in effect until 31.3.2023). From 1.1 2024 it has been a permanent offer.
DOM,Dominican Republic,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Introduced from November 2019 for pregnant women in their 2nd or 3rd trimester (temporary free vaccination offer against epidemic to be in effect until 31.3.2023). From 1.1 2024 it has been a permanent offer.
DOM,Dominican Republic,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Introduced from November 2019 for pregnant women in their 2nd or 3rd trimester (temporary free vaccination offer against epidemic to be in effect until 31.3.2023). From 1.1 2024 it has been a permanent offer.
DOM,Dominican Republic,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,Sólo vacunación en niñas de 9 a 14 años.
DOM,Dominican Republic,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Sólo vacunación en niñas de 9 a 14 años.
DOM,Dominican Republic,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
DOM,Dominican Republic,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
DOM,Dominican Republic,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, other groups"
DOM,Dominican Republic,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12-M23,"Adults with chronic conditions, other groups"
DOM,Dominican Republic,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,"Adults with chronic conditions, other groups"
DOM,Dominican Republic,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M11,Children with chronic conditions
DOM,Dominican Republic,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
DOM,Dominican Republic,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
DOM,Dominican Republic,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
DOM,Dominican Republic,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,M6,"Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única"
DOM,Dominican Republic,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única"
DOM,Dominican Republic,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única"
DOM,Dominican Republic,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,"Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única"
DOM,Dominican Republic,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,Y dosis de refuerzo cada 10 años. Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema
DOM,Dominican Republic,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,>=Y7,Embarazadas de 27 semanas a 36 semanas. 1 dosis (en cada embarazo).
DOM,Dominican Republic,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y1-Y59,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
DZA,Algeria,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,B,Older persons
DZA,Algeria,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,B,Health and care workers
DZA,Algeria,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,B,Pregnant women
DZA,Algeria,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Adults with chronic conditions, residents living in long-term care facilities"
DZA,Algeria,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Children with chronic conditions
DZA,Algeria,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M11,Children with chronic conditions
DZA,Algeria,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
DZA,Algeria,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
DZA,Algeria,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
DZA,Algeria,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
DZA,Algeria,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
DZA,Algeria,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
DZA,Algeria,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
DZA,Algeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y11-Y13,Children with chronic conditions
DZA,Algeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y16-Y18,Children with chronic conditions
ECU,Ecuador,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,<Y1,Children with chronic conditions
ECU,Ecuador,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12-M23,Children with chronic conditions
ECU,Ecuador,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Children with chronic conditions
ECU,Ecuador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Children with chronic conditions
ECU,Ecuador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Children with chronic conditions
ECU,Ecuador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Children with chronic conditions
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M2,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,B,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,niñas
ECU,Ecuador,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,niñas
ECU,Ecuador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
ECU,Ecuador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ECU,Ecuador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ECU,Ecuador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,Other groups
ECU,Ecuador,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,Other groups
ECU,Ecuador,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>M12,Other groups
ECU,Ecuador,AMRO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrasado fIPV1, fIPV2 dosis fraccionadas aplicadas en esquemas tardíos en edades simples de 1 a 5 años"
ECU,Ecuador,AMRO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),2.0,CATCHUP_C,General/routine,NATIONAL,M4,"Esquema atrasado fIPV1, fIPV2 dosis fraccionadas aplicadas en esquemas tardíos en edades simples de 1 a 5 años"
ECU,Ecuador,AMRO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,CATCHUP_C,General/routine,NATIONAL,M2,"Esquema atrasado fIPV1, fIPV2 dosis fraccionadas aplicadas en esquemas tardíos en edades simples de 1 a 5 años"
ECU,Ecuador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y2-Y7,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,CATCHUP_C,General/routine,NATIONAL,M18,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,General/routine,NATIONAL,M12,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y8-Y49,1er contacto viajeros de 8 a 49 años de edad
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,CATCHUP_C,General/routine,NATIONAL,M6,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,CATCHUP_C,General/routine,NATIONAL,M12-M23,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,CATCHUP_C,General/routine,NATIONAL,Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M6,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M2,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M4,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_ADO_W,General/routine,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,+M6,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,+M1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y16-Y49,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Población de 16 a 49 años de edad, incluyendo embarazadas, según esquema de vacunación"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12-M23,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M11,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12-M59,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M12-M23,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
EGY,Egypt,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
EGY,Egypt,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M2,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,high-risk groups
EGY,Egypt,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M6,high-risk groups
EGY,Egypt,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
EGY,Egypt,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
EGY,Egypt,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,pregnant women
EGY,Egypt,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
EGY,Egypt,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
EGY,Egypt,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
EGY,Egypt,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
EGY,Egypt,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
EGY,Egypt,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
EGY,Egypt,EMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
EGY,Egypt,EMRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y4,school children
EGY,Egypt,EMRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y6,school children
EGY,Egypt,EMRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y12,school children
EGY,Egypt,EMRO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,Y15,school children
EGY,Egypt,EMRO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M2,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M4,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,M6,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,M9,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),6.0,TRAVELLERS,General/routine,NATIONAL,M12,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,OPV,OPV (Oral polio vaccine),7.0,TRAVELLERS,General/routine,NATIONAL,M18,travellers to other countries in the meningitis belt
EGY,Egypt,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7-Y8,school children
EGY,Egypt,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y9-Y10,school children
EGY,Egypt,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,women in childbearning age
EGY,Egypt,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,women in childbearning age
EGY,Egypt,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,women in childbearning age
EGY,Egypt,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,women in childbearning age
EGY,Egypt,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,women in childbearning age
EGY,Egypt,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,women in childbearning age
EGY,Egypt,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,women in childbearning age
EGY,Egypt,EMRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M18,women in childbearning age
EGY,Egypt,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M18,travellers to endemic areas
ERI,Eritrea,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
ERI,Eritrea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females 9 years - 14 years
ERI,Eritrea,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females 9 years - 14 years
ERI,Eritrea,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,14 weeks - 11 months
ERI,Eritrea,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,14 weeks - 11 months
ERI,Eritrea,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,FEMALE,General/routine,NATIONAL,M18,18 months -23 months
ERI,Eritrea,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9 months - 18 months
ERI,Eritrea,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,9 months - 18 months
ERI,Eritrea,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,0-11 months
ERI,Eritrea,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
ERI,Eritrea,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
ERI,Eritrea,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
ERI,Eritrea,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,6 weeks - 11 months
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>Y14,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6 months-59 months
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6 months-59 months
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6 months-59 months
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6 months-59 months
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6 months-59 months
ERI,Eritrea,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6 months-59 months
ESP,Spain,EURO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M36,Travellers
ESP,Spain,EURO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,SUBNATIONAL,Y6,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M11,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,Risk groups
ESP,Spain,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M24-Y6,"Subnationally in one region and two cities (Catalonia at 15 months and 6 years, Ceuta and Melilla at 15 months and 24 months)"
ESP,Spain,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M15,"Subnationally in one region and two cities (Catalonia at 15 months and 6 years, Ceuta and Melilla at 15 months and 24 months)"
ESP,Spain,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M15,Risk groups (all Regions)
ESP,Spain,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M15,Health and care workers
ESP,Spain,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M15,Risk groups
ESP,Spain,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered only for newborns of mothers with AgHBs+
ESP,Spain,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Specific children who weren’t immunized in their childhood (migrants and other)
ESP,Spain,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school)"
ESP,Spain,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school)"
ESP,Spain,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1-M2,Risk groups (all regions)
ESP,Spain,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Risk groups (all regions)
ESP,Spain,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Risk groups (all regions)
ESP,Spain,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
ESP,Spain,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
ESP,Spain,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ESP,Spain,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
ESP,Spain,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>=Y65,Travellers
ESP,Spain,EURO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y65,Travellers
ESP,Spain,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,Y12,Travellers
ESP,Spain,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,"Recommended to high-risk individuals: properdin or complement deficiency, multiple episodes of invasive meningococcal disease, specific laboratory personnel, or severe splenic dysfunction."
ESP,Spain,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M4,"Recommended to high-risk individuals: properdin or complement deficiency, multiple episodes of invasive meningococcal disease, specific laboratory personnel, or severe splenic dysfunction."
ESP,Spain,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M12,"In 2 regions, MenACWY-135_conj is administered instead of the second dose of MenC_conj at M12"
ESP,Spain,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,SUBNATIONAL,M12,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,SUBNATIONAL,Y3-Y4,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,SUBNATIONAL,M12-M15,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,SUBNATIONAL,Y3-Y4,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,Risk groups (all regions)
ESP,Spain,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups (all regions)
ESP,Spain,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Risk groups (all regions)
ESP,Spain,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Risk groups (all regions)
ESP,Spain,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,Risk groups (all regions)
ESP,Spain,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y64,Risk groups (all regions)
ESP,Spain,EURO,2023,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y64,Travellers
ESP,Spain,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y64,"Recommended in premature children: between 25-27 weeks (depending on the vaccine used) and 32 weeks of gestation, clinically stable and without contraindications"
ESP,Spain,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Recommended in premature children: between 25-27 weeks (depending on the vaccine used) and 32 weeks of gestation, clinically stable and without contraindications"
ESP,Spain,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y14,"Recommended in premature children: between 25-27 weeks (depending on the vaccine used) and 32 weeks of gestation, clinically stable and without contraindications"
ESP,Spain,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,"Wound prophylaxis, adults without vaccination history"
ESP,Spain,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y14,Certain healthcare workers
ESP,Spain,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,Pregnant women
ESP,Spain,EURO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14,Travellers
ESP,Spain,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14,Travellers
ESP,Spain,EURO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,SUBNATIONAL,M15,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,SUBNATIONAL,Y3-Y4,Some regions administer MMRV instead of MMR and monovalent varicella
ESP,Spain,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y3-Y4,Travellers
ESP,Spain,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65-Y80,65 years old; 2nd dose administered +6 months at lease
ESP,Spain,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,65 years old; 2nd dose administered +6 months at lease
ESP,Spain,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>=Y60,For specific risk groups
EST,Estonia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,D1-D5,For specific risk groups
EST,Estonia,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,D1-D5,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4.5,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_F,General/routine,NATIONAL,Y2,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y7,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Birth dose for risk group newborns (newborn of HIV-positive or untested mother), and vaccination for children with contraindication to pertussis component, children unvaccinated/partially vaccinated against HepB"
EST,Estonia,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Children with contrindication to pertussis component
EST,Estonia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,B,females; catch-up for 2021-2023
EST,Estonia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y12,females; catch-up for 2021-2023
EST,Estonia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females; catch-up for 2021-2023
EST,Estonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
EST,Estonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
EST,Estonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
EST,Estonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
EST,Estonia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
EST,Estonia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
EST,Estonia,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,Risk group(s),NATIONAL,M4.5,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y6-Y7,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y13,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13,Close contacts of measles cases
EST,Estonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Close contacts of measles cases
EST,Estonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Close contacts of measles cases
EST,Estonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4.5,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,Close contacts of measles cases
EST,Estonia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y16,"children >13 years with incomplete vaccination schedule, post-trauma vaccination"
EST,Estonia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y15-Y16,"children >13 years with incomplete vaccination schedule, post-trauma vaccination"
EST,Estonia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,"children >13 years with incomplete vaccination schedule, post-trauma vaccination"
ETH,Ethiopia,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Live births
ETH,Ethiopia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,Surviving infants
ETH,Ethiopia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,Surviving infants
ETH,Ethiopia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,Surviving infants
ETH,Ethiopia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females
ETH,Ethiopia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,Surviving infants
ETH,Ethiopia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,Surviving infants
ETH,Ethiopia,AFRO,2023,MEASLES,Measles vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,Surviving infants; 2nd year of life
ETH,Ethiopia,AFRO,2023,MEASLES,Measles vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,Surviving infants; 2nd year of life
ETH,Ethiopia,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,Surviving infants
ETH,Ethiopia,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,Surviving infants
ETH,Ethiopia,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,Surviving infants
ETH,Ethiopia,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,Surviving infants
ETH,Ethiopia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Surviving infants
ETH,Ethiopia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Surviving infants
ETH,Ethiopia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,Surviving infants
ETH,Ethiopia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Surviving infants
ETH,Ethiopia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Surviving infants
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+W4,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,5-59 months
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,5-59 months
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M18,5-59 months
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,ADULTS,General/routine,NATIONAL,M24,5-59 months
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,ADULTS,General/routine,NATIONAL,M30,5-59 months
ETH,Ethiopia,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,ADULTS,General/routine,NATIONAL,M36,5-59 months
FIN,Finland,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y7,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Specified risk groups
FIN,Finland,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Specified risk groups
FIN,Finland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Specified risk groups
FIN,Finland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Specified risk groups
FIN,Finland,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y18,Catch-up for all under 18 years of age or those in high school or vocational school to start series or complement series.
FIN,Finland,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,Catch-up for all under 18 years of age or those in high school or vocational school to start series or complement series.
FIN,Finland,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,Catch-up for all under 18 years of age or those in high school or vocational school to start series or complement series.
FIN,Finland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y10-Y12,Older persons
FIN,Finland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y10-Y12,Health and care workers
FIN,Finland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y10-Y12,Pregnant women
FIN,Finland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y10-Y12,"Adults with chronic conditions, residents living in long-term care facilities"
FIN,Finland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y7,"Adults with chronic conditions, residents living in long-term care facilities"
FIN,Finland,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y7,Booster if travelling at endemic country for longer than 4 weeks or arriving from such a country and previous booster over 12 months ago
FIN,Finland,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,M6-Y7,Booster if travelling at endemic country for longer than 4 weeks or arriving from such a country and previous booster over 12 months ago
FIN,Finland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,Booster if travelling at endemic country for longer than 4 weeks or arriving from such a country and previous booster over 12 months ago
FIN,Finland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y6,Second dose is administered if child already has protection against varicella
FIN,Finland,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y6,Administered if children also need protection against varicella
FIN,Finland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Administered if children also need protection against varicella
FIN,Finland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,Administered if children also need protection against varicella
FIN,Finland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M12,Administered if children also need protection against varicella
FIN,Finland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Specified risk groups
FIN,Finland,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y5,"For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion"
FIN,Finland,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion"
FIN,Finland,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion"
FIN,Finland,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,"For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion"
FIN,Finland,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,>=Y3,In specified risk areas
FIN,Finland,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,>=Y3,In specified risk areas
FIN,Finland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y45,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y14-Y15,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023,VARICELLA,Varicella vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,Y1.5-Y11,2nd dose catch up: children 1.5-11Y who haven´t had chickenpox
FIN,Finland,EURO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M18,2nd dose catch up: children 1.5-11Y who haven´t had chickenpox
FJI,Fiji,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<M12,and catch-up until 12 months
FJI,Fiji,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,B,and catch-up until 12 months
FJI,Fiji,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y8,and catch-up until 8 years
FJI,Fiji,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W6,and catch-up until 8 years
FJI,Fiji,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,W10,and catch-up until 8 years
FJI,Fiji,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,W14,and catch-up until 8 years
FJI,Fiji,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W6,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+W14,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Pre-term babies are ""special"" booster at 12 months with MR1"
FJI,Fiji,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y8-Y13,Females; class 8
FJI,Fiji,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females; class 8
FJI,Fiji,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
FJI,Fiji,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
FJI,Fiji,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
FJI,Fiji,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,W14,and any age when vaccination is required
FJI,Fiji,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,PW,General/routine,NATIONAL,M12,and any age when vaccination is required
FJI,Fiji,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,PW,General/routine,NATIONAL,M18,and any age when vaccination is required
FJI,Fiji,WPRO,2023,MR,MR (Measles and rubella) vaccine,3.0,PW,General/routine,NATIONAL,Y6,and any age when vaccination is required
FJI,Fiji,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,W6,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W10,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W14,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,M18,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,and at any age when vaccination is required
FJI,Fiji,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y2,and catch-up until 2 years
FJI,Fiji,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W6,and catch-up until 2 years
FJI,Fiji,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,W14,and catch-up until 2 years
FJI,Fiji,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,and catch-up until 2 years
FJI,Fiji,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y11,and catch-up until 2 years
FJI,Fiji,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant mothers
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M12,adminstered every 6 months until 5 years
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M18,adminstered every 6 months until 5 years
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M24,adminstered every 6 months until 5 years
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M30,adminstered every 6 months until 5 years
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M36,adminstered every 6 months until 5 years
FJI,Fiji,WPRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M42,adminstered every 6 months until 5 years
FRA,France,EURO,2023,AP,aP (acellular pertussis) vaccine,1.0,PW,Pregnant women,NATIONAL,M42,Pregnant women first and second trimester
FRA,France,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,SUBNATIONAL,M1-M2,Pregnant women first and second trimester
FRA,France,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,Pregnant women first and second trimester
FRA,France,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,Pregnant women first and second trimester
FRA,France,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M11,Pregnant women first and second trimester
FRA,France,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Pregnant women first and second trimester
FRA,France,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk, adults at risk"
FRA,France,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Professionnal at risk, adults at risk"
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Health professionnels
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health professionnels
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Health professionnels
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies born to a mother infected with hepatitis B
FRA,France,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,"Femmes et hommes 11-14 ans: 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu’à l’âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d’autres hommes."
FRA,France,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Femmes et hommes 11-14 ans: 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu’à l’âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d’autres hommes."
FRA,France,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Femmes et hommes 11-14 ans: 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu’à l’âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d’autres hommes."
FRA,France,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
FRA,France,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
FRA,France,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities"
FRA,France,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
FRA,France,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
FRA,France,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
FRA,France,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
FRA,France,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
FRA,France,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
FRA,France,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
FRA,France,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
FRA,France,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
FRA,France,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
FRA,France,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,Children with chronic conditions
FRA,France,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,and risk groups between 2-65 years
FRA,France,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,risk groups between 2-65 years
FRA,France,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11-Y13,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y13,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",1.0,ADULTS,Adults,NATIONAL,Y45,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",2.0,ADULTS,Adults,NATIONAL,Y65,2 or 3 doses according to the type of vaccine used
FRA,France,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,SUBNATIONAL,M9,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,>=Y4,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M12,French Guyana only; mandatory
FSM,Micronesia (Federated States of),WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y11,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M4,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M6,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,FEMALE,General/routine,NATIONAL,>=Y4,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M12,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,>=M13,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M6,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,FEMALE,General/routine,NATIONAL,M13,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M6,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,FEMALE,General/routine,NATIONAL,>=Y11,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
GAB,Gabon,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Naissances vivantes
GAB,Gabon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,Enfants survivants
GAB,Gabon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,Enfants survivants
GAB,Gabon,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,Enfants survivants
GAB,Gabon,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,W14,Enfants survivants
GAB,Gabon,AFRO,2023,MEASLES,Measles vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M9,Enfants survivants
GAB,Gabon,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,B,Naissances vivantes
GAB,Gabon,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,W6,Naissances vivantes
GAB,Gabon,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_ADO_W,General/routine,NATIONAL,W10,Naissances vivantes
GAB,Gabon,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_ADO_W,General/routine,NATIONAL,W14,Naissances vivantes
GAB,Gabon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes
GAB,Gabon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
GAB,Gabon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
GAB,Gabon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes
GAB,Gabon,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes
GAB,Gabon,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,Enfants survivants
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,D28,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W12,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W16,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,B_2YL_F,General/routine,NATIONAL,M40,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y16,<16 years in clinical risk groups including haemophilia and chronic liver disease. See pg 6 onwards of The Green Book: https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter-17
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y15,Y1 to Y15 in clinical risk groups including haemophilia and chronic liver disease. See pg 6 onwards of The Green Book: https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter-17
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y1-Y15,"Schedule varies depending on risk. Clinical risk groups such as individuals with chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia. Occupational risk such as healthcare workers and lifestyle factors including PWID, MSM, commercial sex workers, inmates of custodial institutions. More on eligibility and the relevant schedules are in The Green Book chapter from pg 7: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y15,"Schedule varies depending on risk. Clinical risk groups such as individuals with chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia. Occupational risk such as healthcare workers and lifestyle factors including PWID, MSM, commercial sex workers, inmates of custodial institutions. More on eligibility and the relevant schedules are in The Green Book chapter from pg 7: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W4,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HIB_MEN_C_CONJ,"Hib (Haemophilus influenzae type B), Meningococcal C conjugate vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Given as a combined vaccine with Men C conjugate and Hib vaccine
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25-Y45,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25-Y45,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y25-Y24,3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y14,"Adults with chronic conditions, residents living in long-term care facilities"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y14,"Adults with chronic conditions, residents living in long-term care facilities"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y14,Children with chronic conditions
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Catch-up available to Y25
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Catch-up available to Y25
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,Y14,Catch-up available to Y25
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,"Individuals at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction, or complement disorders (including those on, or due to commence complement inhibitor treatment, such as eculizumab and ravulizumab). Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"Individuals at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction, or complement disorders (including those on, or due to commence complement inhibitor treatment, such as eculizumab and ravulizumab). Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W16,"Individuals at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction, or complement disorders (including those on, or due to commence complement inhibitor treatment, such as eculizumab and ravulizumab). Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Individuals at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction, or complement disorders (including those on, or due to commence complement inhibitor treatment, such as eculizumab and ravulizumab). Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M40,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W12,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W12,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",1.0,B_ADO_W,General/routine,NATIONAL,Y14,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,Pregnant women from 16 weeks
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6-M12,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W8,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B-D5,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,>Y18,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M3-M6,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M3-M6,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,hour 12
GEO,Georgia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,"Females and males; Females national introduction from August 2019, males from July 2023"
GEO,Georgia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females and males; Females national introduction from August 2019, males from July 2023"
GEO,Georgia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13-Y46,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2-M6,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons aged 60 and older
GEO,Georgia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
GEO,Georgia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
GEO,Georgia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GEO,Georgia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GEO,Georgia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M59,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GEO,Georgia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Children with chronic conditions
GEO,Georgia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
GEO,Georgia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
GEO,Georgia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GEO,Georgia,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14,Travellers
GHA,Ghana,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
GHA,Ghana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
GHA,Ghana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
GHA,Ghana,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
GHA,Ghana,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
GHA,Ghana,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M18,12-23 months
GHA,Ghana,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,9-59 months
GHA,Ghana,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M18,9-59 months
GHA,Ghana,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
GHA,Ghana,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
GHA,Ghana,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
GHA,Ghana,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
GHA,Ghana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
GHA,Ghana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
GHA,Ghana,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
GHA,Ghana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
GHA,Ghana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
GHA,Ghana,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
GHA,Ghana,AFRO,2023,RTS_S,Malaria vaccine,1.0,TRAVELLERS,General/routine,SUBNATIONAL,M6,6-59 months
GHA,Ghana,AFRO,2023,RTS_S,Malaria vaccine,2.0,TRAVELLERS,General/routine,SUBNATIONAL,M7,6-59 months
GHA,Ghana,AFRO,2023,RTS_S,Malaria vaccine,3.0,TRAVELLERS,General/routine,SUBNATIONAL,M9,6-59 months
GHA,Ghana,AFRO,2023,RTS_S,Malaria vaccine,4.0,TRAVELLERS,General/routine,SUBNATIONAL,M18,6-59 months
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15-Y49,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,6-59 months
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,6-59 months
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M18,6-59 months
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,ADULTS,General/routine,NATIONAL,M24,6-59 months
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,ADULTS,General/routine,NATIONAL,M30,6-59 months
GHA,Ghana,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,ADULTS,General/routine,NATIONAL,M36,6-59 months
GHA,Ghana,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,0-11 months
GIN,Guinea,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Naissance vivantes
GIN,Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,Enfants survivants
GIN,Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,Enfants survivants
GIN,Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,Enfants survivants
GIN,Guinea,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W14,Enfants survivants
GIN,Guinea,AFRO,2023,MEASLES,Measles vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,Enfants survivants
GIN,Guinea,AFRO,2023,MEASLES,Measles vaccine,2.0,ADULTS,General/routine,NATIONAL,M18,Enfants survivants
GIN,Guinea,AFRO,2023,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,ADULTS,General/routine,NATIONAL,M15,Enfant survivant
GIN,Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,B,Naissance vivante pour le VPO0 et Enfants survivants de VPO1 à VPO3
GIN,Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W6,Naissance vivante pour le VPO0 et Enfants survivants de VPO1 à VPO3
GIN,Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W10,Naissance vivante pour le VPO0 et Enfants survivants de VPO1 à VPO3
GIN,Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,W14,Naissance vivante pour le VPO0 et Enfants survivants de VPO1 à VPO3
GIN,Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse
GIN,Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse
GIN,Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse
GIN,Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
GIN,Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
GIN,Guinea,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,Enfants survivants
GMB,Gambia,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 months
GMB,Gambia,AFRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,0-11 months
GMB,Gambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,0-11 months
GMB,Gambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,0-11 months
GMB,Gambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,0-11 months
GMB,Gambia,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,0-11 months
GMB,Gambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+Y1,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M2,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M3,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M4,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,FEMALE,General/routine,NATIONAL,M9,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,OPV,OPV (Oral polio vaccine),6.0,FEMALE,General/routine,NATIONAL,M18,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M4,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,from April 2019; 12-24 months
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,"Y15-Y49, pregnant and post-partum mothers"
GNB,Guinea-Bissau,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,PW,General/routine,NATIONAL,W14,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,MEASLES,Measles vaccine,1.0,PW,General/routine,NATIONAL,M9,0-23 mois
GNB,Guinea-Bissau,AFRO,2023,MEASLES,Measles vaccine,2.0,PW,General/routine,NATIONAL,M15-M23,0-23 mois
GNB,Guinea-Bissau,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,PW,General/routine,NATIONAL,M9,0 a 11M
GNB,Guinea-Bissau,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,B,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W6,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W10,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,W14,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 mois
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,M1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,M2,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,M12,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,M24,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 mois
GNB,Guinea-Bissau,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M11,6-59 mois
GNB,Guinea-Bissau,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 mois
GNB,Guinea-Bissau,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M23-M59,6-59 mois
GNB,Guinea-Bissau,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
GNQ,Equatorial Guinea,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,NACIDOS VIVOS
GNQ,Equatorial Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,NACIDOS VIVOS
GNQ,Equatorial Guinea,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W14,NIÑOS SUPERVIVIENTES
GNQ,Equatorial Guinea,AFRO,2023,MEASLES,Measles vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,MEASLES,Measles vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M18,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,B,NIÑOS SUPERVIVIENTES
GNQ,Equatorial Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,W6,NIÑOS SUPERVIVIENTES
GNQ,Equatorial Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,W10,NIÑOS SUPERVIVIENTES
GNQ,Equatorial Guinea,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,W14,NIÑOS SUPERVIVIENTES
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,NIÑOS SUPERVIVIENTES
GRC,Greece,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Only for neonates that belong to high risk groups
GRC,Greece,EURO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,High-risk groups
GRC,Greece,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,High-risk groups
GRC,Greece,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M24,High-risk groups
GRC,Greece,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M30,High-risk groups
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6-M18,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15-M18,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y11,"Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 3 doses (0M, +1–2M, +6M)."
GRC,Greece,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 3 doses (0M, +1–2M, +6M)."
GRC,Greece,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18-Y26,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
GRC,Greece,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
GRC,Greece,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GRC,Greece,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>M6,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6-M18,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y11-Y12,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M24-M47,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M24-M47,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,PCV13 or PCV15
GRC,Greece,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Y19-Y64 high risk groups, and all adults  ≥Y65"
GRC,Greece,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19-Y64,"Y19-Y64 high risk groups, and all adults  ≥Y65"
GRC,Greece,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,≥Y2 -Y18 children who belong to high risk groups
GRC,Greece,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,RV1
GRC,Greece,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,RV1
GRC,Greece,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,RV5
GRC,Greece,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,RV5
GRC,Greece,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,RV5
GRC,Greece,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y18-Y25,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,ADULTS,Adults,NATIONAL,Y18-Y25,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M12-M15,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M24-M47,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60-Y75,"ZVL ≥Y60 -Y75, RΖV ≥Y18 High risk groups"
GRC,Greece,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"ZVL ≥Y60 -Y75, RΖV ≥Y18 High risk groups"
GRD,Grenada,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,4-5 Yr old
GRD,Grenada,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,M18 old
GRD,Grenada,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,6 w to 6 m
GRD,Grenada,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,6 w to 6 m
GRD,Grenada,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,6 w to 6 m
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Live birth
GRD,Grenada,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Target-9-10 years girls/ Grades 4-6 Doses- 1 (1 dose commenced in 2023)
GRD,Grenada,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Target-9-10 years girls/ Grades 4-6 Doses- 1 (1 dose commenced in 2023)
GRD,Grenada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
GRD,Grenada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
GRD,Grenada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
GRD,Grenada,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GRD,Grenada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GRD,Grenada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
GRD,Grenada,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
GRD,Grenada,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,"6wk, 6mths"
GRD,Grenada,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"6wk, 6mths"
GRD,Grenada,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,1yr old and 18 month old
GRD,Grenada,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,1yr old and 18 month old
GRD,Grenada,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,M4 to 14yrs old
GRD,Grenada,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,M4 to 14yrs old
GRD,Grenada,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,M4 to 14yrs old
GRD,Grenada,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y14-Y15,M4 to 14yrs old
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y15,14yrs old
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023,VARICELLA,Varicella vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y1,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Hepatitis B pediátrica se administra a los RN antes de cumplir el 1er. Mes de vida lo más cercano al nacimiento,"
GTM,Guatemala,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,"El AÑO 2023, fue un año de transición para cambiar el esquema de 2 dosis a esquema de 1 dosis (única)además se incrementó el grupo objetivo de esta vacunación para: Niñas de 9 a 16 años de edad, incluyendo a las niñas de 17 años cumplidos siempre y cuando hubieran nacido en el año 2006, Solamente se administró 2da. dosis a todas aquellas niñas que presentarán su carné de vacunación con cita para esa segunda dosis, pero que había sido escrita previamente al año 2023. En el 2018 se inició con 2 cohortes de niñas  en el año 2019 se incremento a 3 cohortes de niñas en el año 2020 se incremento a 5 cohortes de niñas Por lo que en el año 2023, el cambio de esquema permitió que la vacuna alcanzará iniciar a cubrir 9 cohortes niñas nacidas desde año 2006 hasta el año 2014"
GTM,Guatemala,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"El AÑO 2023, fue un año de transición para cambiar el esquema de 2 dosis a esquema de 1 dosis (única)además se incrementó el grupo objetivo de esta vacunación para: Niñas de 9 a 16 años de edad, incluyendo a las niñas de 17 años cumplidos siempre y cuando hubieran nacido en el año 2006, Solamente se administró 2da. dosis a todas aquellas niñas que presentarán su carné de vacunación con cita para esa segunda dosis, pero que había sido escrita previamente al año 2023. En el 2018 se inició con 2 cohortes de niñas  en el año 2019 se incremento a 3 cohortes de niñas en el año 2020 se incremento a 5 cohortes de niñas Por lo que en el año 2023, el cambio de esquema permitió que la vacuna alcanzará iniciar a cubrir 9 cohortes niñas nacidas desde año 2006 hasta el año 2014"
GTM,Guatemala,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
GTM,Guatemala,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
GTM,Guatemala,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
GTM,Guatemala,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
GTM,Guatemala,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12-M35,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
GTM,Guatemala,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M35,Children with chronic conditions
GTM,Guatemala,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y15,"Recuperación de esquema entre 7 a 15 años, si nunca a sido vacunada la persona"
GTM,Guatemala,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,CATCHUP_C,General/routine,NATIONAL,M4,"Recuperación de esquema entre 7 a 15 años, si nunca a sido vacunada la persona"
GTM,Guatemala,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,General/routine,NATIONAL,M2,"Recuperación de esquema entre 7 a 15 años, si nunca a sido vacunada la persona"
GTM,Guatemala,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y10,Recuperación de esquema entre 7 a 10 años
GTM,Guatemala,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,CATCHUP_C,General/routine,NATIONAL,M18,Recuperación de esquema entre 7 a 10 años
GTM,Guatemala,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,General/routine,NATIONAL,M12,Recuperación de esquema entre 7 a 10 años
GTM,Guatemala,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Enfermos crónicos de 2 años de edad en adelante, diciembre 2022 capacitaciones, , los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Enfermos crónicos de 2 años, a partir de 2 años de edad, diciembre 2022 capacitaciones, los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Enfermos crónicos de 2 años, a partir de 2 años de edad, diciembre 2022 capacitaciones, los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Enfermos crónicos de 2 años, a partir de 2 años de edad, diciembre 2022 capacitaciones, los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses despues de la 3ra. dosis SegundoRefuerzo; 6 meses despues del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Ademas Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis segun antecedente vacunal) por mordedura de perro   (cantidad de dosis segun antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y10,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses despues de la 3ra. dosis SegundoRefuerzo; 6 meses despues del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Ademas Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis segun antecedente vacunal) por mordedura de perro   (cantidad de dosis segun antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas (en cada embarazo), Personal de salud (dosis única)"
GTM,Guatemala,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas (en cada embarazo), Personal de salud (dosis única)"
GTM,Guatemala,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Niñas y niños de 6 meses a menores de 1 año
GTM,Guatemala,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6-Y59,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAP,DTaP (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAP,DTaP (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAP,DTaP (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12-M15,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,ADULTS,Adults,NATIONAL,Y19,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,ADULTS,General/routine,NATIONAL,M12,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,ADULTS,General/routine,NATIONAL,M18,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M1-M2,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6-M18,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y19-Y26,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1-M2,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Diabetics 60Y with shared clinical decision
GUM,Guam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M6,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y11-Y12,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,ADULTS,General/routine,NATIONAL,>=M6,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,M2,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M4,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M6-M18,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,ADULTS,General/routine,NATIONAL,Y4-Y6,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,ADULTS,General/routine,NATIONAL,Y11-Y12,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,ADULTS,General/routine,NATIONAL,Y16,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,Adults,NATIONAL,Y19,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,Adults,NATIONAL,+M1,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,General/routine,NATIONAL,Y4-Y6,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M12-M15,"1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series"
GUM,Guam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,Adults 19-64 Y
GUM,Guam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Adults 19-64 Y
GUM,Guam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Adults 19-64 Y
GUM,Guam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,Adults 19-64 Y
GUM,Guam,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,ADULTS,General/routine,NATIONAL,M12-M15,Adults 19-64 Y
GUM,Guam,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,Adults 19-64 Y
GUM,Guam,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Adults 19-64 Y
GUM,Guam,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Adults 19-64 Y
GUM,Guam,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,Adults 19-64 Y
GUM,Guam,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y7,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y19,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant adults and adolescent at every pregnancy 27-36 weeks gestation
GUM,Guam,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y50,"and at 50 years, +M6 for high risk groups/adults"
GUM,Guam,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B-W6,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,SUBNATIONAL,+M6,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,SUBNATIONAL,1st contact,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,SUBNATIONAL,+M1,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,At birth. Began administering from June 2019
GUY,Guyana,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y16,"Vaccine is given to both sexes 9-16 years, at 2 doses for 9-14 years and 3 doses for ages 15-16 years (at 15 years it is given at D0, M1 and M6)"
GUY,Guyana,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Vaccine is given to both sexes 9-16 years, at 2 doses for 9-14 years and 3 doses for ages 15-16 years (at 15 years it is given at D0, M1 and M6)"
GUY,Guyana,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,BOTH,General/routine,NATIONAL,M2,given nationally as first Polio vaccine to all persons and subnationally to HIV exposed groups
GUY,Guyana,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,BOTH,General/routine,NATIONAL,M4,given nationally as first Polio vaccine to all persons and subnationally to HIV exposed groups
GUY,Guyana,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,HIV exposed infants
GUY,Guyana,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,HIV exposed infants
GUY,Guyana,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M45,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women depending on their primary series
GUY,Guyana,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Pregnant women depending on their primary series
GUY,Guyana,AMRO,2023,VARICELLA,Varicella vaccine,1.0,ADULTS,Adults,SUBNATIONAL,Y18,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023,VARICELLA,Varicella vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+M1,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,>=Y16,School Immunisation Teams provide Hepatitis B Vaccine mop-up to Primary 6 students who have not received 3 doses of Hepatitis B Vaccine on schedule.  Adult Hepatitis B vaccine would be provided for school children who are aged 16 and above (mostly studying at special schools).
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,>=Y16,"Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection"
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y16,"Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection"
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection"
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M1,"Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection"
HKG,"China, Hong Kong SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection"
HKG,"China, Hong Kong SAR",WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,female only
HKG,"China, Hong Kong SAR",WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,female only
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,female only
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y50,Health and care workers
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y50,Pregnant women
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y17,Aged 6 months to 17 years (including children aged 18 years or above but still studying at secondary school)
HKG,"China, Hong Kong SAR",WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y17,Children with chronic conditions
HKG,"China, Hong Kong SAR",WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
HKG,"China, Hong Kong SAR",WPRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18-Y6,"Children born on or after 1 Jul 2018 receive MMRV vaccine at 18 months old, and children born between 1 Jan 2013 and 30 Jun 2018 receive MMRV vaccine in Primary 1"
HKG,"China, Hong Kong SAR",WPRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,HW,Health workers,NATIONAL,M18-Y6,"Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong"
HKG,"China, Hong Kong SAR",WPRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18-Y6,"Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong"
HKG,"China, Hong Kong SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong"
HKG,"China, Hong Kong SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong"
HKG,"China, Hong Kong SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong"
HKG,"China, Hong Kong SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Individuals with high risk conditions who have received 23vPPV or who have not received any pneumococcal vaccines before
HKG,"China, Hong Kong SAR",WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Individuals with high risk conditions who have received PCV13 or who have not received any pneumococcal vaccines before / Individuals without high risk conditions who have not received any pneumococcal vaccines before
HKG,"China, Hong Kong SAR",WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
HKG,"China, Hong Kong SAR",WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,Pregnant women
HKG,"China, Hong Kong SAR",WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant women
HKG,"China, Hong Kong SAR",WPRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,Pregnant women
HND,Honduras,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Recien Nacidos con peso mayor de 2,500 gramos y menores de 1 año"
HND,Honduras,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,1 Año
HND,Honduras,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,1 Año
HND,Honduras,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Menor de 1 año hasta menores de 5 años
HND,Honduras,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Menor de 1 año hasta menores de 5 años
HND,Honduras,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Menor de 1 año hasta menores de 5 años
HND,Honduras,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Tradbajadores de Salud
HND,Honduras,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,HW,Health workers,NATIONAL,+M6,Tradbajadores de Salud
HND,Honduras,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,HW,General/routine,NATIONAL,Y1,Población de 1 año
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,4.0,HW,Health workers,NATIONAL,+Y1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Primeras 24 horas de nacido
HND,Honduras,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,Niñas de 11 y 12 años
HND,Honduras,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Niñas de 11 y 12 años
HND,Honduras,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
HND,Honduras,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
HND,Honduras,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
HND,Honduras,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
HND,Honduras,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
HND,Honduras,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12-M23,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
HND,Honduras,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M23,Children with chronic conditions
HND,Honduras,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menor de 1 año
HND,Honduras,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menor de 1 año
HND,Honduras,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Niños con madres con VIH y niños con diagnostico de VIH
HND,Honduras,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Niños con madres con VIH y niños con diagnostico de VIH
HND,Honduras,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Población de 1 año y menor de 5 años
HND,Honduras,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Población de 1 año y menor de 5 años
HND,Honduras,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y5,"Vacuna contra Sarampión, Rubéola y Parotiditis(Cepa Jeryl Lynn)  - Grupos en riesgo mayores de 5 años sin antecedente de haber padecido la enfermedad o de no haber sido vacunado."
HND,Honduras,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menor de 2 años
HND,Honduras,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Menor de 2 años
HND,Honduras,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menor de 1 año
HND,Honduras,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menor de 1 año
HND,Honduras,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menor de 1 año
HND,Honduras,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menor de 1 año
HND,Honduras,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menor de 1 año
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y11,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+M24,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+M36,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M6,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M12,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,3.0,RISKGROUPS,General/routine,NATIONAL,M18,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,4.0,RISKGROUPS,General/routine,NATIONAL,M24,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,5.0,RISKGROUPS,General/routine,NATIONAL,M30,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,VITAMINA,Vitamin A supplements,6.0,RISKGROUPS,General/routine,NATIONAL,M36,"Se suplementa a menores de 5 años. Primera dosis es a los 6 meses, las siguientes dosis son cada 6 meses"
HND,Honduras,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y1,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,D2,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y14,Females and males; in 8th grade of primary school
HRV,Croatia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,Females and males; in 8th grade of primary school
HRV,Croatia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Females and males; in 8th grade of primary school
HRV,Croatia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
HRV,Croatia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
HRV,Croatia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care-facilities"
HRV,Croatia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
HRV,Croatia,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,Y7,Children with chronic conditions
HRV,Croatia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
HRV,Croatia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y7,Children with chronic conditions
HRV,Croatia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
HRV,Croatia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
HRV,Croatia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
HRV,Croatia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y24,Children with chronic conditions
HRV,Croatia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y60,Children with chronic conditions
HRV,Croatia,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,Children with chronic conditions
HTI,Haiti,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,naissances vivantes
HTI,Haiti,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,12-23 mois
HTI,Haiti,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
HTI,Haiti,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
HTI,Haiti,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
HTI,Haiti,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
HTI,Haiti,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,9-11 mois
HTI,Haiti,AMRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M12-M23,9-11 mois
HTI,Haiti,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W0,0-11 mois
HTI,Haiti,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
HTI,Haiti,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
HTI,Haiti,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,M9,0-11 mois
HTI,Haiti,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
HTI,Haiti,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
HTI,Haiti,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,0-11 mois
HTI,Haiti,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,0-11 mois
HTI,Haiti,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,0-11 mois
HTI,Haiti,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
HTI,Haiti,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
HTI,Haiti,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
HTI,Haiti,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
HTI,Haiti,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
HUN,Hungary,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,femmes enceintes
HUN,Hungary,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,femmes enceintes
HUN,Hungary,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M3,femmes enceintes
HUN,Hungary,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M4,femmes enceintes
HUN,Hungary,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,femmes enceintes
HUN,Hungary,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,femmes enceintes
HUN,Hungary,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y12,7th grade school campaign
HUN,Hungary,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,+M6,7th grade school campaign
HUN,Hungary,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Boys and girls; 7th grade school campaign
HUN,Hungary,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Boys and girls; 7th grade school campaign
HUN,Hungary,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,Boys and girls; 7th grade school campaign
HUN,Hungary,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y60,Health and care workers
HUN,Hungary,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y60,Pregnant women
HUN,Hungary,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
HUN,Hungary,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,Children with chronic conditions
HUN,Hungary,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,6th grade school campaign
HUN,Hungary,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y11,6th grade school campaign
HUN,Hungary,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,6th grade school campaign
HUN,Hungary,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,6th grade school campaign
HUN,Hungary,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,6th grade school campaign
HUN,Hungary,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,6th grade school campaign
HUN,Hungary,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M13,6th grade school campaign
HUN,Hungary,EURO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M16,6th grade school campaign
IDN,Indonesia,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B-M1,live birth infant until first month
IDN,Indonesia,SEARO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,DT will given to children Y7 equal specific target 1st grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IDN,Indonesia,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Surviving infants and Children under 2 years
IDN,Indonesia,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3,Surviving infants and Children under 2 years
IDN,Indonesia,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M4,Surviving infants and Children under 2 years
IDN,Indonesia,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Surviving infants and Children under 2 years
IDN,Indonesia,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Live birth infant - given <H24
IDN,Indonesia,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,"The nationwide introduction commenced in August 2023, 5th grade elementary school or 11 years of female in all provinces; meanwhile for the 2nd dose targeted 6th grade elementary school or 12 years of female for 132 districts"
IDN,Indonesia,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y12,"The nationwide introduction commenced in August 2023, 5th grade elementary school or 11 years of female in all provinces; meanwhile for the 2nd dose targeted 6th grade elementary school or 12 years of female for 132 districts"
IDN,Indonesia,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,"1st dose IPV is for surviving infants; meanwhile 2nd dose IPV the nationwide introduction commenced in June 2023, denominator calculation: surviving infants in Jakarta,Banten,Jawa Barat and Yogyakarta) + 7/12 months of surviving infants in remaining 34 provinces"
IDN,Indonesia,SEARO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,"1st dose IPV is for surviving infants; meanwhile 2nd dose IPV the nationwide introduction commenced in June 2023, denominator calculation: surviving infants in Jakarta,Banten,Jawa Barat and Yogyakarta) + 7/12 months of surviving infants in remaining 34 provinces"
IDN,Indonesia,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,FEMALE,General/routine,SUBNATIONAL,M10,Only 9 districts at Bali Province and 14 districts in West Kalimantan province
IDN,Indonesia,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,"Surviving Infant, toddler & 1st grade of elementary school"
IDN,Indonesia,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,"Surviving Infant, toddler & 1st grade of elementary school"
IDN,Indonesia,SEARO,2023,MR,MR (Measles and rubella) vaccine,3.0,FEMALE,General/routine,NATIONAL,Y7,"Surviving Infant, toddler & 1st grade of elementary school"
IDN,Indonesia,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M1,Surviving infants
IDN,Indonesia,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M2,Surviving infants
IDN,Indonesia,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M3,Surviving infants
IDN,Indonesia,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M4,Surviving infants
IDN,Indonesia,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose)
IDN,Indonesia,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose)
IDN,Indonesia,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M12,Surviving infants (1st and 2nd dose) and children under 2 years (3rd dose)
IDN,Indonesia,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,The nationwide introduction commenced in August 2023. Denominator calculation: surviving infants in 21 districts (2022 introduction) + 5/12 months of surviving infants in remaining 493 districts.
IDN,Indonesia,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,The nationwide introduction commenced in August 2023. Denominator calculation: surviving infants in 21 districts (2022 introduction) + 5/12 months of surviving infants in remaining 493 districts.
IDN,Indonesia,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M4,The nationwide introduction commenced in August 2023. Denominator calculation: surviving infants in 21 districts (2022 introduction) + 5/12 months of surviving infants in remaining 493 districts.
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y9-Y10,DT will given to children Y7 equal specific target 1st  grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y7-Y8,DT will given to children Y7 equal specific target 1st  grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IDN,Indonesia,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,B_CHILD_W,General/routine,NATIONAL,M6-M11,Under 5 years
IDN,Indonesia,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,B_CHILD_W,General/routine,NATIONAL,M12-M59,Under 5 years
IND,India,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,0-1 year
IND,India,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M16-M24,1.5 months-7 years
IND,India,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,1.5 months-7 years
IND,India,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,up to 1 year
IND,India,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,up to 1 year
IND,India,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,up to 1 year
IND,India,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,up to 1 year
IND,India,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,B_CHILD_W,General/routine,NATIONAL,W6,fractional dose
IND,India,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),2.0,B_CHILD_W,General/routine,NATIONAL,W14,fractional dose
IND,India,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),3.0,B_CHILD_W,General/routine,NATIONAL,M9,fractional dose
IND,India,SEARO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,B_CHILD_W,General/routine,SUBNATIONAL,M9-M12,"9 months - 2 years (JE vaccine is given in the National Immunization schedule from 9 months to 2 years. The  JE vaccination is given in campaign mode before introduction in routine immunization, in identified districts. This campaign is done in target group of 1-15 years)"
IND,India,SEARO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,B_CHILD_W,General/routine,SUBNATIONAL,M16-M24,"9 months - 2 years (JE vaccine is given in the National Immunization schedule from 9 months to 2 years. The  JE vaccination is given in campaign mode before introduction in routine immunization, in identified districts. This campaign is done in target group of 1-15 years)"
IND,India,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M9-M12,0-5 years
IND,India,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M16-M24,0-5 years
IND,India,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,B,0-5 years
IND,India,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,W6,0-5 years
IND,India,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,B_CHILD_W,General/routine,NATIONAL,W10,0-5 years
IND,India,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,B_CHILD_W,General/routine,NATIONAL,W14,0-5 years
IND,India,SEARO,2023,OPV,OPV (Oral polio vaccine),5.0,B_CHILD_W,General/routine,NATIONAL,M16-M24,0-5 years
IND,India,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,up to 1 year
IND,India,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W14,up to 1 year
IND,India,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M9,up to 1 year
IND,India,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,"up to 1 year, both RV1 and RV5 administered"
IND,India,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y10,"10Y, 16Y, and 2 Td doses for pregnant women"
IND,India,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y16,"10Y, 16Y, and 2 Td doses for pregnant women"
IND,India,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery"
IND,India,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,"Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery"
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,0-5 years
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M18,0-5 years
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M24,0-5 years
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M30,0-5 years
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M36,0-5 years
IND,India,SEARO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M42,0-5 years
IRL,Ireland,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M42,"Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland"
IRL,Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland"
IRL,Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland"
IRL,Ireland,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland"
IRL,Ireland,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,"Child and adult risk groups. In 2015, the National Immunisation Advisory Committee (NIAC) and the Health Information and Quality Authority (HIQA) both recommended that BCG vaccine does not need to be given to all children in Ireland"
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,Healthcare workers
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups
IRL,Ireland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Risk groups
IRL,Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups
IRL,Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups
IRL,Ireland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Risk groups
IRL,Ireland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M13,Risk groups
IRL,Ireland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13,Risk groups
IRL,Ireland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"From 2019, switched to HPV9 and to females and males in first year of secondary school.  Since November 2022 a single dose of HPV vaccine is recommended in Ireland for those aged 9-24 years who are immunocompetent as there is now sufficient evidence that there is no significant difference in vaccine effectiveness between those aged nine to 24 years of age who are immunocompetent who receive one, two, or three vaccine doses."
IRL,Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"From 2019, switched to HPV9 and to females and males in first year of secondary school.  Since November 2022 a single dose of HPV vaccine is recommended in Ireland for those aged 9-24 years who are immunocompetent as there is now sufficient evidence that there is no significant difference in vaccine effectiveness between those aged nine to 24 years of age who are immunocompetent who receive one, two, or three vaccine doses."
IRL,Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
IRL,Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
IRL,Ireland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
IRL,Ireland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y17,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
IRL,Ireland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,Children with chronic conditions
IRL,Ireland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y12,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M13,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Men ACWY-135 conjugate to replace MenC at Y12 from February 2020
IRL,Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M12,Health care workers
IRL,Ireland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Risk groups, outbreaks"
IRL,Ireland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Risk groups, outbreaks"
IRL,Ireland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M6,"Risk groups, outbreaks"
IRL,Ireland,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M13,"Risk groups, outbreaks"
IRL,Ireland,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,and child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,Child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y12-Y13,Child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y12-Y13,Pregnant women from 16 weeks gestation
IRL,Ireland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y12-Y13,Risk groups as per recommendations
IRN,Iran (Islamic Republic of),EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Risk groups as per recommendations
IRN,Iran (Islamic Republic of),EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,M18,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",6.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M2,doses at 2 and 6 months for children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,doses at 2 and 6 months for children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,"No specific target group, however this vaccine is distributed by the private sector"
IRN,Iran (Islamic Republic of),EMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,"No specific target group, however this vaccine is distributed by the private sector"
IRN,Iran (Islamic Republic of),EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,No specific target group however this vaccine is distributed by the private sector
IRN,Iran (Islamic Republic of),EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,No specific target group however this vaccine is distributed by the private sector
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,No specific target group however this vaccine is distributed by the private sector
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M59,"Adults with chronic conditions, residents living in long-term care facilities"
IRN,Iran (Islamic Republic of),EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Children with chronic conditions
IRN,Iran (Islamic Republic of),EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
IRN,Iran (Islamic Republic of),EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
IRN,Iran (Islamic Republic of),EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"outbreak response in dormitories or prisons, military and for Haj pilgrims"
IRN,Iran (Islamic Republic of),EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"outbreak response in dormitories or prisons, military and for Haj pilgrims"
IRN,Iran (Islamic Republic of),EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,"outbreak response in dormitories or prisons, military and for Haj pilgrims"
IRN,Iran (Islamic Republic of),EMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M6,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M18,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y6,outbreak response
IRN,Iran (Islamic Republic of),EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"high risk groups, this vaccine is distributed by private sector"
IRN,Iran (Islamic Republic of),EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"High risk groups for pneumococcal infections, this vaccine distributed by private sector"
IRN,Iran (Islamic Republic of),EMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,animal bite cases and high-risk groups
IRN,Iran (Islamic Republic of),EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25,The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later
IRN,Iran (Islamic Republic of),EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later
IRN,Iran (Islamic Republic of),EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y15,Recommended at 15 Y/O and repeated every 10 years later
IRN,Iran (Islamic Republic of),EMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,"children with lymphatic and hematologic malignancies and their siblings, multiple sclerosis patients who have negative serology test for varicella"
IRN,Iran (Islamic Republic of),EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,travellers to endemic countries
IRQ,Iraq,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers to endemic countries
IRQ,Iraq,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,B,High risk groups
IRQ,Iraq,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,High risk groups
IRQ,Iraq,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,High risk groups
IRQ,Iraq,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,High risk groups
IRQ,Iraq,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,High risk groups
IRQ,Iraq,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,High risk groups
IRQ,Iraq,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >60 years
IRQ,Iraq,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
IRQ,Iraq,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
IRQ,Iraq,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditons, residents living in long-term care facilities, other groups"
IRQ,Iraq,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditons, residents living in long-term care facilities, other groups"
IRQ,Iraq,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditons, residents living in long-term care facilities, other groups"
IRQ,Iraq,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
IRQ,Iraq,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
IRQ,Iraq,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
IRQ,Iraq,EMRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
IRQ,Iraq,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,High risk groups
IRQ,Iraq,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,High risk groups
IRQ,Iraq,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M18,High risk groups
IRQ,Iraq,EMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,High risk groups
IRQ,Iraq,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,High risk groups
IRQ,Iraq,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,High risk groups
IRQ,Iraq,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,High risk groups
IRQ,Iraq,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,High risk groups
IRQ,Iraq,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,High risk groups
IRQ,Iraq,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>Y7,High risk groups
IRQ,Iraq,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M9,High risk groups
IRQ,Iraq,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M18,High risk groups
IRQ,Iraq,EMRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,Y4-Y6,High risk groups
IRQ,Iraq,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y6,High risk groups
ISL,Iceland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,High risk groups
ISL,Iceland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,High risk groups
ISL,Iceland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,High risk groups
ISL,Iceland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M12,"Risk groups: Persons in households with a hepatitis B infected person, healthcare workers whose duties expose them to blood or blood products, patients who require frequent transfusions of blood products or undergo haemodialysis, IV drug users, MSM"
ISL,Iceland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Risk groups: Persons in households with a hepatitis B infected person, healthcare workers whose duties expose them to blood or blood products, patients who require frequent transfusions of blood products or undergo haemodialysis, IV drug users, MSM"
ISL,Iceland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Gender neutral and switch to HPV9 from birth cohort 2011
ISL,Iceland,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Gender neutral and switch to HPV9 from birth cohort 2011
ISL,Iceland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Gender neutral and switch to HPV9 from birth cohort 2011
ISL,Iceland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
ISL,Iceland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
ISL,Iceland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities"
ISL,Iceland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M36,"Adults with chronic conditions, residents living in long-term care facilities"
ISL,Iceland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y3-Y17,"Adults with chronic conditions, residents living in long-term care facilities"
ISL,Iceland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y3-Y17,Children with chronic conditions
ISL,Iceland,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Change from menC M6 and M8 TO menACYW M12 ~April 2023
ISL,Iceland,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6,Change from menC M6 and M8 TO menACYW M12 ~April 2023
ISL,Iceland,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M8,Change from menC M6 and M8 TO menACYW M12 ~April 2023
ISL,Iceland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M18,Change from menC M6 and M8 TO menACYW M12 ~April 2023
ISL,Iceland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y12,Change from menC M6 and M8 TO menACYW M12 ~April 2023
ISL,Iceland,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,HW,Health workers,NATIONAL,Y12,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,HW,Health workers,NATIONAL,Y12,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,B_CHILD_W,General/routine,NATIONAL,Y4,Target groups are those eligible for HIV PrEP as assessed by the ID department at Landspitali University Hospital and HCWs in certain departments where exposure without knowledge of MPOX diagnosis is possible (if unlikely). Two dose dose-sparing regime used.
ISL,Iceland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y4,Pregnant women in 3rd trimester from May 2019
ISL,Iceland,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y14,Pregnant women in 3rd trimester from May 2019
ISL,Iceland,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,May be used for pregnant women in 3rd trimester if IPV indicated or Tdap shortage as of May 2019
ISL,Iceland,EURO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M18,Birth cohort 2019 and later
ISL,Iceland,EURO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,M30,Birth cohort 2019 and later
ISR,Israel,EURO,2022,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M30,Risk groups
ISR,Israel,EURO,2022,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,if pertussis contraindicated
ISR,Israel,EURO,2022,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,if pertussis contraindicated
ISR,Israel,EURO,2022,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,if pertussis contraindicated
ISR,Israel,EURO,2022,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,if pertussis contraindicated
ISR,Israel,EURO,2022,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,if pertussis contraindicated
ISR,Israel,EURO,2022,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,if pertussis contraindicated
ISR,Israel,EURO,2022,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,if pertussis contraindicated
ISR,Israel,EURO,2022,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12,if pertussis contraindicated
ISR,Israel,EURO,2022,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Risk groups
ISR,Israel,EURO,2022,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M12,Travellers
ISR,Israel,EURO,2022,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M18,Travellers
ISR,Israel,EURO,2022,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M24,Travellers
ISR,Israel,EURO,2022,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,Risk groups
ISR,Israel,EURO,2022,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M24,Travellers
ISR,Israel,EURO,2022,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers
ISR,Israel,EURO,2022,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M1,Travellers
ISR,Israel,EURO,2022,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Travellers
ISR,Israel,EURO,2022,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Risk groups
ISR,Israel,EURO,2022,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,females and males
ISR,Israel,EURO,2022,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,females and males
ISR,Israel,EURO,2022,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
ISR,Israel,EURO,2022,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ISR,Israel,EURO,2022,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ISR,Israel,EURO,2022,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
ISR,Israel,EURO,2022,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y18,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
ISR,Israel,EURO,2022,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M59,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
ISR,Israel,EURO,2022,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Children with chronic conditions
ISR,Israel,EURO,2022,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_A,Catch-up adults,NATIONAL,M6-M59,Adult catch-up
ISR,Israel,EURO,2022,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,M6-M59,Catch-up
ISR,Israel,EURO,2022,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Risk groups
ISR,Israel,EURO,2022,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6-M59,Travellers
ISR,Israel,EURO,2022,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Risk groups
ISR,Israel,EURO,2022,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Risk groups
ISR,Israel,EURO,2022,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Risk groups
ISR,Israel,EURO,2022,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Risk groups
ISR,Israel,EURO,2022,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M6,Risk groups
ISR,Israel,EURO,2022,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M18,Risk groups
ISR,Israel,EURO,2022,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Risk groups
ISR,Israel,EURO,2022,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Risk groups
ISR,Israel,EURO,2022,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Risk groups
ISR,Israel,EURO,2022,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"M2, M4, M6, M12 for risk groups"
ISR,Israel,EURO,2022,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"M2, M4, M6, M12 for risk groups"
ISR,Israel,EURO,2022,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,At-risk groups
ISR,Israel,EURO,2022,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,At-risk groups
ISR,Israel,EURO,2022,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,At-risk groups
ISR,Israel,EURO,2022,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,At-risk groups
ISR,Israel,EURO,2022,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6,Travellers (paediatric and adult)
ISR,Israel,EURO,2022,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6,Travellers (paediatric and adult)
ISR,Israel,EURO,2022,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,M6,Every ten years to adult population
ISR,Israel,EURO,2022,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Wound management, +Y5 if the wound is deep"
ISR,Israel,EURO,2022,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Wound management, +Y5 if the wound is deep"
ISR,Israel,EURO,2022,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13,Booster dose in school children
ISR,Israel,EURO,2022,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y13,Pregnant women
ISR,Israel,EURO,2022,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13,Risk groups
ISR,Israel,EURO,2022,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,Booster dose in school children
ISR,Israel,EURO,2022,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,At-risk adults
ISR,Israel,EURO,2022,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,Tetanus prophilaxis in wound management
ISR,Israel,EURO,2022,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y7,Travellers
ISR,Israel,EURO,2022,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y7,Travellers
ISR,Israel,EURO,2022,TYPHOIDHEPA,Typhoid and Hepatitis A,1.0,TRAVELLERS,Travellers,NATIONAL,Y7,Travellers
ISR,Israel,EURO,2022,VARICELLA,Varicella vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,Y7,Catch-up adults
ISR,Israel,EURO,2022,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7,Catch-up children
ISR,Israel,EURO,2022,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,Risk groups
ISR,Israel,EURO,2022,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y7,Travellers
ISR,Israel,EURO,2022,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,>=Y60 all population + >=18 for risk group
ISR,Israel,EURO,2022,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,>=Y60 all population + >=18 for risk group
ITA,Italy,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health workers at high risk
ITA,Italy,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,HW,General/routine,NATIONAL,M3,Health workers at high risk
ITA,Italy,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,HW,General/routine,NATIONAL,M5,Health workers at high risk
ITA,Italy,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,HW,General/routine,NATIONAL,M11,Health workers at high risk
ITA,Italy,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Health workers at high risk
ITA,Italy,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"Recommended for persons with clinical, behavioral or occupational risks"
ITA,Italy,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M13-M14,Endemic region
ITA,Italy,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M24,Endemic region
ITA,Italy,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,"Recommended for persons with clinical, behavioral or occupational risks"
ITA,Italy,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"females and males x2 doses, and MSM x3 doses"
ITA,Italy,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females and males x2 doses, and MSM x3 doses"
ITA,Italy,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,MSM x3 doses
ITA,Italy,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,Recommended since august 2023 instead of monovalent C
ITA,Italy,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y12-Y18,Recommended since august 2023 instead of monovalent C
ITA,Italy,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Recommended since august 2023 instead of monovalent C
ITA,Italy,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5-M6,Recommended since august 2023 instead of monovalent C
ITA,Italy,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Recommended since august 2023 instead of monovalent C
ITA,Italy,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,as of august 2023 replaced with MEN ACWY
ITA,Italy,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13-M15,Subjects of all ages with clinical indications
ITA,Italy,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,Subjects of all ages with clinical indications
ITA,Italy,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y6,Subjects of all ages with clinical indications
ITA,Italy,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,Y5-Y6,Health workers
ITA,Italy,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y6,Risk groups
ITA,Italy,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y6,Risk groups
ITA,Italy,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,Risk groups
ITA,Italy,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,HW,Health workers,NATIONAL,M13-M15,Health workers
ITA,Italy,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M13-M15,Risk groups
ITA,Italy,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Risk groups
ITA,Italy,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M5,Risk groups
ITA,Italy,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M11,Risk groups
ITA,Italy,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3,Risk groups
ITA,Italy,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Subjects of all ages with clinical indications
ITA,Italy,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Subjects of all ages with clinical indications
ITA,Italy,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3,RV1 or RV5 vaccine administered; 3rd dose depends on vaccine presentation
ITA,Italy,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M5,RV1 or RV5 vaccine administered; 3rd dose depends on vaccine presentation
ITA,Italy,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3,RV1 or RV5 vaccine administered; 3rd dose depends on vaccine presentation
ITA,Italy,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M5,RV1 or RV5 vaccine administered; 3rd dose depends on vaccine presentation
ITA,Italy,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M7,RV1 or RV5 vaccine administered; 3rd dose depends on vaccine presentation
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,1st contact,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,+Y10,Pregnant women
ITA,Italy,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y12-Y18,Pregnant women
ITA,Italy,EURO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y5-Y6,Pregnant women
ITA,Italy,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M13-M15,Pregnant women
ITA,Italy,EURO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,M13-M15,Health workers
ITA,Italy,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13-M15,Risk groups
ITA,Italy,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,Risk groups
JAM,Jamaica,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Birth cohort
JAM,Jamaica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Children <7 yrs
JAM,Jamaica,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Children <7 yrs
JAM,Jamaica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Routine
JAM,Jamaica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3,Routine
JAM,Jamaica,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Routine
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCWs
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,HCWs
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,HCWs
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Birth cohort
JAM,Jamaica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,"Females 9-26 years, Males 9-14 years (Main target is secondary school entry (grade 7) which is children Y11-12)"
JAM,Jamaica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females 9-26 years, Males 9-14 years (Main target is secondary school entry (grade 7) which is children Y11-12)"
JAM,Jamaica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
JAM,Jamaica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
JAM,Jamaica,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
JAM,Jamaica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M36-Y17,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
JAM,Jamaica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M35,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
JAM,Jamaica,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M35,Children with chronic conditions
JAM,Jamaica,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,Routine
JAM,Jamaica,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Routine
JAM,Jamaica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Routine
JAM,Jamaica,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Routine
JAM,Jamaica,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,Routine
JAM,Jamaica,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Routine
JAM,Jamaica,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Routine
JAM,Jamaica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M15,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Persons with Sickle Cell Disease
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Routine
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>M12,Travellers to endemic countries
JOR,Jordan,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers to endemic countries
JOR,Jordan,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Travellers to endemic countries
JOR,Jordan,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers to endemic countries
JOR,Jordan,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M5,Travellers to endemic countries
JOR,Jordan,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Travellers to endemic countries
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,Y15,Travellers to endemic countries
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,B_2YL_W,General/routine,NATIONAL,+M6,Travellers to endemic countries
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,B_2YL_W,General/routine,NATIONAL,+M1,Travellers to endemic countries
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
JOR,Jordan,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
JOR,Jordan,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,pregnant women
JOR,Jordan,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
JOR,Jordan,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
JOR,Jordan,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
JOR,Jordan,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
JOR,Jordan,EMRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
JOR,Jordan,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
JOR,Jordan,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
JOR,Jordan,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
JOR,Jordan,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
JOR,Jordan,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
JOR,Jordan,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
JOR,Jordan,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
JOR,Jordan,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
JOR,Jordan,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
JOR,Jordan,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
JOR,Jordan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Children with chronic conditions
JOR,Jordan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_F,General/routine,NATIONAL,Y16,Children with chronic conditions
JOR,Jordan,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
JOR,Jordan,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
JOR,Jordan,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
JOR,Jordan,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
JOR,Jordan,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
JOR,Jordan,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,pregnant women
JOR,Jordan,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M18,pregnant women
JPN,Japan,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,Y1,between M5-M8
JPN,Japan,WPRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,PW,General/routine,NATIONAL,Y11,between M5-M8
JPN,Japan,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4.5,between M5-M8
JPN,Japan,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6,between M5-M8
JPN,Japan,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,between M5-M8
JPN,Japan,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,between M5-M8
JPN,Japan,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M7,between M5-M8
JPN,Japan,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,between M5-M8
JPN,Japan,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,between M5-M8
JPN,Japan,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,Y1,between M5-M8
JPN,Japan,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,3.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,FEMALE,HPV for females only,NATIONAL,Y13,between M5-M8
JPN,Japan,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,FEMALE,General/routine,NATIONAL,M36,between M5-M8
JPN,Japan,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,FEMALE,General/routine,NATIONAL,M37,between M5-M8
JPN,Japan,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,3.0,FEMALE,General/routine,NATIONAL,Y4,between M5-M8
JPN,Japan,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,4.0,FEMALE,General/routine,NATIONAL,Y9,between M5-M8
JPN,Japan,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,Y1,between M5-M8
JPN,Japan,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,Y5,between M5-M8
JPN,Japan,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,between M5-M8
JPN,Japan,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M4,between M5-M8
JPN,Japan,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,FEMALE,General/routine,NATIONAL,Y1,between M5-M8
JPN,Japan,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,between M5-M8
JPN,Japan,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,between M5-M8
JPN,Japan,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,between M5-M8
JPN,Japan,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M3,between M5-M8
JPN,Japan,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M4,between M5-M8
JPN,Japan,WPRO,2023,VARICELLA,Varicella vaccine,1.0,ADULTS,General/routine,NATIONAL,M12,between M5-M8
JPN,Japan,WPRO,2023,VARICELLA,Varicella vaccine,2.0,ADULTS,General/routine,NATIONAL,M18,between M5-M8
KAZ,Kazakhstan,EURO,2023,ANTHRAX,Anthrax vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M4,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,Y2,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_2YL_W,General/routine,NATIONAL,Y2.5,в стационарно неблагополучных пунктах и группа риска по профдеятельности
KAZ,Kazakhstan,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y2.5,"непривитые медработники, контактные в очагах"
KAZ,Kazakhstan,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2.5,"непривитые медработники, контактные в очагах"
KAZ,Kazakhstan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"непривитые медработники, контактные в очагах"
KAZ,Kazakhstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
KAZ,Kazakhstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
KAZ,Kazakhstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
KAZ,Kazakhstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
KAZ,Kazakhstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
KAZ,Kazakhstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
KAZ,Kazakhstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
KAZ,Kazakhstan,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,по клиническим показаниям
KAZ,Kazakhstan,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M12,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y26,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y36,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y46,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y56,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y66,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_F,General/routine,NATIONAL,Y16,жители эндемичных территорий
KAZ,Kazakhstan,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y16,в природных очагах туляремии
KAZ,Kazakhstan,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,группы риска по роду профессинальной деятельности
KEN,Kenya,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,группы риска по роду профессинальной деятельности
KEN,Kenya,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,группы риска по роду профессинальной деятельности
KEN,Kenya,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,группы риска по роду профессинальной деятельности
KEN,Kenya,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,группы риска по роду профессинальной деятельности
KEN,Kenya,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y14,from October 2019; females
KEN,Kenya,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,from October 2019; females
KEN,Kenya,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
KEN,Kenya,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
KEN,Kenya,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
KEN,Kenya,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KEN,Kenya,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KEN,Kenya,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KEN,Kenya,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
KEN,Kenya,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
KEN,Kenya,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
KEN,Kenya,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
KEN,Kenya,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Children with chronic conditions
KEN,Kenya,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
KEN,Kenya,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W10,Children with chronic conditions
KEN,Kenya,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
KEN,Kenya,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
KEN,Kenya,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,Children with chronic conditions
KEN,Kenya,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
KEN,Kenya,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
KEN,Kenya,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,Children with chronic conditions
KEN,Kenya,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
KEN,Kenya,AFRO,2023,RTS_S,Malaria vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M6,pilot targeting areas with high prevalence of malaria under the malaria vaccine implementation programme
KEN,Kenya,AFRO,2023,RTS_S,Malaria vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M7,pilot targeting areas with high prevalence of malaria under the malaria vaccine implementation programme
KEN,Kenya,AFRO,2023,RTS_S,Malaria vaccine,3.0,RISKGROUPS,General/routine,SUBNATIONAL,M9,pilot targeting areas with high prevalence of malaria under the malaria vaccine implementation programme
KEN,Kenya,AFRO,2023,RTS_S,Malaria vaccine,4.0,RISKGROUPS,General/routine,SUBNATIONAL,M24,pilot targeting areas with high prevalence of malaria under the malaria vaccine implementation programme
KEN,Kenya,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
KEN,Kenya,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
KEN,Kenya,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
KEN,Kenya,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KEN,Kenya,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,Pregnant women
KEN,Kenya,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,Pregnant women
KEN,Kenya,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,SUBNATIONAL,M9,Pregnant women
KGZ,Kyrgyzstan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Pregnant women
KGZ,Kyrgyzstan,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Pregnant women
KGZ,Kyrgyzstan,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_F,General/routine,NATIONAL,Y2,Pregnant women
KGZ,Kyrgyzstan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_F,General/routine,NATIONAL,M2,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_F,General/routine,NATIONAL,M3.5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_F,General/routine,NATIONAL,M5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_F,General/routine,NATIONAL,B,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,11 лет
KGZ,Kyrgyzstan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,11 лет
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y11,Older persons
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y11,Health and care workers
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant women
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y11,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y11,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KGZ,Kyrgyzstan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11,Children with chronic conditions
KGZ,Kyrgyzstan,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M3.5,Children with chronic conditions
KGZ,Kyrgyzstan,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
KGZ,Kyrgyzstan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
KGZ,Kyrgyzstan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
KGZ,Kyrgyzstan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3.5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3.5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y11,Дети до 1 года
KGZ,Kyrgyzstan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y16,Дети до 1 года
KHM,Cambodia,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Дети до 1 года
KHM,Cambodia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,Дети до 1 года
KHM,Cambodia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,Дети до 1 года
KHM,Cambodia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,Дети до 1 года
KHM,Cambodia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Дети до 1 года
KHM,Cambodia,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9y
KHM,Cambodia,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,9y
KHM,Cambodia,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9y
KHM,Cambodia,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9y
KHM,Cambodia,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,9y
KHM,Cambodia,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W10,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
KHM,Cambodia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
KHM,Cambodia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
KHM,Cambodia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KHM,Cambodia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KHM,Cambodia,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M59,Twice a year (May & November)
KHM,Cambodia,WPRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M6-M59,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B-Y1,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B-W2,Twice a year (May & November)
KIR,Kiribati,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Female
KIR,Kiribati,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,Female
KIR,Kiribati,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,Female
KIR,Kiribati,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,Y6,Female
KIR,Kiribati,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,15 years and above womens
KIR,Kiribati,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,15 years and above womens
KIR,Kiribati,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,15 years and above womens
KIR,Kiribati,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,1 year
KIR,Kiribati,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,1 year
KIR,Kiribati,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,1 year
KIR,Kiribati,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,1 year
KIR,Kiribati,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,1 year
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+W4,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15,15 years and above womens
KIR,Kiribati,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,15 years and above womens
KIR,Kiribati,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,15 years and above womens
KIR,Kiribati,WPRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B-M11,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",6.0,B_CHILD_W,General/routine,NATIONAL,Y16,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4.5-Y5,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,3 doses given to adults as required
KNA,Saint Kitts and Nevis,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,3 doses given to adults as required
KNA,Saint Kitts and Nevis,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Given to boys and girls in grade 6 (Primary school) at 1st dose and 2nd dose six months later
KNA,Saint Kitts and Nevis,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y11,Older persons
KNA,Saint Kitts and Nevis,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y11,Health and care workers
KNA,Saint Kitts and Nevis,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant women
KNA,Saint Kitts and Nevis,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4.5-Y5,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y16,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_F,General/routine,NATIONAL,Y16,"Adults with chronic conditions, residents living in long-term care facilities"
KNA,Saint Kitts and Nevis,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y16,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B-M1,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAP,DTaP (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAP,DTaP (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAP,DTaP (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M12-M23,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,+M6-M18,Required for travellers to endemic countries
KOR,Republic of Korea,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,+M6-M18,older children
KOR,Republic of Korea,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,+M6-M18,older children
KOR,Republic of Korea,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B-M1,older children
KOR,Republic of Korea,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,ADULTS,General/routine,NATIONAL,M1,older children
KOR,Republic of Korea,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,older children
KOR,Republic of Korea,WPRO,2023,HFRS,Hemorrhagic fever with renal syndrome vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk groups
KOR,Republic of Korea,WPRO,2023,HFRS,Hemorrhagic fever with renal syndrome vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk groups
KOR,Republic of Korea,WPRO,2023,HFRS,Hemorrhagic fever with renal syndrome vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M12,high risk groups
KOR,Republic of Korea,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,high risk groups
KOR,Republic of Korea,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,high risk groups
KOR,Republic of Korea,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,high risk groups
KOR,Republic of Korea,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,high risk groups
KOR,Republic of Korea,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females
KOR,Republic of Korea,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females
KOR,Republic of Korea,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,females
KOR,Republic of Korea,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
KOR,Republic of Korea,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
KOR,Republic of Korea,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KOR,Republic of Korea,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y9,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KOR,Republic of Korea,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M6-Y13,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
KOR,Republic of Korea,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y13,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6-M18,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12-M23,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,+D7-D30,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,+M12,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,5.0,RISKGROUPS,General/routine,NATIONAL,Y12,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12-M23,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,+M12,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
KOR,Republic of Korea,WPRO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk groups only
KOR,Republic of Korea,WPRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,high risk groups only
KWT,Kuwait,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,high risk groups only
KWT,Kuwait,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M3,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_F,General/routine,NATIONAL,Y3.6,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_F,General/routine,NATIONAL,M2,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_F,General/routine,NATIONAL,M4,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_F,General/routine,NATIONAL,M6,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,where pertussis is contraindicated
KWT,Kuwait,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,ADULTS,Adults,NATIONAL,M18,for citizen born before 1990 and health care personnel
KWT,Kuwait,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,M18,for citizen born before 1990 and health care personnel
KWT,Kuwait,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,SUBNATIONAL,M18,for citizens born before 1990 and health care personnel
KWT,Kuwait,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,SUBNATIONAL,M18,for citizens born before 1990 and health care personnel
KWT,Kuwait,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,for citizens born before 1990 and health care personnel
KWT,Kuwait,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y45,Y9-Y45 males and females
KWT,Kuwait,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons at 65
KWT,Kuwait,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
KWT,Kuwait,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
KWT,Kuwait,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
KWT,Kuwait,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
KWT,Kuwait,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y18,"Adults with chronic conditions, residents living in long-term care facilities, travellers (i.e. Hajj), other groups"
KWT,Kuwait,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y18,Children with chronic conditions
KWT,Kuwait,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
KWT,Kuwait,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
KWT,Kuwait,EMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
KWT,Kuwait,EMRO,2023,MEN_AC_CONJ,Meningococcal AC conjugate vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M6,for special expatriate working groups
KWT,Kuwait,EMRO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2,for special expatriate working groups
KWT,Kuwait,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,for special expatriate working groups
KWT,Kuwait,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M24,for special expatriate working groups
KWT,Kuwait,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y12,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M12,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M18,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,Y3.5,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,3rd dose at Y10-Y12 is for females
KWT,Kuwait,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"pilgrims, high risk groups"
KWT,Kuwait,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M2,high risk adults
KWT,Kuwait,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,high risk adults
KWT,Kuwait,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,high risk adults
KWT,Kuwait,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,high risk adults
KWT,Kuwait,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10-Y12,high risk adults
KWT,Kuwait,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,7.0,B_ADO_W,General/routine,NATIONAL,Y16-Y18,high risk adults
KWT,Kuwait,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y16-Y18,Pregnant women
KWT,Kuwait,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,HW,Health workers,SUBNATIONAL,Y16-Y18,"people exposed to accidents, healthcare workers"
KWT,Kuwait,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y16-Y18,"people exposed to accidents, healthcare workers"
KWT,Kuwait,EMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y16-Y18,food handlers
KWT,Kuwait,EMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y2,food handlers
KWT,Kuwait,EMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y1,food handlers
KWT,Kuwait,EMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,Y1,HCWs at risk
KWT,Kuwait,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,Y1,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers to at risk areas
LAO,Lao People's Democratic Republic,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,from March 2020; females
LAO,Lao People's Democratic Republic,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11-Y15,from March 2020; females
LAO,Lao People's Democratic Republic,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,Y11-Y15,Older persons
LAO,Lao People's Democratic Republic,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,Y11-Y15,Health and care workers
LAO,Lao People's Democratic Republic,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,Y11-Y15,Pregnant women
LAO,Lao People's Democratic Republic,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y15,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W10,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,"Adults with chronic conditions, residents living in long-term care facilities."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y1,not routine
LAO,Lao People's Democratic Republic,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M59,x2/year
LBN,Lebanon,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Exceptional dose for children with history of allergic reaction to Pertussis
LBN,Lebanon,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
LBN,Lebanon,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
LBN,Lebanon,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Adults with chronic conditions
LBN,Lebanon,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y10-Y12,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y16-Y18,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y10-Y12,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y16-Y18,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,B_ADO_W,General/routine,NATIONAL,M9,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,B_ADO_W,General/routine,NATIONAL,M12,Children with chronic conditions.
LBN,Lebanon,EMRO,2023,VITAMINA,Vitamin A supplements,3.0,B_ADO_W,General/routine,NATIONAL,M18,Children with chronic conditions.
LBR,Liberia,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B-M11,0-11 months
LBR,Liberia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,0-23 months
LBR,Liberia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,0-23 months
LBR,Liberia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,0-23 months
LBR,Liberia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9-14 years Female
LBR,Liberia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,9-14 years Female
LBR,Liberia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
LBR,Liberia,AFRO,2023,MEASLES,Measles vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9-23 months
LBR,Liberia,AFRO,2023,MEASLES,Measles vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,9-23 months
LBR,Liberia,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,0-11 months
LBR,Liberia,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
LBR,Liberia,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
LBR,Liberia,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
LBR,Liberia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,0-23 months
LBR,Liberia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,0-23 months
LBR,Liberia,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,0-23 months
LBR,Liberia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,0-23 months
LBR,Liberia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,0-23 months
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+M12,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+M12,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+M12,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+M12,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+W4,15-49 Y
LBR,Liberia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,15-49 Y
LBR,Liberia,AFRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,9-23 months
LBR,Liberia,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6-M11,6-23 months
LBR,Liberia,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,9-23 months
LBY,Libya,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,9-23 months
LBY,Libya,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,9-23 months
LBY,Libya,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,9-23 months
LBY,Libya,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,9-23 months
LBY,Libya,EMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,9-23 months
LBY,Libya,EMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,9-23 months
LBY,Libya,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,high risk groups (non-vaccinated)
LBY,Libya,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,high risk groups (non-vaccinated)
LBY,Libya,EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females
LBY,Libya,EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M2,females
LBY,Libya,EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,FEMALE,HPV for females only,NATIONAL,+M4,females
LBY,Libya,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M4,Older persons
LBY,Libya,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M4,Health and care workers
LBY,Libya,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M4,Pregnant women
LBY,Libya,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M4,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
LBY,Libya,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M4,Children with chronic conditions
LBY,Libya,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
LBY,Libya,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
LBY,Libya,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y12,Children with chronic conditions
LBY,Libya,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
LBY,Libya,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
LBY,Libya,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Children with chronic conditions
LBY,Libya,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
LBY,Libya,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
LBY,Libya,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
LBY,Libya,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
LBY,Libya,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
LBY,Libya,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
LBY,Libya,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
LBY,Libya,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15,Children with chronic conditions
LBY,Libya,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,travellers
LCA,Saint Lucia,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,travellers
LCA,Saint Lucia,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers
LCA,Saint Lucia,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,travellers
LCA,Saint Lucia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,travellers
LCA,Saint Lucia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,travellers
LCA,Saint Lucia,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,travellers
LCA,Saint Lucia,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,M6,Adults
LCA,Saint Lucia,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Adults
LCA,Saint Lucia,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,from February 2019; females and males; in grade 6
LCA,Saint Lucia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
LCA,Saint Lucia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
LCA,Saint Lucia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
LCA,Saint Lucia,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
LCA,Saint Lucia,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
LCA,Saint Lucia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, residents living in long-term care facilities"
LCA,Saint Lucia,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M6,"Adults with chronic conditions, residents living in long-term care facilities"
LCA,Saint Lucia,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,and to adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,and to adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,Adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M18,Adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y5,Adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y11-Y12,Adolecents and adults with no evidence of vaccination history
LCA,Saint Lucia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,Older children with chronic diseases
LCA,Saint Lucia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y2-Y18,Adults
LCA,Saint Lucia,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Adults
LCA,Saint Lucia,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Based on request
LCA,Saint Lucia,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W6,Based on request
LCA,Saint Lucia,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Adult travellers
LKA,Sri Lanka,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Adult travellers
LKA,Sri Lanka,SEARO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Adult travellers
LKA,Sri Lanka,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Adult travellers
LKA,Sri Lanka,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Adult travellers
LKA,Sri Lanka,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,Adult travellers
LKA,Sri Lanka,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Adult travellers
LKA,Sri Lanka,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y11,"10-11 year girls at schools in Grade 6 and field clinics if missed or if any drop outs, 2nd dose after 6 months"
LKA,Sri Lanka,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"10-11 year girls at schools in Grade 6 and field clinics if missed or if any drop outs, 2nd dose after 6 months"
LKA,Sri Lanka,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,FEMALE,General/routine,NATIONAL,M2,fractional dose
LKA,Sri Lanka,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),2.0,FEMALE,General/routine,NATIONAL,M4,fractional dose
LKA,Sri Lanka,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,FEMALE,General/routine,NATIONAL,Y1,fractional dose
LKA,Sri Lanka,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M9,fractional dose
LKA,Sri Lanka,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,Y3,fractional dose
LKA,Sri Lanka,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,fractional dose
LKA,Sri Lanka,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M4,fractional dose
LKA,Sri Lanka,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M6,fractional dose
LKA,Sri Lanka,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M18,fractional dose
LKA,Sri Lanka,SEARO,2023,OPV,OPV (Oral polio vaccine),5.0,FEMALE,General/routine,NATIONAL,Y5,fractional dose
LKA,Sri Lanka,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,fractional dose
LKA,Sri Lanka,SEARO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"x2 doses 6 weeks apart in 1st pregnancy, and x3 doses in subsequent pregnancies"
LKA,Sri Lanka,SEARO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"high risk categories, food handlers, based on transmission pattern and data, districts are selected to provide vaccination"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M6,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M12,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,3.0,RISKGROUPS,General/routine,NATIONAL,M18,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,4.0,RISKGROUPS,General/routine,NATIONAL,M24,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,5.0,RISKGROUPS,General/routine,NATIONAL,M30,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,VITAMINA,Vitamin A supplements,6.0,RISKGROUPS,General/routine,NATIONAL,M36,"<5 years, every 6 months"
LKA,Sri Lanka,SEARO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M36,provided only for travellers to YF endemic countries
LSO,Lesotho,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
LSO,Lesotho,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,TRAVELLERS,General/routine,NATIONAL,M18,18 months
LSO,Lesotho,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
LSO,Lesotho,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
LSO,Lesotho,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
LSO,Lesotho,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
LSO,Lesotho,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 months
LSO,Lesotho,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M18,0-11 months
LSO,Lesotho,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
LSO,Lesotho,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
LSO,Lesotho,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
LSO,Lesotho,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
LSO,Lesotho,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
LSO,Lesotho,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
LSO,Lesotho,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
LSO,Lesotho,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
LSO,Lesotho,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Children from the age of 5 to 9 years
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y9,Children from the age of 5 to 9 years
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Expected pregnancies
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Expected pregnancies
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Expected pregnancies
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Expected pregnancies
LSO,Lesotho,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Expected pregnancies
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 months
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 months
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 months
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 months
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 months
LSO,Lesotho,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 months
LSO,Lesotho,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M36,Travellers to endemic countries
LTU,Lithuania,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,D2-D3,Travellers to endemic countries
LTU,Lithuania,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers to endemic countries
LTU,Lithuania,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers to endemic countries
LTU,Lithuania,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,Travellers to endemic countries
LTU,Lithuania,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Travellers to endemic countries
LTU,Lithuania,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y7,Travellers to endemic countries
LTU,Lithuania,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Travellers to endemic countries
LTU,Lithuania,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M1,Travellers to endemic countries
LTU,Lithuania,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Travellers to endemic countries
LTU,Lithuania,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,11 years (a minimum of 6 months betweeen first and second doses)
LTU,Lithuania,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,11 years (a minimum of 6 months betweeen first and second doses)
LTU,Lithuania,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Males and females (from February 1)
LTU,Lithuania,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Males and females (from February 1)
LTU,Lithuania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >65 years
LTU,Lithuania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
LTU,Lithuania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,Pregnant women
LTU,Lithuania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents living in long-term care facilities"
LTU,Lithuania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y17,"Adults with chronic conditions, residents living in long-term care facilities"
LTU,Lithuania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y17,Children with chronic conditions
LTU,Lithuania,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
LTU,Lithuania,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
LTU,Lithuania,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children with chronic conditions
LTU,Lithuania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15-M16,Children with chronic conditions
LTU,Lithuania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6-Y7,Children with chronic conditions
LTU,Lithuania,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,10-valent for routine immunization
LTU,Lithuania,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,10-valent for routine immunization
LTU,Lithuania,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,10-valent for routine immunization
LTU,Lithuania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,Children and adults who have specific conditions according to ICD-10-AM (and who were not vaccinated against pneumococcal infection before)
LTU,Lithuania,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,Rabies post-exposure prophylaxis is recommended after contact with animals
LTU,Lithuania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Rabies post-exposure prophylaxis is recommended after contact with animals
LTU,Lithuania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Rabies post-exposure prophylaxis is recommended after contact with animals
LTU,Lithuania,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Rabies post-exposure prophylaxis is recommended after contact with animals
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y25,Every 10 years
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,Every 10 years
LUX,Luxembourg,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,Every 10 years
LUX,Luxembourg,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M3,Every 10 years
LUX,Luxembourg,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M13,Every 10 years
LUX,Luxembourg,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,Every 10 years
LUX,Luxembourg,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,Every 10 years
LUX,Luxembourg,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y12,Catch-up vaccination against Hepatitis B if this vaccine has not yet been done
LUX,Luxembourg,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered to babies born to a mother infected with hepatitis B
LUX,Luxembourg,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,Females and males
LUX,Luxembourg,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
LUX,Luxembourg,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Older persons
LUX,Luxembourg,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
LUX,Luxembourg,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
LUX,Luxembourg,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
LUX,Luxembourg,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,<W33,Recommendation to vaccinate premature children <33 weeks in their 2 first years of life
LUX,Luxembourg,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<W33,Children with chronic conditions
LUX,Luxembourg,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M12,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W8-M6,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M13,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y15-Y16,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15-M23,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M4,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,D2-D5,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M6,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12-M15,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For hemodialize patients (x3 doses)
LVA,Latvia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For hemodialize patients (x3 doses)
LVA,Latvia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For hemodialize patients (x3 doses)
LVA,Latvia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
LVA,Latvia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
LVA,Latvia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Females and males
LVA,Latvia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
LVA,Latvia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
LVA,Latvia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
LVA,Latvia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M23,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
LVA,Latvia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M23,Children with chronic conditions
LVA,Latvia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children with chronic conditions
LVA,Latvia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y7,Children with chronic conditions
LVA,Latvia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
LVA,Latvia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
LVA,Latvia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children with chronic conditions
LVA,Latvia,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,For patients after exposure with suspicious animals
LVA,Latvia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,For patients after exposure with suspicious animals
LVA,Latvia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,For patients after exposure with suspicious animals
LVA,Latvia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,For patients after exposure with suspicious animals
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,Y1-Y17,Children living in highly endemic territories
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,Y1-Y17,Children living in highly endemic territories
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,General/routine,SUBNATIONAL,Y1-Y17,Children living in highly endemic territories
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,RISKGROUPS,General/routine,SUBNATIONAL,Y1-Y17,Children living in highly endemic territories
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Adult vaccination and revaccination
LVA,Latvia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,Adult vaccination and revaccination
LVA,Latvia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,"Pregnant women, 28-32 gestation weeks"
LVA,Latvia,EURO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12-M15,"Pregnant women, 28-32 gestation weeks"
LVA,Latvia,EURO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y7,"Pregnant women, 28-32 gestation weeks"
MAC,"China, Macao SAR",WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Pregnant women, 28-32 gestation weeks"
MAC,"China, Macao SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y5-Y6,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M1,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y14,"2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >Y65
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y3,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MAC,"China, Macao SAR",WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y3,Children with chronic conditions
MAC,"China, Macao SAR",WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,2nd dose of MMR is replaced by MMRV at 18 months of age from September 2018
MAC,"China, Macao SAR",WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M12,Adults(>=Y18) born in or after 1970 who have neither been infected with measles nor received one dose of measles vaccine after their 1st birthday.  Non-immune health workers who have not received any measles vaccine after their 1st birthday. Full-time students enrolling in local higher education institutions for the first time who are not immune and have not received two doses of measles vaccine. Women of childbearing age(Y18 - Y50) with no immune of rubella.
MAC,"China, Macao SAR",WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,Adults(>=Y18) born in or after 1970 who have neither been infected with measles nor received one dose of measles vaccine after their 1st birthday.  Non-immune health workers who have not received any measles vaccine after their 1st birthday. Full-time students enrolling in local higher education institutions for the first time who are not immune and have not received two doses of measles vaccine. Women of childbearing age(Y18 - Y50) with no immune of rubella.
MAC,"China, Macao SAR",WPRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,2nd dose of MMR is replaced by MMRV at 18 months of age from September 2018
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,ADULTS,General/routine,NATIONAL,M15,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y22,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y32,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y42,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y52,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y62,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y72,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018) plus IPV for children at or above 7 years old during school grade 1 vaccination. Tdap is used to replace Td for school grade 6 vaccination (11-12 years old) starting from September 2018. In some situations, when children have already competed 5th dose of IPV/OPV before school grade 1, we will then offer Tdap instead of Tdap-IPV for Tetanus booster."
MAC,"China, Macao SAR",WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018) plus IPV for children at or above 7 years old during school grade 1 vaccination. Tdap is used to replace Td for school grade 6 vaccination (11-12 years old) starting from September 2018. In some situations, when children have already competed 5th dose of IPV/OPV before school grade 1, we will then offer Tdap instead of Tdap-IPV for Tetanus booster."
MAC,"China, Macao SAR",WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11-Y12,Pregnant women in each pregnancy(between 27-36 weeks); adults(>=Y18) with no vaccination history of pertussis; adults and adolescents(>=Y7) with no vaccination history of DTP
MAC,"China, Macao SAR",WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,Pregnant women in each pregnancy(between 27-36 weeks); adults(>=Y18) with no vaccination history of pertussis; adults and adolescents(>=Y7) with no vaccination history of DTP
MAC,"China, Macao SAR",WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Since 1 September 2020, all people are given administration of DTaP-IPV or Tdap-IPV."
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y22,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,Y32,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,Y42,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,Y52,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,Y62,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,Y72,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023,VARICELLA,Varicella vaccine,1.0,ADULTS,General/routine,NATIONAL,M12,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,M1,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018
MAR,Morocco,EMRO,2019,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,healthcare workers
MAR,Morocco,EMRO,2019,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,pregnant women in T2 and T3
MAR,Morocco,EMRO,2019,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M3,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M1,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M18,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M4,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y5,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,TT,TT (Tetanus toxoid) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,TT,TT (Tetanus toxoid) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,TT,TT (Tetanus toxoid) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,"adults with chronic conditions, Hajj or other travellers"
MAR,Morocco,EMRO,2019,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,"adults with chronic conditions, Hajj or other travellers"
MCO,Monaco,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y5,enfants de moins de 5 ans à risque de contracter une tuberculose
MCO,Monaco,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk, adults at risk"
MCO,Monaco,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Professionnal at risk, adults at risk"
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health professionnels
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Health professionnels
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Health professionnels
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies born to a mother infected with hepatitis B
MCO,Monaco,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,"Femmes et hommes 11-14 ans; 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Femmes et hommes 11-14 ans; 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workes
MCO,Monaco,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
MCO,Monaco,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>M6,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>M6,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M5,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M16,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Residents living in long-term care facilities, other groups"
MCO,Monaco,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11-Y13,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y13,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",1.0,ADULTS,Adults,NATIONAL,Y45,and risk groups between 2-65 years
MCO,Monaco,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",2.0,ADULTS,Adults,NATIONAL,Y65,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,D2,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_F,General/routine,NATIONAL,Y2,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_F,General/routine,NATIONAL,M2,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_F,General/routine,NATIONAL,M4,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_F,General/routine,NATIONAL,M6,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,д1
MDA,Republic of Moldova,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y10,девочкам. На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,девочкам. На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
MDA,Republic of Moldova,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
MDA,Republic of Moldova,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M6,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,Y2,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y7,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,RISKGROUPS,General/routine,NATIONAL,Y15,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y2,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y7,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,"Residents living in long-term care facilities, other groups"
MDA,Republic of Moldova,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M2,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M4,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y20,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y30,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y40,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y50,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y60,На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,На территории Приднестровья вакцина не внеднена
MDG,Madagascar,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,0-11 mois
MDG,Madagascar,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,0-11 mois
MDG,Madagascar,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,0-11 mois
MDG,Madagascar,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,0-11 mois
MDG,Madagascar,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,W14,0-11 mois
MDG,Madagascar,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,M9,0-11 mois
MDG,Madagascar,AFRO,2023,MEASLES,Measles vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M9,0-23 mois
MDG,Madagascar,AFRO,2023,MEASLES,Measles vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M15-M23,0-23 mois
MDG,Madagascar,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,B,0-11 mois
MDG,Madagascar,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,W6,0-11 mois
MDG,Madagascar,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_ADO_W,General/routine,NATIONAL,W10,0-11 mois
MDG,Madagascar,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_ADO_W,General/routine,NATIONAL,W14,0-11 mois
MDG,Madagascar,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,0-11 mois
MDG,Madagascar,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,0-11 mois
MDG,Madagascar,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,0-11 mois
MDG,Madagascar,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,0-11 mois
MDG,Madagascar,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,0-11 mois
MDG,Madagascar,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes
MDV,Maldives,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,All infants
MDV,Maldives,SEARO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y2,Travellers to endemic countries
MDV,Maldives,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,All children aged 4 years
MDV,Maldives,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,All infants
MDV,Maldives,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,All infants
MDV,Maldives,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,All infants
MDV,Maldives,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,All newborns
MDV,Maldives,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Females aged 10 years
MDV,Maldives,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females aged 10 years
MDV,Maldives,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
MDV,Maldives,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
MDV,Maldives,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
MDV,Maldives,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, other groups"
MDV,Maldives,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,+M6,"Adults with chronic conditions, other groups"
MDV,Maldives,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,+M6,"Adults with chronic conditions, other groups"
MDV,Maldives,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Children with chronic conditions
MDV,Maldives,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M6,All infants
MDV,Maldives,SEARO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y2,All travellers to Haj and Umrah and as per country travel requirements
MDV,Maldives,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,All children aged 18 months; MR is given as MCV1 at 9 months of age and MMR is given as MCV2 at 18 months of age
MDV,Maldives,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,All infants; MR is given as MCV1 at 9 months of age and MMR is given as MCV2 at 18 months of age
MDV,Maldives,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,M2,All infants
MDV,Maldives,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M4,All infants
MDV,Maldives,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M6,All infants
MDV,Maldives,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>M9,1. For pilgrims travelling to Haj and Umrah and 2. Travellers to Polio endemic countries
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y2,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y2,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,>Y15 CBAW
MDV,Maldives,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>Y15,>Y15 CBAW
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M9,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M18,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M24,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,4.0,ADULTS,General/routine,NATIONAL,M30,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,5.0,ADULTS,General/routine,NATIONAL,M36,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,VITAMINA,Vitamin A supplements,6.0,ADULTS,General/routine,NATIONAL,M42,Every 6 months till 5 years aged to all children
MDV,Maldives,SEARO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>M9,All travellers to endemic countries
MEX,Mexico,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,< 15 años de edad.
MEX,Mexico,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,< 5 años de edad.
MEX,Mexico,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,< 5 años de edad.
MEX,Mexico,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,< 5 años de edad.
MEX,Mexico,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,< 5 años de edad.
MEX,Mexico,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,< 7 años de edad.
MEX,Mexico,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y1,Niños de 1 año de edad inscritos en guarderias o estancias infantiles
MEX,Mexico,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,> de 20 años sin antecedente vacunal. La vacuna unicamente se coloca al personal de salud que no tenga esquema completo o no tenga antecedente vacunal
MEX,Mexico,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y20,> de 20 años sin antecedente vacunal. La vacuna unicamente se coloca al personal de salud que no tenga esquema completo o no tenga antecedente vacunal
MEX,Mexico,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Primeras 24 horas. 1-7 días de vida. La vacuna Hexavalente acelular (DTaPHibHepBI PV) se aplica de forma universal en todas las instituciones del Sector Salud del país. Debido a que aún se contaba con vacuna pentavalente acelular (DTaPHibIPV) en el 2021, se indicó aplicarla en conjunto con una dosis de Hepatitis B, para su equivalencia con la vacuna Hexavalente."
MEX,Mexico,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y13,"Para la campaña de recuperación de coberturas 2023 se consideró como población blanco a: Niñas y/o adolescentes de quinto año de primaria o de 11 años no escolarizadas. Niñas y/o adolescentes de sexto año de primaria o de 12 años no escolarizadas, Niñas y/o adolescentes de 1 de secundaria o de 13 años no escolarizadas."
MEX,Mexico,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y49,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
MEX,Mexico,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
MEX,Mexico,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, other groups"
MEX,Mexico,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M35,"Adults with chronic conditions, other groups"
MEX,Mexico,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M36-M59,"Adults with chronic conditions, other groups"
MEX,Mexico,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M36-M59,Children with chronic conditions
MEX,Mexico,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Hasta el año 2027, para niñas y niños que cumplan 6 años de edad, el esquema de vacunación será: 1a dosis a los 12 meses de edad y la 2a dosis a los 6 años de edad. Para las cohortes de nacimiento a partir del año 2022, el esquema de vacunación será el siguiente: 1a dosis a los 12 meses de edad y 2a dosis a los 18 meses de edad"
MEX,Mexico,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18-Y6,"Hasta el año 2027, para niñas y niños que cumplan 6 años de edad, el esquema de vacunación será: 1a dosis a los 12 meses de edad y la 2a dosis a los 6 años de edad. Para las cohortes de nacimiento a partir del año 2022, el esquema de vacunación será el siguiente: 1a dosis a los 12 meses de edad y 2a dosis a los 18 meses de edad"
MEX,Mexico,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y10,"10 años y más sin antecedente vacunal (Se administra de forma general a toda la población mayor de 10 años sin antecedente vacunal, lo cual incluye al personal de salud)."
MEX,Mexico,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,Personas de 60 y más años sin factores de riesgo recibirán dosis única con esta vacuna. Personas de 60 y más años con factores de riesgo recibirán una dosis con esta vacuna y al año de aplicación recibirán una dosis de refuerzo con vacuna Neumocócica polisacárida 23 valente
MEX,Mexico,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"En personas < 5 años de edad  se aplicarán 3 dosis, con edades óptimas de aplicación: 1a dosis a los 2 meses de edad, 2a dosis a los 4 meses de edad, y 3a dosis al cumplir 1 año de edad."
MEX,Mexico,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,"En personas < 5 años de edad  se aplicarán 3 dosis, con edades óptimas de aplicación: 1a dosis a los 2 meses de edad, 2a dosis a los 4 meses de edad, y 3a dosis al cumplir 1 año de edad."
MEX,Mexico,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"En personas < 5 años de edad  se aplicarán 3 dosis, con edades óptimas de aplicación: 1a dosis a los 2 meses de edad, 2a dosis a los 4 meses de edad, y 3a dosis al cumplir 1 año de edad."
MEX,Mexico,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y61,Personas de 61 años y más con factores de riesgo (12 meses después de haber recibido la vacuna antineumocócica conugada)
MEX,Mexico,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,< 8 meses de edad.
MEX,Mexico,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,< 8 meses de edad.
MEX,Mexico,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,"En población con  esquema primario completo, se vacuna con Td a población de primer año de educación secundaria y de 15 años no escolarizados , con refuerzo cada 10 años"
MEX,Mexico,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,>=Y15,"En población con  esquema primario completo, se vacuna con Td a población de primer año de educación secundaria y de 15 años no escolarizados , con refuerzo cada 10 años"
MEX,Mexico,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,>=Y10,10 años y mas sin antecedente vacunal o con esquema incompleto.
MEX,Mexico,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,>=Y10,Para iniciar o completar esquemas en personas embarazadas - A partir de la semana 20 de Gestación.
MEX,Mexico,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y1,Niños inscritos en estancias infantiles
MEX,Mexico,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M11,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MEX,Mexico,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M12-M59,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M12,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M2,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M12,6 a 59 meses de edad en algunas Jornadas Nacionales de Salud Pública
MHL,Marshall Islands,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,females
MHL,Marshall Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,females
MHL,Marshall Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M4,females
MHL,Marshall Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M6,females
MHL,Marshall Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,FEMALE,General/routine,NATIONAL,Y4-Y6,females
MHL,Marshall Islands,WPRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,FEMALE,General/routine,NATIONAL,Y11-Y12,adolescents in school
MHL,Marshall Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M12,adolescents in school
MHL,Marshall Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,M13,adolescents in school
MHL,Marshall Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,adolescents in school
MHL,Marshall Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,adolescents in school
MHL,Marshall Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M6,adolescents in school
MHL,Marshall Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,FEMALE,General/routine,NATIONAL,M12,adolescents in school
MHL,Marshall Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,children up to 59 months
MHL,Marshall Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,children up to 59 months
MHL,Marshall Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M6,children up to 59 months
MHL,Marshall Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,4.0,FEMALE,General/routine,NATIONAL,M12,children up to 59 months
MHL,Marshall Islands,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,children up to 59 months
MHL,Marshall Islands,WPRO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,children up to 59 months
MHL,Marshall Islands,WPRO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,children up to 59 months
MHL,Marshall Islands,WPRO,2023,VARICELLA,Varicella vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M6,children up to 59 months
MHL,Marshall Islands,WPRO,2023,VARICELLA,Varicella vaccine,4.0,B_ADO_W,General/routine,NATIONAL,M12,children up to 59 months
MKD,North Macedonia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,children up to 59 months
MKD,North Macedonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,children up to 59 months
MKD,North Macedonia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M6,children up to 59 months
MKD,North Macedonia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,children up to 59 months
MKD,North Macedonia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,children up to 59 months
MKD,North Macedonia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,children up to 59 months
MKD,North Macedonia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,children up to 59 months
MKD,North Macedonia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,Females only
MKD,North Macedonia,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females only
MKD,North Macedonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >65 years
MKD,North Macedonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
MKD,North Macedonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,Pregnant women
MKD,North Macedonia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents living in long-term care facilities"
MKD,North Macedonia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities"
MKD,North Macedonia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
MKD,North Macedonia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
MKD,North Macedonia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
MKD,North Macedonia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
MKD,North Macedonia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
MKD,North Macedonia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
MKD,North Macedonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
MKD,North Macedonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
MKD,North Macedonia,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
MKD,North Macedonia,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,Children with chronic conditions
MKD,North Macedonia,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y18,"This is the last (7th dose) of Tetanus toxoid vaccine, according to Immunization Schedule for all children from 0-18 years of age"
MLI,Mali,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,naissances vivantes
MLI,Mali,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,enfants ayant survécus
MLI,Mali,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,enfants ayant survécus
MLI,Mali,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,enfants ayant survécus
MLI,Mali,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W14,enfants ayant survécus
MLI,Mali,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M9,enfants ayant survécus
MLI,Mali,AFRO,2023,MEASLES,Measles vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,enfants ayant survécus
MLI,Mali,AFRO,2023,MEASLES,Measles vaccine,2.0,ADULTS,General/routine,NATIONAL,M12-M23,enfants ayant survécus
MLI,Mali,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,enfants ayant survécus
MLI,Mali,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,B,"naissances vivantes, enfants ayant survécus"
MLI,Mali,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W6,"naissances vivantes, enfants ayant survécus"
MLI,Mali,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W10,"naissances vivantes, enfants ayant survécus"
MLI,Mali,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,W14,"naissances vivantes, enfants ayant survécus"
MLI,Mali,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,enfants ayant survécus
MLI,Mali,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,enfants ayant survécus
MLI,Mali,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,enfants ayant survécus
MLI,Mali,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,enfants ayant survécus
MLI,Mali,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,enfants ayant survécus
MLI,Mali,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,enfants ayant survécus
MLI,Mali,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,enfants ayant survécus
MLI,Mali,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,Y1,enfants ayant survécus
MLI,Mali,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,enfants ayant survécus
MLT,Malta,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W4,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,W8,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y13-Y14,"As July 2023, we started a catch up campaign vaccinating all boys aged 13-14. These children wouldneed only 2 doses 6 months apart. a concomittant opportunistic campaign vaccinating boys 15 to 23 (boys born as of the year 2000 and being 12 years and over) when they present for other vaccines like travel vaccines or the DTP and Men ACWY vaccines."
MLT,Malta,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
MLT,Malta,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
MLT,Malta,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,Females and males
MLT,Malta,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
MLT,Malta,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
MLT,Malta,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
MLT,Malta,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M59,"Adults with chronic conditions, residents living in long-term care facilities"
MLT,Malta,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5-Y16,"Adults with chronic conditions, residents living in long-term care facilities"
MLT,Malta,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y16,Children with chronic diseases
MLT,Malta,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,All children born from 2020 onwards
MLT,Malta,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M13,All children born from 2020 onwards
MLT,Malta,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y14,All children born from 2020 onwards
MLT,Malta,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,All children born from 2020 onwards
MLT,Malta,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,All children born from 2020 onwards
MLT,Malta,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,All children born from 2020 onwards
MLT,Malta,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13,All children born from 2020 onwards
MLT,Malta,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y3-Y4,All children born from 2020 onwards
MLT,Malta,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,All children born in 2016 onwards and aged less than 5 years old
MLT,Malta,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,All children born in 2016 onwards and aged less than 5 years old
MLT,Malta,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,All children born in 2016 onwards and aged less than 5 years old
MLT,Malta,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y14,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B-M2,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M6,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,All children born in 2016 onwards and aged less than 5 years old
MMR,Myanmar,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9-10 years old girls
MMR,Myanmar,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,9-10 years old girls
MMR,Myanmar,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9-10 years old girls
MMR,Myanmar,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9-10 years old girls
MMR,Myanmar,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,9-10 years old girls
MMR,Myanmar,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,9-10 years old girls
MMR,Myanmar,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M4,9-10 years old girls
MMR,Myanmar,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M6,9-10 years old girls
MMR,Myanmar,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,9-10 years old girls
MMR,Myanmar,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,9-10 years old girls
MMR,Myanmar,SEARO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M6,9-10 years old girls
MMR,Myanmar,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,9-10 years old girls
MMR,Myanmar,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,9-10 years old girls
MMR,Myanmar,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MMR,Myanmar,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MMR,Myanmar,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M59,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MNE,Montenegro,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MNE,Montenegro,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y6,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,W9,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,W17,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W23,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,occasional birth dose for babies born by HBsAg+ mothers
MNE,Montenegro,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W5,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,W9,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M13,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,"HPV vaccination program in Montenegro started September, 26th 2022 in the primary group of girls of 9 y.o. (birth cohort 2013). Since March, 1st 2023 we started vaccination in all girls 9-14 y.o. and we decided to switch to one dose schedule (one dose for 9-20 y.o; two doses for 21-26 y.o; two doses for immunosuppressed people)."
MNE,Montenegro,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y14,one dose for 9-20 y.o; two doses for 21-26 y.o; two doses for immunosuppressed people
MNE,Montenegro,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y14,one dose for 9-20 y.o; two doses for 21-26 y.o; two doses for immunosuppressed people
MNE,Montenegro,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
MNE,Montenegro,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
MNE,Montenegro,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
MNE,Montenegro,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MNE,Montenegro,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MNE,Montenegro,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
MNE,Montenegro,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13,Children with chronic conditions
MNE,Montenegro,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
MNE,Montenegro,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y18,Children with chronic conditions
MNE,Montenegro,EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,Children with chronic conditions
MNG,Mongolia,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Children with chronic conditions
MNG,Mongolia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,Children with chronic conditions
MNG,Mongolia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M3,Children with chronic conditions
MNG,Mongolia,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M4,Children with chronic conditions
MNG,Mongolia,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M14,Children with chronic conditions
MNG,Mongolia,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y2,Children with chronic conditions
MNG,Mongolia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,Epidemiologically linked cases and for voluntary individuals
MNG,Mongolia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Epidemiologically linked cases and for voluntary individuals
MNG,Mongolia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,B,Health and care workers
MNG,Mongolia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,B,Pregnant women
MNG,Mongolia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Adults with chronic conditions, other groups"
MNG,Mongolia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y5,"Adults with chronic conditions, other groups"
MNG,Mongolia,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M5,"Adults with chronic conditions, other groups"
MNG,Mongolia,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M5,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M9,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y2,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M3,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M4,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M9,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y7,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y15,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,B_ADO_W,General/routine,NATIONAL,M6-M59,Epidemiologically linked cases and for valuntary individuals
MNG,Mongolia,WPRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M59,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y19,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,ADULTS,General/routine,NATIONAL,M12,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,ADULTS,General/routine,NATIONAL,+M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,ADULTS,General/routine,NATIONAL,W6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,ADULTS,General/routine,NATIONAL,M15-M18,Epidemiologically linked cases and for valuntary individuals
MNP,Northern Mariana Islands,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"Both Male and Females are offered HPV  at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months."
MNP,Northern Mariana Islands,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Both Male and Females are offered HPV  at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months."
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, other groups"
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, other groups"
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, other groups"
MNP,Northern Mariana Islands,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y11,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y16,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15-M18,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y7-Y18,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M12,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
MNP,Northern Mariana Islands,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y50-Y85,Children with chronic conditions
MOZ,Mozambique,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Live Birth
MOZ,Mozambique,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Children less than 1 year
MOZ,Mozambique,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,M3,Children less than 1 year
MOZ,Mozambique,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,M4,Children less than 1 year
MOZ,Mozambique,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females 9
MOZ,Mozambique,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females 9
MOZ,Mozambique,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,Children less than 1 year
MOZ,Mozambique,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,Children less than 1 year
MOZ,Mozambique,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,Children less than 24 months
MOZ,Mozambique,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,Children less than 24 months
MOZ,Mozambique,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,Children less than 1 year
MOZ,Mozambique,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M2,Children less than 1 year
MOZ,Mozambique,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,M3,Children less than 1 year
MOZ,Mozambique,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M4,Children less than 1 year
MOZ,Mozambique,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,Children less than 1 year
MOZ,Mozambique,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M4,Children less than 1 year
MOZ,Mozambique,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M9,Children less than 1 year
MOZ,Mozambique,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M2,Children less than 1 year
MOZ,Mozambique,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M3,Children less than 1 year
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,school age
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,+M1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y15-Y49,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_F,General/routine,NATIONAL,Y7,school age
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,B_ADO_F,General/routine,NATIONAL,M6,Children between 6 and 59 months
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,B_ADO_F,General/routine,NATIONAL,M12,Children between 6 and 59 months
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,B_ADO_F,General/routine,NATIONAL,M18,Children between 6 and 59 months
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,B_ADO_F,General/routine,NATIONAL,M24,Children between 6 and 59 months
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,B_ADO_F,General/routine,NATIONAL,M30,Children between 6 and 59 months
MOZ,Mozambique,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,B_ADO_F,General/routine,NATIONAL,M36,Children between 6 and 59 months
MRT,Mauritania,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,B,naissances vivantes
MRT,Mauritania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,W6,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_F,General/routine,NATIONAL,W10,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_F,General/routine,NATIONAL,W14,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_ADO_F,General/routine,NATIONAL,B,naissances vivantes
MRT,Mauritania,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,fils âgé de 9 ans
MRT,Mauritania,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,fils âgé de 9 ans
MRT,Mauritania,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,enfants de moins d'un an
MRT,Mauritania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
MRT,Mauritania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
MRT,Mauritania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
MRT,Mauritania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
MRT,Mauritania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
MSR,Montserrat,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,M2,M0-11
MSR,Montserrat,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4.5,Y4 1/2 -5
MSR,Montserrat,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,Y4 1/2 -5
MSR,Montserrat,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,M0-11
MSR,Montserrat,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,M0-11
MSR,Montserrat,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,M0-11
MSR,Montserrat,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,given to at risk person if not previously vaccinated
MSR,Montserrat,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Newborns
MSR,Montserrat,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y13,females
MSR,Montserrat,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,females
MSR,Montserrat,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
MSR,Montserrat,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
MSR,Montserrat,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,ADULTS,Adults,NATIONAL,Y25-Y35,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M12,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,General/routine,NATIONAL,M18,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M6,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,M18,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,ADULTS,General/routine,NATIONAL,Y4.5,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,OPV,OPV (Oral polio vaccine),6.0,ADULTS,General/routine,NATIONAL,Y14.5,"Adults with chronic conditions, residents living in long-term care facilities"
MSR,Montserrat,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,M0-11
MSR,Montserrat,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,M0-11
MSR,Montserrat,AMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,M0-11
MSR,Montserrat,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,M0-11
MSR,Montserrat,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,travellers to endemic countries
MUS,Mauritius,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M1,travellers to endemic countries
MUS,Mauritius,AFRO,2023,DTWPHIBHEPBIPV,DTwP-Hib-HepB-IPV (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,travellers to endemic countries
MUS,Mauritius,AFRO,2023,DTWPHIBHEPBIPV,DTwP-Hib-HepB-IPV (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,travellers to endemic countries
MUS,Mauritius,AFRO,2023,DTWPHIBHEPBIPV,DTwP-Hib-HepB-IPV (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,travellers to endemic countries
MUS,Mauritius,AFRO,2023,DTWPHIBHEPBIPV,DTwP-Hib-HepB-IPV (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers to endemic countries
MUS,Mauritius,AFRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M18,Persons travelling abroad
MUS,Mauritius,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M18,Health workers
MUS,Mauritius,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Workers at risk, dialysis patients"
MUS,Mauritius,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,females aged 9 years old
MUS,Mauritius,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females aged 9 years old
MUS,Mauritius,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,females aged 9 years old
MUS,Mauritius,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
MUS,Mauritius,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
MUS,Mauritius,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
MUS,Mauritius,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions
MUS,Mauritius,AFRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y60,Persons travelling abroad
MUS,Mauritius,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M9,Persons travelling abroad
MUS,Mauritius,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M17,Persons travelling abroad
MUS,Mauritius,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Persons travelling abroad
MUS,Mauritius,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W14,Persons travelling abroad
MUS,Mauritius,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M10,Persons travelling abroad
MUS,Mauritius,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Persons travelling abroad
MUS,Mauritius,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Persons travelling abroad
MUS,Mauritius,AFRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,Primary school leavers
MUS,Mauritius,AFRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11,Pregnant women
MUS,Mauritius,AFRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Pregnant women
MUS,Mauritius,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Injured persons
MUS,Mauritius,AFRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y5,Persons travelling abroad
MUS,Mauritius,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y5,Persons travelling abroad
MWI,Malawi,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Persons travelling abroad
MWI,Malawi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Persons travelling abroad
MWI,Malawi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Persons travelling abroad
MWI,Malawi,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Persons travelling abroad
MWI,Malawi,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,from January 2019; females
MWI,Malawi,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+Y1,from January 2019; females
MWI,Malawi,AFRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,from January 2019; females
MWI,Malawi,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,from January 2019; females
MWI,Malawi,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,from January 2019; females
MWI,Malawi,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,from January 2019; females
MWI,Malawi,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,from January 2019; females
MWI,Malawi,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,from January 2019; females
MWI,Malawi,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,from January 2019; females
MWI,Malawi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,from January 2019; females
MWI,Malawi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,from January 2019; females
MWI,Malawi,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,from January 2019; females
MWI,Malawi,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,from January 2019; females
MWI,Malawi,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,from January 2019; females
MWI,Malawi,AFRO,2023,RTS_S,Malaria vaccine,1.0,FEMALE,General/routine,SUBNATIONAL,M5,from April 2019 - children under 2 years
MWI,Malawi,AFRO,2023,RTS_S,Malaria vaccine,2.0,FEMALE,General/routine,SUBNATIONAL,M6,from April 2019 - children under 2 years
MWI,Malawi,AFRO,2023,RTS_S,Malaria vaccine,3.0,FEMALE,General/routine,SUBNATIONAL,M7,from April 2019 - children under 2 years
MWI,Malawi,AFRO,2023,RTS_S,Malaria vaccine,4.0,FEMALE,General/routine,SUBNATIONAL,M22,from April 2019 - children under 2 years
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 months
MWI,Malawi,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,postnatal mothers
MYS,Malaysia,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,postnatal mothers
MYS,Malaysia,WPRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,postnatal mothers
MYS,Malaysia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,From November 2020 onwards
MYS,Malaysia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M3,From November 2020 onwards
MYS,Malaysia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M5,From November 2020 onwards
MYS,Malaysia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,From November 2020 onwards
MYS,Malaysia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCWs
MYS,Malaysia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,HCWs
MYS,Malaysia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,HCWs
MYS,Malaysia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,"Until November 2020. From November 2020 onwards, only Hep B borth dose given. Subsequent doses given as hexavalent vaccine"
MYS,Malaysia,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,Given to female students only as part of School Health programme
MYS,Malaysia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,"and older persons >=60 years (recommended but not as part of the national immunization programme, purchase on own from private sectors)"
MYS,Malaysia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers (National program for Ministry of Health frontliners)
MYS,Malaysia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,"Pregnant women (recommended but not as part of the national immunization programme, purchase on own from private sectors)"
MYS,Malaysia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term (recommended but not as part of the national immunization programme, purchase on own from private sectors)"
MYS,Malaysia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Recommended but not as part of the national immunization programme, purchase on own from private sectors"
MYS,Malaysia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,"Children with chronic conditions (recommended but not as part of the national immunization programme, purchase on own from private sectors)"
MYS,Malaysia,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M9,Sarawak state only
MYS,Malaysia,WPRO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M21,Sarawak state only
MYS,Malaysia,WPRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M6,Sabah state only
MYS,Malaysia,WPRO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Hajj pilgrims only
MYS,Malaysia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M9,children born July 2015 onwards
MYS,Malaysia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M12,children born July 2015 onwards
MYS,Malaysia,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,M12,From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards
MYS,Malaysia,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,M6,From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards
MYS,Malaysia,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,M15,From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards
MYS,Malaysia,WPRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,M4,From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards
MYS,Malaysia,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,CATCHUP_C,General/routine,NATIONAL,Y15,From 1 December 2020 onwards with catch-up vaccination for children born from 1 January 2020 onwards
MYS,Malaysia,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,Y15,Pregnant women (2nd and 3rd trimester)
MYS,Malaysia,WPRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
MYS,Malaysia,WPRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y3,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y5,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,B_CHILD_W,General/routine,NATIONAL,Y10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,W14,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,M9,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M9,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M15,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,B,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,W6,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_CHILD_W,General/routine,NATIONAL,W10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_CHILD_W,General/routine,NATIONAL,W14,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,B_CHILD_W,General/routine,NATIONAL,Y5,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,OPV,OPV (Oral polio vaccine),6.0,B_CHILD_W,General/routine,NATIONAL,Y10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,CBAW
NAM,Namibia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15-Y49,CBAW
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,<Y5
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,<Y5
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M18,<Y5
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,ADULTS,General/routine,NATIONAL,M24,<Y5
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,ADULTS,General/routine,NATIONAL,M30,<Y5
NAM,Namibia,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,ADULTS,General/routine,NATIONAL,M36,<Y5
NCL,New Caledonia,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,<Y5
NCL,New Caledonia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,<Y5
NCL,New Caledonia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,ADULTS,General/routine,NATIONAL,M11,<Y5
NCL,New Caledonia,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,<Y5
NCL,New Caledonia,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,<Y5
NCL,New Caledonia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,<Y5
NCL,New Caledonia,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y14,"filles et rattrapage pour les filles de 14 ans; Elargissement aux garçons à partir de novembre 2022, et avancement de l'âge à 9 ans. Cependant, les campagnes scolairee de vaccination se font à l'âge de 11 ans."
NCL,New Caledonia,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"filles et rattrapage pour les filles de 14 ans; Elargissement aux garçons à partir de novembre 2022, et avancement de l'âge à 9 ans. Cependant, les campagnes scolairee de vaccination se font à l'âge de 11 ans."
NCL,New Caledonia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >=65 years
NCL,New Caledonia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
NCL,New Caledonia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,Pregnant women
NCL,New Caledonia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
NCL,New Caledonia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
NCL,New Caledonia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M16,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",6.0,ADULTS,Adults,NATIONAL,Y25,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",1.0,ADULTS,Adults,NATIONAL,Y45,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",2.0,ADULTS,Adults,NATIONAL,Y65,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",3.0,ADULTS,Adults,NATIONAL,Y75,Children with chronic conditions
NCL,New Caledonia,WPRO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",4.0,ADULTS,Adults,NATIONAL,Y85,Children with chronic conditions
NER,Niger,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,0-11 mois
NER,Niger,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
NER,Niger,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
NER,Niger,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
NER,Niger,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
NER,Niger,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M9,0-11 mois
NER,Niger,AFRO,2023,MEASLES,Measles vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,9-23 mois
NER,Niger,AFRO,2023,MEASLES,Measles vaccine,2.0,ADULTS,General/routine,NATIONAL,M16,9-23 mois
NER,Niger,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,0-11 mois
NER,Niger,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,B,0-11 mois
NER,Niger,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
NER,Niger,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
NER,Niger,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
NER,Niger,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
NER,Niger,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
NER,Niger,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
NER,Niger,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
NER,Niger,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
NER,Niger,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,0-23 mois
NER,Niger,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,0-23 mois
NER,Niger,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,0-23 mois
NER,Niger,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M23,0-23 mois
NER,Niger,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
NGA,Nigeria,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Live Births
NGA,Nigeria,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,surviving infants
NGA,Nigeria,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,surviving infants
NGA,Nigeria,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,surviving infants
NGA,Nigeria,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,Live Births
NGA,Nigeria,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y9,9 years
NGA,Nigeria,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
NGA,Nigeria,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
NGA,Nigeria,AFRO,2023,MEASLES,Measles vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,surviving infants
NGA,Nigeria,AFRO,2023,MEASLES,Measles vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,surviving infants
NGA,Nigeria,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,Surviving infants
NGA,Nigeria,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,Surviving infants
NGA,Nigeria,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,Surviving infants
NGA,Nigeria,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,Surviving infants
NGA,Nigeria,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,Surviving infants
NGA,Nigeria,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
NGA,Nigeria,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,surviving infants
NGA,Nigeria,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
NGA,Nigeria,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
NGA,Nigeria,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,surviving infants
NGA,Nigeria,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
NGA,Nigeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
NGA,Nigeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
NGA,Nigeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
NGA,Nigeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
NGA,Nigeria,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
NGA,Nigeria,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-23 months
NGA,Nigeria,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-23 months
NGA,Nigeria,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,surviving infants
NIC,Nicaragua,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,surviving infants
NIC,Nicaragua,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Grupo de 18 meses y el de 6 años
NIC,Nicaragua,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Grupo de 18 meses y el de 6 años
NIC,Nicaragua,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Menor de 1 año
NIC,Nicaragua,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Menor de 1 año
NIC,Nicaragua,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Menor de 1 año
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"10 años sexo femenino. Durante el primer año de introducción también se vacuna con dos dosis a niñas de 11,12,13 y 14 años"
NIC,Nicaragua,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"10 años sexo femenino. Durante el primer año de introducción también se vacuna con dos dosis a niñas de 11,12,13 y 14 años"
NIC,Nicaragua,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
NIC,Nicaragua,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
NIC,Nicaragua,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Adults with chronic conditions
NIC,Nicaragua,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Children with chronic conditions
NIC,Nicaragua,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 1 año
NIC,Nicaragua,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 1 año
NIC,Nicaragua,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Grupo de 1 año
NIC,Nicaragua,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Grupo de 1 año
NIC,Nicaragua,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,HW,Health workers,NATIONAL,M18,"Grupos de Riesgo: trabajadores de la salud, adultos y trabajadores de embarcaciones, sin documentación de su historia y es un requisito, se le aplica esta vacuna. Vacunacion adultos en un brote."
NIC,Nicaragua,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y13,"Grupos de Riesgo: trabajadores de la salud, adultos y trabajadores de embarcaciones, sin documentación de su historia y es un requisito, se le aplica esta vacuna. Vacunacion adultos en un brote."
NIC,Nicaragua,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menor de 1 año y de 1 año
NIC,Nicaragua,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Menor de 1 año y de 1 año
NIC,Nicaragua,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menores de 1 año
NIC,Nicaragua,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menores de 1 año
NIC,Nicaragua,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Menores de 1 año
NIC,Nicaragua,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y50,Cohorte de 50 años y algunos pacientes adultos con esplenectomia
NIC,Nicaragua,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Menor de 1 año
NIC,Nicaragua,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Menor de 1 año
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y20,Grupo de 10 y 20 años
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Grupo de 10 y 20 años
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Embarazadas - 1 dosis en el primer embarazo
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9-Y59,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIC,Nicaragua,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M9-Y59,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M3,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M5,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,TRAVELLERS,General/routine,NATIONAL,M15,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,females and males; x2 doses administered to all persons <=14 years (2nd dose administered +6 months after the 1st dose)
NIU,Niue,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,females and males; x2 doses administered to all persons <=14 years (2nd dose administered +6 months after the 1st dose)
NIU,Niue,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
NIU,Niue,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
NIU,Niue,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
NIU,Niue,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
NIU,Niue,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Children with chronic conditions
NIU,Niue,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
NIU,Niue,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4,Children with chronic conditions
NIU,Niue,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
NIU,Niue,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
NIU,Niue,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
NIU,Niue,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
NIU,Niue,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
NIU,Niue,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
NIU,Niue,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y45,Children with chronic conditions
NIU,Niue,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,Children with chronic conditions
NIU,Niue,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11,Children with chronic conditions
NIU,Niue,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11,Pregnancy
NIU,Niue,WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",4.0,B_CHILD_W,General/routine,NATIONAL,Y4,Pregnancy
NIU,Niue,WPRO,2023,VARICELLA,Varicella vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M15,Pregnancy
NLD,Netherlands (Kingdom of the),EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M3,Pregnancy
NLD,Netherlands (Kingdom of the),EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M5,Pregnancy
NLD,Netherlands (Kingdom of the),EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M11,Pregnancy
NLD,Netherlands (Kingdom of the),EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Additional vaccination at M2 when mother is not vaccinated against pertussis during pregnancy and in some other special situaions
NLD,Netherlands (Kingdom of the),EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,Additional vaccination at M2 when mother is not vaccinated against pertussis during pregnancy and in some other special situaions
NLD,Netherlands (Kingdom of the),EURO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,MSM and sex workers
NLD,Netherlands (Kingdom of the),EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Immigrants from endemic countries
NLD,Netherlands (Kingdom of the),EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<D2,<H48; children of carrier mothers
NLD,Netherlands (Kingdom of the),EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,Females and males
NLD,Netherlands (Kingdom of the),EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
NLD,Netherlands (Kingdom of the),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Females and males
NLD,Netherlands (Kingdom of the),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
NLD,Netherlands (Kingdom of the),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
NLD,Netherlands (Kingdom of the),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
NLD,Netherlands (Kingdom of the),EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M14,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y14,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M14,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y9,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,Children with chronic conditions
NLD,Netherlands (Kingdom of the),EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,M11,"In 2023, this was administered to people born between 1 January 1953 and 31 December 1956"
NLD,Netherlands (Kingdom of the),EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,M11,"Pregnant women, >W22 of pregnancy"
NLD,Netherlands (Kingdom of the),EURO,2023,TDIPV_S,"Td-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y9,"Pregnant women, >W22 of pregnancy"
NOR,Norway,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Defined risk groups
NOR,Norway,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Defined risk groups
NOR,Norway,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Defined risk groups
NOR,Norway,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Defined risk groups
NOR,Norway,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Defined risk groups (premature born)
NOR,Norway,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y7,Defined risk groups (premature born)
NOR,Norway,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Defined risk groups
NOR,Norway,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Defined risk groups
NOR,Norway,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Defined risk groups
NOR,Norway,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M5,Defined risk groups
NOR,Norway,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Defined risk groups
NOR,Norway,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
NOR,Norway,EURO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
NOR,Norway,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Females and males
NOR,Norway,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
NOR,Norway,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
NOR,Norway,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
NOR,Norway,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
NOR,Norway,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
NOR,Norway,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y11,Children with chronic conditions
NOR,Norway,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
NOR,Norway,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
NOR,Norway,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
NOR,Norway,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
NOR,Norway,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
NOR,Norway,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y15,Children with chronic conditions
NPL,Nepal,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,<1 year
NPL,Nepal,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,<1 year
NPL,Nepal,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,<1 year
NPL,Nepal,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,<1 year
NPL,Nepal,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,B_ADO_W,General/routine,NATIONAL,W14,<1 year
NPL,Nepal,SEARO,2023,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),2.0,B_ADO_W,General/routine,NATIONAL,M9,<1 year
NPL,Nepal,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M12,12-23 months
NPL,Nepal,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M9,<1 year and 12-23 months
NPL,Nepal,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M15,<1 year and 12-23 months
NPL,Nepal,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,W6,<1 year
NPL,Nepal,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,W10,<1 year
NPL,Nepal,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,B_ADO_W,General/routine,NATIONAL,W14,<1 year
NPL,Nepal,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,<1 year
NPL,Nepal,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,<1 year
NPL,Nepal,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M9,<1 year
NPL,Nepal,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,<1 year
NPL,Nepal,SEARO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,<1 year
NPL,Nepal,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women; at first visit during first pregnancy, 1 month interval after first dose, 1 dose each in subsequent pregnancy"
NPL,Nepal,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women; at first visit during first pregnancy, 1 month interval after first dose, 1 dose each in subsequent pregnancy"
NPL,Nepal,SEARO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,PW,General/routine,NATIONAL,M15,15-23 months
NPL,Nepal,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M59,M6-<Y5
NPL,Nepal,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,+M6,M6-<Y5
NRU,Nauru,WPRO,2021,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,M6-<Y5
NRU,Nauru,WPRO,2021,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,M6-<Y5
NRU,Nauru,WPRO,2021,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,M6-<Y5
NRU,Nauru,WPRO,2021,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,M6-<Y5
NRU,Nauru,WPRO,2021,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,M6-<Y5
NRU,Nauru,WPRO,2021,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,M6-<Y5
NRU,Nauru,WPRO,2021,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,M6-<Y5
NRU,Nauru,WPRO,2021,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y14,M6-<Y5
NRU,Nauru,WPRO,2021,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11-Y14,M6-<Y5
NRU,Nauru,WPRO,2021,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,M6-<Y5
NRU,Nauru,WPRO,2021,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,M6-<Y5
NRU,Nauru,WPRO,2021,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,M6-<Y5
NRU,Nauru,WPRO,2021,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,M6-<Y5
NRU,Nauru,WPRO,2021,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,M6-<Y5
NRU,Nauru,WPRO,2021,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,M6-<Y5
NRU,Nauru,WPRO,2021,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,M6-<Y5
NRU,Nauru,WPRO,2021,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,M6-<Y5
NRU,Nauru,WPRO,2021,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,M6-<Y5
NRU,Nauru,WPRO,2021,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,M6-<Y5
NRU,Nauru,WPRO,2021,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W14,M6-<Y5
NRU,Nauru,WPRO,2021,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,W14,Pregnant women: 1st dose in 1st trimester and 2nd dose in 2nd trimester
NRU,Nauru,WPRO,2021,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,W14,Pregnant women: 1st dose in 1st trimester and 2nd dose in 2nd trimester
NZL,New Zealand,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,At-risk neonates
NZL,New Zealand,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,At-risk neonates
NZL,New Zealand,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,At-risk neonates
NZL,New Zealand,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,At-risk neonates
NZL,New Zealand,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,"Revaccination for children aged <10y post HSCT or chemotherapy, pre- or post- splenectomy, pre- or post solid organ transplant, dialysis, or other severely immunosuppressive regimens"
NZL,New Zealand,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,"Revaccination for children aged <10y post HSCT or chemotherapy, pre- or post- splenectomy, pre- or post solid organ transplant, dialysis, or other severely immunosuppressive regimens"
NZL,New Zealand,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"for children who have previously had meningococcal disease of any group, patients pre- or post-splenectomy or with functional asplenia, HIV infection, complement deficiency, pre- or post-solid organ transplant or HSCT, following immunosuppression, and close contacts of meningococcal cases"
NZL,New Zealand,WPRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"transplant patients, close contacts of Hepatitis A cases"
NZL,New Zealand,WPRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"transplant patients, children with chronic liver disease, close contacts of Hepatitis A cases"
NZL,New Zealand,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"household/sexual contacts of HBsAg-positive, HIV-positive, Hepatitis C-positive, prior to or following solid organ transplant, post-HSCT, dialysis patients; prior to planned or"
NZL,New Zealand,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,infants born to mothers who are HBs-AG-positive; and other risk groups and children <18 years who require vaccination to achieve positive serology or to complete primary series of vaccination
NZL,New Zealand,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15,infants born to mothers who are HBs-AG-positive; and other risk groups and children <18 years who require vaccination to achieve positive serology or to complete primary series of vaccination
NZL,New Zealand,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y13,"females and males; x2 doses in school years 7 and 8, 3rd dose if started from Y15+. HPV immunisation is also funded in general practice for anyone aged 9 to 26 years"
NZL,New Zealand,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y13,"females and males; x2 doses in school years 7 and 8, 3rd dose if started from Y15+. HPV immunisation is also funded in general practice for anyone aged 9 to 26 years"
NZL,New Zealand,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y13,"partially vaccinated or previously unvaccinated individuals, or revaccination following immunosuppression"
NZL,New Zealand,WPRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y13,"patients pre- or post- splenectomy or with functional asplenia, HIV infection, complement deficiency, pre- or post- solid-organ transplant or HSCT, following immunosuppression, and close contacts of meningococcal cases, Y13-25 in close living situation"
NZL,New Zealand,WPRO,2023,MEN_B,Meningococcal B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y11-Y13,See https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Meningococcal+B+multicomponent+vaccine
NZL,New Zealand,WPRO,2023,MEN_B,Meningococcal B vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,Y11-Y13,See https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Meningococcal+B+multicomponent+vaccine
NZL,New Zealand,WPRO,2023,MEN_B,Meningococcal B vaccine,2.0,CATCHUP_C,General/routine,NATIONAL,Y11-Y13,See https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Meningococcal+B+multicomponent+vaccine
NZL,New Zealand,WPRO,2023,MEN_B,Meningococcal B vaccine,3.0,CATCHUP_C,General/routine,NATIONAL,Y11-Y13,See https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Meningococcal+B+multicomponent+vaccine
NZL,New Zealand,WPRO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y13,See https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Meningococcal+B+multicomponent+vaccine
NZL,New Zealand,WPRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y13,"patients pre- or post- splenectomy or with functional asplenia, HIV infection, complement deficiency, pre- or post- solid-organ transplant or HSCT, following immunosuppression, and close contacts of meningococcal cases"
NZL,New Zealand,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15,Changed from M15/Y4 in 2020
NZL,New Zealand,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Changed from M15/Y4 in 2020
NZL,New Zealand,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,adults susceptible to one of MMR; no documented measles lgG anitbody; revaccination after immunosuppression
NZL,New Zealand,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Replaced PCV10 from 1 November 2022
NZL,New Zealand,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Replaced PCV10 from 1 November 2022
NZL,New Zealand,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Replaced PCV10 from 1 November 2022
NZL,New Zealand,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"As part of the extended immunisation programme for high-risk groups, PCV13 and PPV23 are funded for eligible individuals, as shown in https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=pcv13"
NZL,New Zealand,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"As part of the extended immunisation programme for high-risk groups, PCV13 and PPV23 are funded for eligible individuals as shown in https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=ppv23"
NZL,New Zealand,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,"As part of the extended immunisation programme for high-risk groups, PCV13 and PPV23 are funded for eligible individuals as shown in https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=ppv23"
NZL,New Zealand,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,"As part of the extended immunisation programme for high-risk groups, PCV13 and PPV23 are funded for eligible individuals as shown in https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=ppv23"
NZL,New Zealand,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y65,"Y45 dose if for persons who have not had 4 previous tetanus vaccines, Y65 for all adults, and for pregnancy between 28 and 38 weeks' gestation"
NZL,New Zealand,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11-Y13,"Y45 dose if for persons who have not had 4 previous tetanus vaccines, Y65 for all adults, and for pregnancy between 28 and 38 weeks' gestation"
NZL,New Zealand,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11-Y13,Pregnancy between 28 and 38 weeks' gestation
NZL,New Zealand,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y45,"Y45 dose if for persons who have not had 4 previous tetanus vaccines, Y65 for all adults, and for pregnancy between 28 and 38 weeks' gestation"
NZL,New Zealand,WPRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"Excerpt from varicella criteria: Maximum of one dose for primary vaccination for either: a. Any infant born on or after 1 April 2016; or b. For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox)"
NZL,New Zealand,WPRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M15,certain high-risk groups
NZL,New Zealand,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"in December 2022, NZ changed from a one-dose live varicella-zoster virus vaccine, to a two-dose adjuvanted recombinant subunit zoster vaccine"
NZL,New Zealand,WPRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,"in December 2022, NZ changed from a one-dose live varicella-zoster virus vaccine, to a two-dose adjuvanted recombinant subunit zoster vaccine"
OMN,Oman,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,"in December 2022, NZ changed from a one-dose live varicella-zoster virus vaccine, to a two-dose adjuvanted recombinant subunit zoster vaccine"
OMN,Oman,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,school students at grade 1
OMN,Oman,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,school students at grade 1
OMN,Oman,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,school students at grade 1
OMN,Oman,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,school students at grade 1
OMN,Oman,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,school students at grade 1
OMN,Oman,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,school students at grade 1
OMN,Oman,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M24,school students at grade 1
OMN,Oman,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M24,HCWs
OMN,Oman,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,Renal dialysis patients
OMN,Oman,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Renal dialysis patients
OMN,Oman,EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,immunocompromised
OMN,Oman,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,immunocompromised
OMN,Oman,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
OMN,Oman,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
OMN,Oman,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, other groups"
OMN,Oman,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M24,"Adults with chronic conditions, other groups"
OMN,Oman,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,Children with chronic conditions
OMN,Oman,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,lab technician
OMN,Oman,EMRO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M24,"hajj and umra pilgrims, travellers to pandemic areas"
OMN,Oman,EMRO,2023,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M24,"hajj and umra pilgrims, travellers to pandemic areas"
OMN,Oman,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,ADULTS,Adults,NATIONAL,>Y34,post partum
OMN,Oman,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M12,post partum
OMN,Oman,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,General/routine,NATIONAL,M18,post partum
OMN,Oman,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,M4,post partum
OMN,Oman,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M6,post partum
OMN,Oman,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M18,post partum
OMN,Oman,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,post partum
OMN,Oman,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,post partum
OMN,Oman,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M13,post partum
OMN,Oman,EMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13,Animal contact and post exposure
OMN,Oman,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y12,Animal contact and post exposure
OMN,Oman,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y16,Animal contact and post exposure
OMN,Oman,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y16,healthcare workers
OMN,Oman,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y16,pregnant women
OMN,Oman,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,wound management
OMN,Oman,EMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y16,Food handler and travellers to high risk area
OMN,Oman,EMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y16,Food handler and travellers to high risk area
OMN,Oman,EMRO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12,Food handler and travellers to high risk area
OMN,Oman,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,TRAVELLERS,General/routine,NATIONAL,M12,Food handler and travellers to high risk area
OMN,Oman,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,TRAVELLERS,General/routine,NATIONAL,M18,Food handler and travellers to high risk area
OMN,Oman,EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M18,travellers to pandemic areas
PAK,Pakistan,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Live births
PAK,Pakistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Surviving infants
PAK,Pakistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Surviving infants
PAK,Pakistan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Surviving infants
PAK,Pakistan,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,SUBNATIONAL,B,Live births; in some selected hospitals in Punjab province only
PAK,Pakistan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,Surviving infants
PAK,Pakistan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M9,Surviving infants
PAK,Pakistan,EMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,Surviving infants
PAK,Pakistan,EMRO,2023,MR,MR (Measles and rubella) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M15,Surviving infants
PAK,Pakistan,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,Surviving infants
PAK,Pakistan,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,Surviving infants
PAK,Pakistan,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,Surviving infants
PAK,Pakistan,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,Surviving infants
PAK,Pakistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Surviving infants
PAK,Pakistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Surviving infants
PAK,Pakistan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Surviving infants
PAK,Pakistan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Surviving infants; introduced natinoally in April 2018
PAK,Pakistan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Surviving infants; introduced natinoally in April 2018
PAK,Pakistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
PAK,Pakistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
PAK,Pakistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
PAK,Pakistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
PAK,Pakistan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
PAK,Pakistan,EMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,PW,General/routine,NATIONAL,M9,Surviving infants
PAN,Panama,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,<15 años
PAN,Panama,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,<15 años
PAN,Panama,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,<15 años
PAN,Panama,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6,<15 años
PAN,Panama,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,<15 años
PAN,Panama,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,<15 años
PAN,Panama,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,>=Y19,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,RN PRIMERAS 12 HORAS
PAN,Panama,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"NIÑOS Y NIÑAS DE 10 AÑOS ADEMAS VICTIMAS DE VIOLACION SEXUAL A PARTIR DE LOS 10 AÑOS, PACIENTES VIH RECLUIDOS EN CLINICA RETRO VIRALES"
PAN,Panama,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,"NIÑOS Y NIÑAS DE 10 AÑOS ADEMAS VICTIMAS DE VIOLACION SEXUAL A PARTIR DE LOS 10 AÑOS, PACIENTES VIH RECLUIDOS EN CLINICA RETRO VIRALES"
PAN,Panama,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y10,"NIÑOS Y NIÑAS DE 10 AÑOS ADEMAS VICTIMAS DE VIOLACION SEXUAL A PARTIR DE LOS 10 AÑOS, PACIENTES VIH RECLUIDOS EN CLINICA RETRO VIRALES"
PAN,Panama,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >Y60
PAN,Panama,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
PAN,Panama,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
PAN,Panama,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PAN,Panama,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,<Y1,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PAN,Panama,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=Y1,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PAN,Panama,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y1,Children with chronic conditions
PAN,Panama,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,PACIENTES INMUNOSUPRIMIDOS
PAN,Panama,AMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,PACIENTES INMUNOSUPRIMIDOS
PAN,Panama,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"UNA DOSIS, SOLO MANEJO DE BROTES"
PAN,Panama,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Hasta los 19 años
PAN,Panama,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Hasta los 19 años
PAN,Panama,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y19,"MAYORES DE 19 AÑOS, PUERPERAS, MEF"
PAN,Panama,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y19,"MAYORES DE 19 AÑOS, PUERPERAS, MEF"
PAN,Panama,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,"ADICIONAL PACIENTES CON ENF, CRONICA INDEPENDIENTE DE LA EDAD."
PAN,Panama,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y60,"ADICIONAL PACIENTES CON ENF, CRONICA INDEPENDIENTE DE LA EDAD."
PAN,Panama,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Pre Exposición
PAN,Panama,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Pre Exposición
PAN,Panama,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Pre Exposición
PAN,Panama,AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pre Exposición
PAN,Panama,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Pre Exposición
PAN,Panama,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Pre Exposición
PAN,Panama,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,NIÑOS A PARTIR DE LOS 6 AÑOS Y ADULTOS ETC DOS DOSIS Y UN REF
PAN,Panama,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,>=Y6,NIÑOS A PARTIR DE LOS 6 AÑOS Y ADULTOS ETC DOS DOSIS Y UN REF
PAN,Panama,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y6,"Embarazada - A1, A2. NIÑOS A PARTIR DE LOS 6 AÑOS Y ADULTOS ETC DOS DOSIS Y UN REF"
PAN,Panama,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,>=Y6,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PAN,Panama,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y10,niños y niñas 10 años
PAN,Panama,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y10,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PAN,Panama,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y64,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PAN,Panama,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PAN,Panama,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y4,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PAN,Panama,AMRO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,Y4,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M6,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M12,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,3.0,RISKGROUPS,General/routine,NATIONAL,M18,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,4.0,RISKGROUPS,General/routine,NATIONAL,M24,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,5.0,RISKGROUPS,General/routine,NATIONAL,M30,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,VITAMINA,Vitamin A supplements,6.0,RISKGROUPS,General/routine,NATIONAL,M36,"Func Y Est de Ciencias de la  Salud, y Manejo de brotes."
PAN,Panama,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,Y1,SOLO EN 3 REGIONES Y A NIVEL DE VACUNACION INTERNACIONAL
PAN,Panama,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,SOLO EN 3 REGIONES  Y A NIVEL DE VACUNACION INTERNACIONAL.
PER,Peru,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,SOLO EN 3 REGIONES  Y A NIVEL DE VACUNACION INTERNACIONAL.
PER,Peru,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M6,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M15,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y5,Población que no recibio el esquema primario
PER,Peru,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Población que no recibio el esquema primario
PER,Peru,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Población que no recibio el esquema primario
PER,Peru,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,B,Población que no recibio el esquema primario
PER,Peru,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,in case of contradiction to pentavalent vaccine
PER,Peru,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M6,in case of contradiction to pentavalent vaccine
PER,Peru,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Se aplica dosis UNICA en el 5to grado de primaria, aplicada a mujeres y varones"
PER,Peru,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Se aplica dosis UNICA en el 5to grado de primaria, aplicada a mujeres y varones"
PER,Peru,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
PER,Peru,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Prenant women
PER,Peru,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,PW,General/routine,NATIONAL,M6-M11,Prenant women
PER,Peru,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,PW,General/routine,NATIONAL,Y1-Y4,Prenant women
PER,Peru,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,M2,Prenant women
PER,Peru,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,PW,General/routine,NATIONAL,M4,Prenant women
PER,Peru,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,PW,General/routine,NATIONAL,M6,Prenant women
PER,Peru,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,PW,General/routine,NATIONAL,M12,Prenant women
PER,Peru,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,PW,General/routine,NATIONAL,M18,Prenant women
PER,Peru,AMRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,M18,Prenant women
PER,Peru,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,Y4,Prenant women
PER,Peru,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M12,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M2,+M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario
PER,Peru,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,+M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario
PER,Peru,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y12,+M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario
PER,Peru,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y12,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PER,Peru,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PER,Peru,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M15,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,"Gestantes a las 27 Semanas de gestación, DOSIS UNICA"
PHL,Philippines,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y9-Y14,females; grade 4
PHL,Philippines,WPRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,females; grade 4
PHL,Philippines,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,females; grade 4
PHL,Philippines,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W14,females; grade 4
PHL,Philippines,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M9,females; grade 4
PHL,Philippines,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,ADULTS,General/routine,NATIONAL,M9,females; grade 4
PHL,Philippines,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,ADULTS,General/routine,NATIONAL,M12,females; grade 4
PHL,Philippines,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y5-Y6,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,ADULTS,General/routine,NATIONAL,Y12-Y13,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W6,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W10,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W14,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,"School based immunization, all Grade 1 and Grade 7 students shall receive another dose of MCV vaccines in the form of MR. In 2021, SBI was turned into community-based and hence the target was shifted to age groups 5-6 and 12-13 years old"
PHL,Philippines,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,Indigent elderly
PHL,Philippines,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Indigent elderly
PHL,Philippines,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y10,Indigent elderly
PHL,Philippines,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,all pregnant women in 1st trimester
PHL,Philippines,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,DTAP,DTaP (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,1st contact,Females upon 1st contact
PLW,Palau,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females upon 1st contact
PLW,Palau,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
PLW,Palau,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
PLW,Palau,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
PLW,Palau,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
PLW,Palau,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
PLW,Palau,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
PLW,Palau,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Children with chronic conditions
PLW,Palau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
PLW,Palau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
PLW,Palau,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
PLW,Palau,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
PLW,Palau,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
PLW,Palau,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children with chronic conditions
PLW,Palau,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M7,Children with chronic conditions
PLW,Palau,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
PLW,Palau,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
PLW,Palau,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
PLW,Palau,WPRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
PLW,Palau,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,>=Y10,Children with chronic conditions
PNG,Papua New Guinea,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B-M11,0-11 months
PNG,Papua New Guinea,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M1,0-11 months
PNG,Papua New Guinea,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M2,0-11 months
PNG,Papua New Guinea,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M3,0-11 months
PNG,Papua New Guinea,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,0-11 months
PNG,Papua New Guinea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,M3,0-11 months
PNG,Papua New Guinea,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,M9,0-11 months
PNG,Papua New Guinea,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M9,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M18,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,MR,MR (Measles and rubella) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,Y7,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,MR,MR (Measles and rubella) vaccine,4.0,B_ADO_W,General/routine,NATIONAL,Y13,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_ADO_W,General/routine,NATIONAL,M1,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_ADO_W,General/routine,NATIONAL,M2,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_ADO_W,General/routine,NATIONAL,M3,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M1,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M2,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M3,"MR 0 dose is given to any infants at M6-8. Y7 dose is school vaccintion entry, Y13 dose is school vaccination exit"
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y13,"Y7 dose is school vaccination entry, Y13 is school vaccination at exit"
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Y7 dose is school vaccination entry, Y13 is school vaccination at exit"
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M18,Both adults and pregnant women
POL,Poland,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Both adults and pregnant women
POL,Poland,EURO,2023,D_S,Diphtheria vaccine for older children and adults,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Post-exposure prophylaxis
POL,Poland,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,W7-W8,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M4,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M5-M6,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M16-M18,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W7-W8,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M4,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M5-M6,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M16-M18,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W7-W8,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3-M4,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5-M6,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M16-M18,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M16-M18,Specified risk groups
POL,Poland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Specified risk groups
POL,Poland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W7-W8,Specified risk groups
POL,Poland,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M7,Specified risk groups
POL,Poland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Specified risk groups
POL,Poland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Specified risk groups
POL,Poland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5-M6,Specified risk groups
POL,Poland,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M16-M18,Specified risk groups
POL,Poland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >75 years
POL,Poland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
POL,Poland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
POL,Poland,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
POL,Poland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
POL,Poland,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>M6,Children with chronic conditions
POL,Poland,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M16-M18,Children with chronic conditions
POL,Poland,EURO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
POL,Poland,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
POL,Poland,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M5-M6,Children with chronic conditions
POL,Poland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,Children with chronic conditions
POL,Poland,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
POL,Poland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
POL,Poland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
POL,Poland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M13-M15,Children with chronic conditions
POL,Poland,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13-M15,Children and adult specified risk groups
POL,Poland,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M13-M15,For persons exposed to infection as a result of contact with an animal suffering from rabies or suspected of being infected with rabies (free of charge)
POL,Poland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Routinely at Y19 and free of charge (mandatory) post-exposure prophylaxis at a later age
POL,Poland,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19,Routinely at Y19 and free of charge (mandatory) post-exposure prophylaxis at a later age
POL,Poland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,1st and 2nd booster doses
POL,Poland,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,1st and 2nd booster doses
POL,Poland,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,Free of charge (mandatory) post-exposure prophylaxis
POL,Poland,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y12,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Specified risk groups
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,B,Older persons
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,B,Health and care workers
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,B,Pregnant women
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,B,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PRK,Democratic People's Republic of Korea,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M15,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W10,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,Children with chronic conditions
PRK,Democratic People's Republic of Korea,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,W14,Pregnant women at M3 and at M4
PRK,Democratic People's Republic of Korea,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,W14,Pregnant women at M3 and at M4
PRK,Democratic People's Republic of Korea,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M11,Pregnant women at M3 and at M4
PRK,Democratic People's Republic of Korea,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12-M59,Pregnant women at M3 and at M4
PRT,Portugal,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,D0-Y5,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Specific risk group
PRT,Portugal,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Specific risk group
PRT,Portugal,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Specific risk group
PRT,Portugal,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Very specific risk groups (hepatic transplant candidates)
PRT,Portugal,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Very specific risk groups (hepatic transplant candidates)
PRT,Portugal,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y5,Healthcare workers
PRT,Portugal,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Specific risk groups
PRT,Portugal,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Specific risk groups
PRT,Portugal,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Specific risk groups
PRT,Portugal,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,Females and males
PRT,Portugal,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
PRT,Portugal,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Females and males
PRT,Portugal,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
PRT,Portugal,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
PRT,Portugal,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PRT,Portugal,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions
PRT,Portugal,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,HW,Health workers,NATIONAL,>=Y60,Health care workers at risk
PRT,Portugal,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Travellers and other specific risk groups
PRT,Portugal,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>=Y60,Travellers and other specific risk groups
PRT,Portugal,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Very specific risk groups (asplenic and complement deficit)
PRT,Portugal,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Very specific risk groups (asplenic and complement deficit)
PRT,Portugal,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Very specific risk groups (asplenic and complement deficit)
PRT,Portugal,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Very specific risk groups (asplenic and complement deficit)
PRT,Portugal,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Specific risk groups
PRT,Portugal,EURO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Specific risk groups
PRT,Portugal,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Specific risk groups
PRT,Portugal,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Specific risk groups
PRT,Portugal,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M12,Healthcare workers
PRT,Portugal,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,M12,Travellers
PRT,Portugal,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,D28,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Post-exposure prophylaxis
PRT,Portugal,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Specific risk groups
PRT,Portugal,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Specific risk groups
PRT,Portugal,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Specific risk groups
PRT,Portugal,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6,Travellers
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y45,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y65,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Adults
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y10,Travellers; Specific risk groups
PRT,Portugal,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y10,Travellers; Specific risk groups
PRT,Portugal,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y10,"Risk group - Pregnant women, 1 dose per pregnancy"
PRT,Portugal,EURO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y10,Travellers
PRT,Portugal,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y10,Travellers
PRY,Paraguay,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers
PRY,Paraguay,AMRO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"En inmuno comprometidos, Enfermos hepáticos crónico."
PRY,Paraguay,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"En inmuno comprometidos, Enfermos hepáticos crónico."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"a) niños menores de 5 años que requieran realizarse una esplenoctomía programada con esquema primario completo y dosis de refuerzo, podrán beneficiarse con una dosis adicional de vacuna conjugada contra Hib administrada 7-10 días antes del procedimiento, b) infección por VIH, c) deficít de inmunoglobulina subclase 2 (IgG2), d) oncológicos, e) trasplantados con precursores hematopoyéticos y f) trasplante de órgano sólido g) niños entre 12 - 59 meses con afección subyacente que no fueron inmunizados o sólo hayan recibido una única dosis antes de los 12 meses de edad, deben recibir dos dosis de vacuna anti - haemophilus influenzae b (con intervalos de 2 meses entre dosis) y en caso de haber recibido dos dosis antes de los 12 meses de vida se recomienda administrar una dosis adicional."
PRY,Paraguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"a) niños menores de 5 años que requieran realizarse una esplenoctomía programada con esquema primario completo y dosis de refuerzo, podrán beneficiarse con una dosis adicional de vacuna conjugada contra Hib administrada 7-10 días antes del procedimiento, b) infección por VIH, c) deficít de inmunoglobulina subclase 2 (IgG2), d) oncológicos, e) trasplantados con precursores hematopoyéticos y f) trasplante de órgano sólido g) niños entre 12 - 59 meses con afección subyacente que no fueron inmunizados o sólo hayan recibido una única dosis antes de los 12 meses de edad, deben recibir dos dosis de vacuna anti - haemophilus influenzae b (con intervalos de 2 meses entre dosis) y en caso de haber recibido dos dosis antes de los 12 meses de vida se recomienda administrar una dosis adicional."
PRY,Paraguay,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,Niñas de 9 a 14 años de edad.
PRY,Paraguay,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Niñas de 9 a 14 años de edad.
PRY,Paraguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=60 years
PRY,Paraguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
PRY,Paraguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
PRY,Paraguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Residents living in long-term care facilities, other groups"
PRY,Paraguay,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M35,"Residents living in long-term care facilities, other groups"
PRY,Paraguay,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=Y3,"Residents living in long-term care facilities, other groups"
PRY,Paraguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,"Residents living in long-term care facilities, other groups"
PRY,Paraguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adicionalmente se administra a grupos de alto riesgo, pacientes con inmunocompromiso. Las personas inmunodeprimidas, por las mismas características de la inmunodefensa, no deben recibir vacunas compuestos por agentes vivos atenuados. De tal manera a que una de las indicaciones es recibir vacunas inactivadas como es el caso de la vacuna frente al Polio Virus Antipoliomielitica Inactivada (IPV). Indicada además en Pacientes que padecen alguna inmunodeficiencia primaria o secundaria, al igual que sus contactos cercanos, por el riesgo de parálisis asociada a la vacuna OPV. Mayores de 18 años que requieren completar esquemas o reforzarlos ante situaciones de riesgo (viajeros, epidemias)."
PRY,Paraguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Adicionalmente se administra a grupos de alto riesgo, pacientes con inmunocompromiso. Las personas inmunodeprimidas, por las mismas características de la inmunodefensa, no deben recibir vacunas compuestos por agentes vivos atenuados. De tal manera a que una de las indicaciones es recibir vacunas inactivadas como es el caso de la vacuna frente al Polio Virus Antipoliomielitica Inactivada (IPV). Indicada además en Pacientes que padecen alguna inmunodeficiencia primaria o secundaria, al igual que sus contactos cercanos, por el riesgo de parálisis asociada a la vacuna OPV. Mayores de 18 años que requieren completar esquemas o reforzarlos ante situaciones de riesgo (viajeros, epidemias)."
PRY,Paraguay,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"La vacuna neumococica polisacarida 23 valente se administra a toda persona de igual o mayor edad a 60 años, adicionalmente a personas de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae. La vacuna 23 valente está indicada para los niños a partir de los dos años de edad y en adultos que integran los grupos de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae, dictados a continuación: anemia drepanocítica, cardiopatia congénita, enfermedades pulmonares crónicas, diabetes mellitus, hepatopatía crónica, fistula de LCR, asplenia funcional o anatómica, implante coclear, 60 años o mayor, infección por VIH, leucemias, neoplasias, falla renal crónica, sindrome nefrótico, tabaquismo."
PRY,Paraguay,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"La vacuna neumococica polisacarida 23 valente se administra a toda persona de igual o mayor edad a 60 años, adicionalmente a personas de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae. La vacuna 23 valente está indicada para los niños a partir de los dos años de edad y en adultos que integran los grupos de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae, dictados a continuación: anemia drepanocítica, cardiopatia congénita, enfermedades pulmonares crónicas, diabetes mellitus, hepatopatía crónica, fistula de LCR, asplenia funcional o anatómica, implante coclear, 60 años o mayor, infección por VIH, leucemias, neoplasias, falla renal crónica, sindrome nefrótico, tabaquismo."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D7,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,RABIES,Rabies vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+Y1,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,1st contact,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,+M1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,>=Y7,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y10,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y10,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y10,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y59,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PRY,Paraguay,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y2-Y59,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W1,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,B,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,Adults with chronic conditions
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,Adults with chronic conditions
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M1,Children with chronic conditions
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y6,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,Special groups
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y15,Pregnant women
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M10,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,Travellers to high risk areas
PYF,French Polynesia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers
PYF,French Polynesia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers
PYF,French Polynesia,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Healthcare workers
PYF,French Polynesia,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,Healthcare workers
PYF,French Polynesia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Healthcare workers
PYF,French Polynesia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y60,Health and care workers
PYF,French Polynesia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y60,Pregnant women
PYF,French Polynesia,WPRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
PYF,French Polynesia,WPRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y60,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M10,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
PYF,French Polynesia,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Preterm or risk of invasive pneumococcal infection (chronic disease)
PYF,French Polynesia,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y5,Preterm or risk of invasive pneumococcal infection (chronic disease)
PYF,French Polynesia,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
PYF,French Polynesia,WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,DTAPHIB,DTaP-Hib (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,DTAPHIBHEPB,DTaP-Hib-HepB (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M18,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M2,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"Males and females aged 11-26 years: 9-14 years x2 doses of 0.5ml at 0, 6 months; 15 years and above x3 doses of 0.5ml at 0, 1 and 6 months"
QAT,Qatar,EMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Males and females aged 11-26 years: 9-14 years x2 doses of 0.5ml at 0, 6 months; 15 years and above x3 doses of 0.5ml at 0, 1 and 6 months"
QAT,Qatar,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years
QAT,Qatar,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
QAT,Qatar,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
QAT,Qatar,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
QAT,Qatar,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,"Adults with chronic conditions, residents living in long-term care facilities"
QAT,Qatar,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y6,"Adults with chronic conditions, residents living in long-term care facilities"
QAT,Qatar,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y6,Children with chronic conditions
QAT,Qatar,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y6,Recommended for defaulters in the Defaulters schedule for those children who have never received any IPV containing vaccines
QAT,Qatar,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,travellers and high risk
QAT,Qatar,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y2,travellers and high risk
QAT,Qatar,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,travellers and high risk
QAT,Qatar,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,travellers and high risk
QAT,Qatar,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,M6,travellers and high risk
QAT,Qatar,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M18,travellers and high risk
QAT,Qatar,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y6,travellers and high risk
QAT,Qatar,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,travellers and high risk
QAT,Qatar,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,travellers and high risk
QAT,Qatar,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,travellers and high risk
QAT,Qatar,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,TRAVELLERS,General/routine,NATIONAL,M15,travellers and high risk
QAT,Qatar,EMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,high risk groups
QAT,Qatar,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,high risk groups
QAT,Qatar,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,high risk groups
QAT,Qatar,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13-Y18,high risk groups
QAT,Qatar,EMRO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M12,high risk groups
QAT,Qatar,EMRO,2023,VARICELLA,Varicella vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y4-Y6,high risk groups
ROU,Romania,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,high risk groups
ROU,Romania,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,high risk groups
ROU,Romania,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,high risk groups
ROU,Romania,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M11,high risk groups
ROU,Romania,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,high risk groups
ROU,Romania,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y6,"Currently, this type of vaccination is done within hepatitis A foci."
ROU,Romania,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y6,"Currently, this type of vaccination is done within hepatitis A foci."
ROU,Romania,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y6,Private sector
ROU,Romania,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Private sector
ROU,Romania,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y18,11-18 y girls on request
ROU,Romania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years old
ROU,Romania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ROU,Romania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ROU,Romania,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities"
ROU,Romania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y3,"Adults with chronic conditions, residents living in long-term care facilities"
ROU,Romania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y3,"Adults with chronic conditions, residents living in long-term care facilities"
ROU,Romania,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y3,Children with chronic conditions
ROU,Romania,EURO,2023,MEN_AC_CONJ,Meningococcal AC conjugate vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,>Y3,Travellers
ROU,Romania,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,>Y3,Travellers
ROU,Romania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,Travellers
ROU,Romania,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y5,Travellers
ROU,Romania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers
ROU,Romania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers
ROU,Romania,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M11,Travellers
ROU,Romania,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M11,Private sector
ROU,Romania,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y14,Private sector
ROU,Romania,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,Pregnant women
ROU,Romania,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,In case of injuries
ROU,Romania,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,Y14,Travellers
ROU,Romania,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,Private sector
ROU,Romania,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,Y14,Travellers
RUS,Russian Federation,EURO,2023,ANTHRAX,Anthrax vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023,ANTHRAX,Anthrax vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+М1,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023,ANTHRAX,Anthrax vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y1-Y2,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,D3,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y7,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023,D_S,Diphtheria vaccine for older children and adults,1.0,ADULTS,Adults,NATIONAL,Y7,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,DIP,"Diphtheria vaccine, children's dose",1.0,ADULTS,General/routine,NATIONAL,>=Y6,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4.5,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,"В соответствии с Национальным календарем профилактических прививок Российской Федерации курс первичной вакцинации состоит из 3-х доз вакцины, вводимых с интервалом в 1.5 мес: ревакцинацию проводят однократно в возрасте 18 месяцев"
RUS,Russian Federation,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4.5,"В соответствии с Национальным календарем профилактических прививок Российской Федерации курс первичной вакцинации состоит из 3-х доз вакцины, вводимых с интервалом в 1.5 мес: ревакцинацию проводят однократно в возрасте 18 месяцев"
RUS,Russian Federation,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"В соответствии с Национальным календарем профилактических прививок Российской Федерации курс первичной вакцинации состоит из 3-х доз вакцины, вводимых с интервалом в 1.5 мес: ревакцинацию проводят однократно в возрасте 18 месяцев"
RUS,Russian Federation,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"В соответствии с Национальным календарем профилактических прививок Российской Федерации курс первичной вакцинации состоит из 3-х доз вакцины, вводимых с интервалом в 1.5 мес: ревакцинацию проводят однократно в возрасте 18 месяцев"
RUS,Russian Federation,EURO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M3,Прививки АКДС-вакциной проводят в возрасте от 3 месяцев до достижения возраста 3 года 11 мес 29 дней.Дети с противопоказаниями к применению АКДС-вакцины могут быть привиты АДС-анатоксином.
RUS,Russian Federation,EURO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4.5,Прививки АКДС-вакциной проводят в возрасте от 3 месяцев до достижения возраста 3 года 11 мес 29 дней.Дети с противопоказаниями к применению АКДС-вакцины могут быть привиты АДС-анатоксином.
RUS,Russian Federation,EURO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,Прививки АКДС-вакциной проводят в возрасте от 3 месяцев до достижения возраста 3 года 11 мес 29 дней.Дети с противопоказаниями к применению АКДС-вакцины могут быть привиты АДС-анатоксином.
RUS,Russian Federation,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Прививки АКДС-вакциной проводят в возрасте от 3 месяцев до достижения возраста 3 года 11 мес 29 дней.Дети с противопоказаниями к применению АКДС-вакцины могут быть привиты АДС-анатоксином.
RUS,Russian Federation,EURO,2023,DTWPHEPB,DTwP-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,"Детям, привитым моновакциной гепатитаВ в первые 24 ч жизни и не относящимся к группам риска назначают  иммунизацию вакциной АКДС-ГепВ в  6 мес. Данная вакцина может применяться в соответствии с прививочным статусом ребенка."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,HW,Health workers,SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,General/routine,SUBNATIONAL,+M6-M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,General/routine,SUBNATIONAL,>M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+M6-M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Обычно  прививка делается в первые сутки рождения.
RUS,Russian Federation,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M1,Обычно  прививка делается в первые сутки рождения.
RUS,Russian Federation,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Обычно  прививка делается в первые сутки рождения.
RUS,Russian Federation,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,М3,"Всем детям в рамках национального календаря профилактических прививок. В 2023 г. закупок данной вакцины не было, но она производится и будет поставлена в 2024 г."
RUS,Russian Federation,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4.5,"Всем детям в рамках национального календаря профилактических прививок. В 2023 г. закупок данной вакцины не было, но она производится и будет поставлена в 2024 г."
RUS,Russian Federation,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,М6,"Всем детям в рамках национального календаря профилактических прививок. В 2023 г. закупок данной вакцины не было, но она производится и будет поставлена в 2024 г."
RUS,Russian Federation,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,М18,"Всем детям в рамках национального календаря профилактических прививок. В 2023 г. закупок данной вакцины не было, но она производится и будет поставлена в 2024 г."
RUS,Russian Federation,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y12-Y14,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M2,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=Y60
RUS,Russian Federation,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
RUS,Russian Federation,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
RUS,Russian Federation,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
RUS,Russian Federation,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y7,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
RUS,Russian Federation,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y7,"Adults with chronic conditions, residents living in long-term care facilities, other risk groups"
RUS,Russian Federation,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y7,Children with chronic conditions
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M3,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4.5,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,M20,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,IPV,IPV (Inactivated polio vaccine),6.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023,MEASLES,Measles vaccine,3.0,ADULTS,Adults,NATIONAL,Y18-Y35,"С 18-35 все, с 36 до 55 группы риска"
RUS,Russian Federation,EURO,2023,MEASLES,Measles vaccine,2.0,ADULTS,General/routine,NATIONAL,Y6,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MEASLES,Measles vaccine,1.0,ADULTS,General/routine,NATIONAL,M12,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y36-Y55,"С 18-35 все, с 36 до 55 группы риска"
RUS,Russian Federation,EURO,2023,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,ADULTS,Adults,SUBNATIONAL,>Y18,"Вакцинация детей старше 1 года, подростков и взрослых:  в очагах менингококковой инфекции, вызванной менингококками серогруппы А; в эндемичных районах, а также в случае эпидемии, вызванной менингококками серогруппы А; вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y1,"Вакцинация детей старше 1 года, подростков и взрослых:  в очагах менингококковой инфекции, вызванной менингококками серогруппы А; в эндемичных районах, а также в случае эпидемии, вызванной менингококками серогруппы А; вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,ADULTS,Adults,SUBNATIONAL,Y18-Y60,"Вакцинация взрослых от 18 до 60 лет:  - в очагах менингококковой инфекции, вызванной менингококками серогрупп А или С;  - в эндемичных регионах, а также в случае эпидемии, вызванной менингококками серогрупп А или С;  - вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y18,"Вакцинация взрослых от 18 до 60 лет:  - в очагах менингококковой инфекции, вызванной менингококками серогрупп А или С;  - в эндемичных регионах, а также в случае эпидемии, вызванной менингококками серогрупп А или С;  - вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"по эпидпоказаниям, для паломников, детей в рамках региональных календарей профилактических прививок. В региональных календарях подлежат дети  в возрасте с 3-6 лет перед поступлением в детские дошкольные образовательные организации ."
RUS,Russian Federation,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,"по эпидпоказаниям, для паломников, детей в рамках региональных календарей профилактических прививок. В региональных календарях подлежат дети  в возрасте с 3-6 лет перед поступлением в детские дошкольные образовательные организации ."
RUS,Russian Federation,EURO,2023,MM,MM (Measles and mumps) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MM,MM (Measles and mumps) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y6,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MUMPS,Mumps vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться, как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,MUMPS,Mumps vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y6,"В дополнение к дивакцине в рамках национального календаря профилактических прививок, могут применяться и другие противокоревые вакцины моновакцина, КП и КПК, которые могут закупаться, как за средства федерального бюджета, так и за региональные средства."
RUS,Russian Federation,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M20,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4.5,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M15,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,>Y18,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+Y3,Изменения по срокам введения вакцины  ОПВ  произошли в соответствии с новым национальны календарем прививок с 2022г.
RUS,Russian Federation,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+D7,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+D30,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y1,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,M2,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,SUBNATIONAL,M3,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,SUBNATIONAL,М4.5,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RUBELLA,Rubella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RUBELLA,Rubella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y6,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023,RUBELLA,Rubella vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y18-Y25,"Применяется для иммунизации женщин в возрасте от 18 до 25 лет включительно, ранее не привитых, привитых однократно и не болевших краснухой"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,ADULTS,Adults,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,4.0,ADULTS,Adults,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,4.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,General/routine,SUBNATIONAL,Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,TRAVELLERS,General/routine,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,TRAVELLERS,General/routine,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,TRAVELLERS,General/routine,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y24,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y7,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y14,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,SUBNATIONAL,Y14,В региональных календарях иммунизации  подлежат дети с  6-летнего  возраста и взрослые.
RUS,Russian Federation,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y6,В региональных календарях иммунизации  подлежат дети с  6-летнего  возраста и взрослые.
RUS,Russian Federation,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Активная иммунизация препаратом АС  проводится у лиц, ранее не привитых против столбняка, в т.ч. по эпидемическим показаниям (травмы и тд.)."
RUS,Russian Federation,EURO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Активная иммунизация препаратом АС  проводится у лиц, ранее не привитых против столбняка, в т.ч. по эпидемическим показаниям (травмы и тд.)."
RUS,Russian Federation,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023,TULAREMIA,Tularemia vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+Y5,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023,TULAREMIA,Tularemia vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y5,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Для групп риска ревакцинация каждые 3 года
RUS,Russian Federation,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,Для групп риска ревакцинация каждые 3 года
RUS,Russian Federation,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,SUBNATIONAL,>=М12,Для групп риска ревакцинация каждые 3 года
RUS,Russian Federation,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,>М9,для выезжающих в эндемичные страны
RUS,Russian Federation,EURO,2023,YF,YF (Yellow fever) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y10,для выезжающих в эндемичные страны
RWA,Rwanda,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,Live birth
RWA,Rwanda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,Surviving enfant
RWA,Rwanda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,Surviving enfant
RWA,Rwanda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,Surviving enfant
RWA,Rwanda,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,12 years old females
RWA,Rwanda,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,12 years old females
RWA,Rwanda,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,Surviving enfant
RWA,Rwanda,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,Surviving enfant
RWA,Rwanda,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,Surviving enfant
RWA,Rwanda,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,Surviving enfant
RWA,Rwanda,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,Surviving enfant
RWA,Rwanda,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,Surviving enfant
RWA,Rwanda,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,Surviving enfant
RWA,Rwanda,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,Surviving enfant
RWA,Rwanda,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Surviving enfant
RWA,Rwanda,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Surviving enfant
RWA,Rwanda,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,Surviving enfant
RWA,Rwanda,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Surviving enfant
RWA,Rwanda,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Surviving enfant
RWA,Rwanda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
RWA,Rwanda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
RWA,Rwanda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
RWA,Rwanda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
RWA,Rwanda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SAU,Saudi Arabia,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,M6,pregnant women
SAU,Saudi Arabia,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y7,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,DTAPHIB,DTaP-Hib (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M24,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,Y11,High risk groups
SAU,Saudi Arabia,EMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,Y12,High risk groups
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons 50Y
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,Pregnant women
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents in long-term care facilities"
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y5,"Adults with chronic conditions, residents in long-term care facilities"
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,"Adults with chronic conditions, residents in long-term care facilities"
SAU,Saudi Arabia,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y5,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
SAU,Saudi Arabia,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+D30,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M6,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M12,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M18,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y6,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M12,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,High risk groups
SAU,Saudi Arabia,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,High risk groups
SAU,Saudi Arabia,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,High risk groups
SAU,Saudi Arabia,EMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,High risk groups
SAU,Saudi Arabia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=Y7,High risk groups
SAU,Saudi Arabia,EMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,>=Y7,Pregnant women between 27-36 weeks
SAU,Saudi Arabia,EMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M18,Pregnant women between 27-36 weeks
SAU,Saudi Arabia,EMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y4-Y6,Pregnant women between 27-36 weeks
SAU,Saudi Arabia,EMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,50 years and above
SAU,Saudi Arabia,EMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2-M6,50 years and above
SDN,Sudan,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,Live Birth
SDN,Sudan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,Surviving infants
SDN,Sudan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,Surviving infants
SDN,Sudan,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,Surviving infants
SDN,Sudan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W6,Surviving infants
SDN,Sudan,EMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W14,Surviving infants
SDN,Sudan,EMRO,2023,MEASLES,Measles vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,Surviving infants
SDN,Sudan,EMRO,2023,MEASLES,Measles vaccine,2.0,ADULTS,General/routine,NATIONAL,M18,Surviving infants
SDN,Sudan,EMRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,Surviving infants
SDN,Sudan,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,W6,Surviving infants
SDN,Sudan,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W10,Surviving infants
SDN,Sudan,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W14,Surviving infants
SDN,Sudan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,Surviving infants
SDN,Sudan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,Surviving infants
SDN,Sudan,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,Surviving infants
SDN,Sudan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,Surviving infants
SDN,Sudan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,Surviving infants
SDN,Sudan,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,Surviving infants
SDN,Sudan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
SDN,Sudan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
SDN,Sudan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
SDN,Sudan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SDN,Sudan,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SEN,Senegal,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Pregnant women
SEN,Senegal,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,Pregnant women
SEN,Senegal,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,Pregnant women
SEN,Senegal,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,Pregnant women
SEN,Senegal,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,Pregnant women
SEN,Senegal,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,filles de 9-14 ans
SEN,Senegal,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,filles de 9-14 ans
SEN,Senegal,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,filles de 9-14 ans
SEN,Senegal,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W14,filles de 9-14 ans
SEN,Senegal,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,filles de 9-14 ans
SEN,Senegal,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,filles de 9-14 ans
SEN,Senegal,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,filles de 9-14 ans
SEN,Senegal,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,filles de 9-14 ans
SEN,Senegal,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,filles de 9-14 ans
SEN,Senegal,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,filles de 9-14 ans
SEN,Senegal,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,filles de 9-14 ans
SEN,Senegal,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,filles de 9-14 ans
SEN,Senegal,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,filles de 9-14 ans
SEN,Senegal,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,filles de 9-14 ans
SEN,Senegal,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,filles de 9-14 ans
SEN,Senegal,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,filles de 9-14 ans
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,M2,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,M4,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,M18,Catch-up
SGP,Singapore,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,B,Catch-up
SGP,Singapore,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,B,Catch-up
SGP,Singapore,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,females
SGP,Singapore,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y14,females
SGP,Singapore,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_A,Catch-up adults,NATIONAL,Y14,Catch-up
SGP,Singapore,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_A,General/routine,NATIONAL,M12,Catch-up
SGP,Singapore,WPRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,CATCHUP_A,General/routine,NATIONAL,M15,Catch-up
SGP,Singapore,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,M4,Catch-up
SGP,Singapore,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,CATCHUP_A,General/routine,NATIONAL,M6,Catch-up
SGP,Singapore,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,CATCHUP_A,General/routine,NATIONAL,M12,Catch-up
SGP,Singapore,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,high risk groups
SGP,Singapore,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y17,high risk groups
SGP,Singapore,WPRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,high risk groups
SGP,Singapore,WPRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y2-Y17,pregnant women
SGP,Singapore,WPRO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y11,pregnant women
SGP,Singapore,WPRO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,Y11,pregnant women
SGP,Singapore,WPRO,2023,VARICELLA,Varicella vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,M12,pregnant women
SLB,Solomon Islands,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,B,pregnant women
SLB,Solomon Islands,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,W6,pregnant women
SLB,Solomon Islands,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,CATCHUP_A,General/routine,NATIONAL,W10,pregnant women
SLB,Solomon Islands,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,CATCHUP_A,General/routine,NATIONAL,W14,pregnant women
SLB,Solomon Islands,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_A,General/routine,NATIONAL,B,pregnant women
SLB,Solomon Islands,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females
SLB,Solomon Islands,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,Females
SLB,Solomon Islands,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,Females
SLB,Solomon Islands,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,Females
SLB,Solomon Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,Females
SLB,Solomon Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,Females
SLB,Solomon Islands,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,Females
SLB,Solomon Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Females
SLB,Solomon Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Females
SLB,Solomon Islands,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,Females
SLB,Solomon Islands,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Females
SLB,Solomon Islands,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Females
SLB,Solomon Islands,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact pregnancy
SLE,Sierra Leone,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 months
SLE,Sierra Leone,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,0-11 months
SLE,Sierra Leone,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,0-11 months
SLE,Sierra Leone,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,0-11 months
SLE,Sierra Leone,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Females upon 1st contact
SLE,Sierra Leone,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females upon 1st contact
SLE,Sierra Leone,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
SLE,Sierra Leone,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,0-11 months
SLE,Sierra Leone,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9-24 months
SLE,Sierra Leone,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M15,9-24 months
SLE,Sierra Leone,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,0-11 months
SLE,Sierra Leone,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
SLE,Sierra Leone,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
SLE,Sierra Leone,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
SLE,Sierra Leone,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
SLE,Sierra Leone,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
SLE,Sierra Leone,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
SLE,Sierra Leone,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
SLE,Sierra Leone,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st contact,WCBA
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M6,0-59 months
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,ADULTS,General/routine,NATIONAL,M12,0-59 months
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,ADULTS,General/routine,NATIONAL,M18,0-59 months
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,ADULTS,General/routine,NATIONAL,M24,0-59 months
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,ADULTS,General/routine,NATIONAL,M30,0-59 months
SLE,Sierra Leone,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,ADULTS,General/routine,NATIONAL,M36,0-59 months
SLE,Sierra Leone,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,0-11 months
SLV,El Salvador,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,"RN con peso mayor de 2,000gr antes de cumplir el año de vida"
SLV,El Salvador,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M15-M18,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18,Como 1° refuerzo a los 18 meses de edad
SLV,El Salvador,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Segundo refuerzo a los 4 años
SLV,El Salvador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,"1° dosis a los 2 meses, 2° dosis a los 4 meses y 3° dosis a los 6 meses de edad, se utilizo como refuerzo a los 18 meses hasta el mes de julio 2023"
SLV,El Salvador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,"1° dosis a los 2 meses, 2° dosis a los 4 meses y 3° dosis a los 6 meses de edad, se utilizo como refuerzo a los 18 meses hasta el mes de julio 2023"
SLV,El Salvador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,"1° dosis a los 2 meses, 2° dosis a los 4 meses y 3° dosis a los 6 meses de edad, se utilizo como refuerzo a los 18 meses hasta el mes de julio 2023"
SLV,El Salvador,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,"1° dosis a los 2 meses, 2° dosis a los 4 meses y 3° dosis a los 6 meses de edad, se utilizo como refuerzo a los 18 meses hasta el mes de julio 2023"
SLV,El Salvador,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M15,Primera dosis niños de 15 meses y segunda dosis a los 24 meses (vacuna incorporada al esquema a partir de julio 2023)
SLV,El Salvador,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M24,Primera dosis niños de 15 meses y segunda dosis a los 24 meses (vacuna incorporada al esquema a partir de julio 2023)
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Personal de salud
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Personal de salud
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Personal de salud
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Recien Nacido en las primeras 24 horas de vida
SLV,El Salvador,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,niñas de 9 años
SLV,El Salvador,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,niñas de 9 años
SLV,El Salvador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,niñas de 9 años
SLV,El Salvador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y60,Health and care workers
SLV,El Salvador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y60,Pregnant women
SLV,El Salvador,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,Adults with chronic conditions
SLV,El Salvador,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y4,Adults with chronic conditions
SLV,El Salvador,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Niños de 2 meses, 4 meses y 6 meses"
SLV,El Salvador,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Niños de 2 meses, 4 meses y 6 meses"
SLV,El Salvador,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Niños de 2 meses, 4 meses y 6 meses"
SLV,El Salvador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Primera dosis a los 12 meses y segunda dosis a los 18 meses
SLV,El Salvador,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15-M18,Primera dosis a los 12 meses y segunda dosis a los 18 meses
SLV,El Salvador,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M15-M18,"15 a 18 meses y 2° refuerzo a los 4 años de edad, a partir del mes de julio 2023 se dio en cambio de primer refuerzo con Hexavalente"
SLV,El Salvador,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,"15 a 18 meses y 2° refuerzo a los 4 años de edad, a partir del mes de julio 2023 se dio en cambio de primer refuerzo con Hexavalente"
SLV,El Salvador,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"Personas  con enfermedades cronicas de alto riesgo , mayores de 60 años de edad"
SLV,El Salvador,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,"Niños de 2, 4 meses y 1 año de edad"
SLV,El Salvador,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,Y1,"Niños de 2, 4 meses y 1 año de edad"
SLV,El Salvador,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,"Niños de 2, 4 meses y 1 año de edad"
SLV,El Salvador,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Personas  con enfermedades cronicas de alto riesgo , mayores de 60 años de edad"
SLV,El Salvador,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"Adultos  Mayores de 60 años, Grupos de riesgo y personas con enfermedades cronicas"
SLV,El Salvador,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,"Adultos  Mayores de 60 años, Grupos de riesgo y personas con enfermedades cronicas"
SLV,El Salvador,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y60,Personas agredidas por animal transmisor de rabia según lineamiento
SLV,El Salvador,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Dos dosis a los 2 y 4 meses
SLV,El Salvador,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Dos dosis a los 2 y 4 meses
SLV,El Salvador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,M4,"Mujeres embarazadas se utiliza la Td, si el esquema de vacuna no esta completo o no hay evidencia de vacunación previa, se coloca tdpa a las 20 semanas y luego 4 semanas posterior se colocara la Td a completar esquema, luego cada 10 años se da un refuerzo."
SLV,El Salvador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,niños de 10 año de edad
SLV,El Salvador,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y10,"Mujeres embarazadas se utiliza la Td, si el esquema de vacuna no esta completo o no hay evidencia de vacunación previa, se coloca tdpa a las 20 semanas y luego 4 semanas posterior se colocara la Td a completar esquema, luego cada 10 años se da un refuerzo."
SLV,El Salvador,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y10,Mujeres embarazadas a partir de la 20a semana de edad gestacional en cada embarazo .Personal de salud que este en contacto directo con recién nacidos o lactantes
SLV,El Salvador,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y10,Mujeres embarazadas a partir de la 20a semana de edad gestacional en cada embarazo .Personal de salud que este en contacto directo con recién nacidos o lactantes
SLV,El Salvador,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M15,Primera dosis en niños de 15 meses y 4 años (vacuna incorporada al esquema a partir de julio 2023)
SLV,El Salvador,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y4,Primera dosis en niños de 15 meses y 4 años (vacuna incorporada al esquema a partir de julio 2023)
SLV,El Salvador,AMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,se inicia a lo 6 meses de edad y posteriormente a los 11 meses al año de edad
SLV,El Salvador,AMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M11,se inicia a lo 6 meses de edad y posteriormente a los 11 meses al año de edad
SLV,El Salvador,AMRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,Y1,se inicia a lo 6 meses de edad y posteriormente a los 11 meses al año de edad
SLV,El Salvador,AMRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,Y4,se inicia a lo 6 meses de edad y posteriormente a los 11 meses al año de edad
SLV,El Salvador,AMRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,Y5,se inicia a lo 6 meses de edad y posteriormente a los 11 meses al año de edad
SLV,El Salvador,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y1,"una dosis a los Viajeros a países endemicos, a partir del  1 año de edad"
SMR,San Marino,EURO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y1,Travellers
SMR,San Marino,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,Travellers
SMR,San Marino,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,Travellers
SMR,San Marino,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M11,Travellers
SMR,San Marino,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Travellers
SMR,San Marino,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y15,Travellers
SMR,San Marino,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,"Risk categories, outbreaks, travellers"
SMR,San Marino,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,"Risk categories, outbreaks, travellers"
SMR,San Marino,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,"Risk categories, outbreaks, travellers"
SMR,San Marino,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y15,"Risk categories, outbreaks, travellers"
SMR,San Marino,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,Risk categories (workers not yet covered by vaccination are also included)
SMR,San Marino,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered to newborns of HBSaG positive mothers
SMR,San Marino,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Risk categories
SMR,San Marino,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y14,Females
SMR,San Marino,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
SMR,San Marino,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,Females
SMR,San Marino,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
SMR,San Marino,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
SMR,San Marino,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
SMR,San Marino,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,Children with chronic conditions
SMR,San Marino,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>Y65,Travellers
SMR,San Marino,EURO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y65,Travellers (given in Italy)
SMR,San Marino,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M13,Travellers (given in Italy)
SMR,San Marino,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y13,Travellers (given in Italy)
SMR,San Marino,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y13,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M4,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MEN_B,Meningococcal B vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M6,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MEN_B,Meningococcal B vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M13,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M15,"Risk categories, travellers"
SMR,San Marino,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y6,"Risk categories, travellers"
SMR,San Marino,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M3,"Risk categories, travellers"
SMR,San Marino,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M5,"Risk categories, travellers"
SMR,San Marino,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M11,"Risk categories, travellers"
SMR,San Marino,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,Risk categories
SMR,San Marino,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,Risk categories
SMR,San Marino,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,Risk categories
SMR,San Marino,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11,Risk categories
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y25,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y15,Adults every 10 years
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,+Y10,Travellers
SMR,San Marino,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,+Y10,Travellers
SMR,San Marino,EURO,2023,VARICELLA,Varicella vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M15,Travellers
SMR,San Marino,EURO,2023,VARICELLA,Varicella vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,Y6,Travellers
SMR,San Marino,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y6,Travellers (given in Italy)
SMR,San Marino,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,Risk categories
SOM,Somalia,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Live birth
SOM,Somalia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,<1 year
SOM,Somalia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,<1 year
SOM,Somalia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,<1 year
SOM,Somalia,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,given at 14 weeks with Penta3
SOM,Somalia,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M9,given at 14 weeks with Penta3
SOM,Somalia,EMRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,<1 year
SOM,Somalia,EMRO,2023,MEASLES,Measles vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M15,<1 year
SOM,Somalia,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,<1 year
SOM,Somalia,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,<1 year
SOM,Somalia,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W10,<1 year
SOM,Somalia,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,W14,<1 year
SOM,Somalia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
SOM,Somalia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
SOM,Somalia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
SOM,Somalia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SOM,Somalia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SOM,Somalia,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,pregnant women
SOM,Somalia,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,pregnant women
SOM,Somalia,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,pregnant women
SOM,Somalia,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,pregnant women
SOM,Somalia,EMRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,pregnant women
SOM,Somalia,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,ADULTS,General/routine,NATIONAL,M36,pregnant women
SRB,Serbia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,pregnant women
SRB,Serbia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,ADULTS,General/routine,NATIONAL,W8,pregnant women
SRB,Serbia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,ADULTS,General/routine,NATIONAL,W14,pregnant women
SRB,Serbia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,ADULTS,General/routine,NATIONAL,W20,pregnant women
SRB,Serbia,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,pregnant women
SRB,Serbia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,pregnant women
SRB,Serbia,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y7,Travellers
SRB,Serbia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,Y7,"Health and care workers, medical and other health-related students"
SRB,Serbia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,"Post-exposure profilaxis, newborns of HBs Ag positive mothers, partners and household contacts of HBs Ag positive persons, iv drug users, persons with comorbidities includng HIV and Hepatitis C, residents of long-term health facilities, residents of long-term health facilities, health and care workers, medical and other health-related students"
SRB,Serbia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,"Post-exposure profilaxis, newborns of HBs Ag positive mothers, partners and household contacts of HBs Ag positive persons, iv drug users, persons with comorbidities includng HIV and Hepatitis C, residents of long-term health facilities, residents of long-term health facilities, health and care workers, medical and other health-related students"
SRB,Serbia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W4,"Post-exposure profilaxis, newborns of HBs Ag positive mothers, partners and household contacts of HBs Ag positive persons, iv drug users, persons with comorbidities includng HIV and Hepatitis C, residents of long-term health facilities, residents of long-term health facilities, health and care workers, medical and other health-related students"
SRB,Serbia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,"Post-exposure profilaxis, newborns of HBs Ag positive mothers, partners and household contacts of HBs Ag positive persons, iv drug users, persons with comorbidities includng HIV and Hepatitis C, residents of long-term health facilities, residents of long-term health facilities, health and care workers, medical and other health-related students"
SRB,Serbia,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Immunocompromised persons
SRB,Serbia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y19,"Recommended HPV 9 vaccine is free of charge (funded by National Health Insurance Fund) for children of both genders aged 9 to 19 years. The number of doses depends on age: two dose schedule (0, 6 months) is predicted for children aged 9 to 14 years while three dose schedule is predicted for children aged 15 to 19 years (regimen 0, 2, 6 months)."
SRB,Serbia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Recommended HPV 9 vaccine is free of charge (funded by National Health Insurance Fund) for children of both genders aged 9 to 19 years. The number of doses depends on age: two dose schedule (0, 6 months) is predicted for children aged 9 to 14 years while three dose schedule is predicted for children aged 15 to 19 years (regimen 0, 2, 6 months)."
SRB,Serbia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"Recommended HPV 9 vaccine is free of charge (funded by National Health Insurance Fund) for children of both genders aged 9 to 19 years. The number of doses depends on age: two dose schedule (0, 6 months) is predicted for children aged 9 to 14 years while three dose schedule is predicted for children aged 15 to 19 years (regimen 0, 2, 6 months)."
SRB,Serbia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
SRB,Serbia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
SRB,Serbia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
SRB,Serbia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,Children with chronic conditions
SRB,Serbia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,>Y65,"Immunocompromised persons, travellers, exposed health workers in laboratories"
SRB,Serbia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Immunocompromised persons, travellers, exposed health workers in laboratories"
SRB,Serbia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y65,"Immunocompromised persons, travellers, exposed health workers in laboratories"
SRB,Serbia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,>12M
SRB,Serbia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y7,>12M
SRB,Serbia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,Y7,"Health and care workers, susceptible contacts of measles cases, seronegative women of reproductive age"
SRB,Serbia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,"Health and care workers, susceptible contacts of measles cases, seronegative women of reproductive age"
SRB,Serbia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W20,"Health and care workers, susceptible contacts of measles cases, seronegative women of reproductive age"
SRB,Serbia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M18,"Health and care workers, susceptible contacts of measles cases, seronegative women of reproductive age"
SRB,Serbia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W8,"Health and care workers, susceptible contacts of measles cases, seronegative women of reproductive age"
SRB,Serbia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W8,"Immunocompromised persons, persons with comorbidities, residents of long-term health facilities"
SRB,Serbia,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W8,"Immunocompromised persons, persons with comorbidities, residents of long-term health facilities"
SRB,Serbia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14,"Immunocompromised persons, persons with comorbidities, residents of long-term health facilities"
SRB,Serbia,EURO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,In case of injury
SRB,Serbia,EURO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14,Travellers
SRB,Serbia,EURO,2023,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,Y14,health and care workers
SRB,Serbia,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y14,"suspectible contacts of varicella cases, children aged 12y who did not contracted varicella, seronegative women of reproductive age, household contacts of susceptible persons in risk of severe  health and care workers"
SRB,Serbia,EURO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y14,Travellers
SSD,South Sudan,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 months
SSD,South Sudan,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
SSD,South Sudan,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
SSD,South Sudan,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
SSD,South Sudan,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
SSD,South Sudan,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 months
SSD,South Sudan,AFRO,2023,MEASLES,Measles vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 months
SSD,South Sudan,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 months
SSD,South Sudan,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 months
SSD,South Sudan,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 months
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15,15-45 years
SSD,South Sudan,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,15-45 years
STP,Sao Tome and Principe,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,B,naissances vivantes
STP,Sao Tome and Principe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,naissances vivantes
STP,Sao Tome and Principe,AFRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,9-18 mois
STP,Sao Tome and Principe,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,ADULTS,General/routine,NATIONAL,M18,9-18 mois
STP,Sao Tome and Principe,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,B,0-18 mois
STP,Sao Tome and Principe,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,W6,0-18 mois
STP,Sao Tome and Principe,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,W10,0-18 mois
STP,Sao Tome and Principe,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,W14,0-18 mois
STP,Sao Tome and Principe,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,ADULTS,General/routine,NATIONAL,M15,0-18 mois
STP,Sao Tome and Principe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,W6,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,W10,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,W14,0-11 mois
STP,Sao Tome and Principe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,"6-11 mois, 12-59 mois et postpartum"
STP,Sao Tome and Principe,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,postpartum
STP,Sao Tome and Principe,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,0-11 mois
SUR,Suriname,AMRO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTAP,DTaP (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,For those unable to receive penta
SUR,Suriname,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,For those unable to receive penta
SUR,Suriname,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For those unable to receive penta
SUR,Suriname,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y13,Females
SUR,Suriname,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
SUR,Suriname,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
SUR,Suriname,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
SUR,Suriname,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
SUR,Suriname,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
SUR,Suriname,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
SUR,Suriname,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
SUR,Suriname,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
SUR,Suriname,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
SUR,Suriname,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M6,children
SUR,Suriname,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,M18,children
SUR,Suriname,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,Y4-Y5,children
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,5.0,TRAVELLERS,Travellers,NATIONAL,+D28,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,4.0,TRAVELLERS,Travellers,NATIONAL,+D14,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+D7,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D3,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M12,Travellers
SVK,Slovakia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers
SVK,Slovakia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers
SVK,Slovakia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M10,Travellers
SVK,Slovakia,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Travellers
SVK,Slovakia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered only to high risk groups (newborns of HepB positive mothers)
SVK,Slovakia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,12-14 years old girls and boys; 2nd dose of HPV is applicated 5M-13M after the first dose according to SPC for Gardasil-9; vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination
SVK,Slovakia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,12-14 years old girls and boys; 2nd dose of HPV is applicated 5M-13M after the first dose according to SPC for Gardasil-9; vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination
SVK,Slovakia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=59 years
SVK,Slovakia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
SVK,Slovakia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
SVK,Slovakia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
SVK,Slovakia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y15,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
SVK,Slovakia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>Y15,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
SVK,Slovakia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y15,Children with chronic conditions
SVK,Slovakia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M14,Children with chronic conditions
SVK,Slovakia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y10,Children born until the year 2015 (included) get the second dose at 11-th year of life. Children born in 2016 and afterwards should get the second dose at 5-th year of life.
SVK,Slovakia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M10,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M10,10 and 13 valent vaccines administered; 15 valent vaccine is also available sine 2024
SVK,Slovakia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y30,Vaccination in adults when reaching 30 years and than the revaccination every 15 years
SVK,Slovakia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,7.0,ADULTS,Adults,NATIONAL,+Y15,Vaccination in adults when reaching 30 years and than the revaccination every 15 years
SVK,Slovakia,EURO,2023,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y12,Vaccination in adults when reaching 30 years and than the revaccination every 15 years
SVN,Slovenia,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Epidemiological indications
SVN,Slovenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Children born after 1.10.2019
SVN,Slovenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Children born after 1.10.2019
SVN,Slovenia,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11-M18,Children born after 1.10.2019
SVN,Slovenia,EURO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Epidemiological indications
SVN,Slovenia,EURO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Risk groups
SVN,Slovenia,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Epidemiological indications
SVN,Slovenia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M11-M18,Healthcare workers
SVN,Slovenia,EURO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,"Epidemiological indications, risk groups"
SVN,Slovenia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV
SVN,Slovenia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV
SVN,Slovenia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV
SVN,Slovenia,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"HepBBD only administered to newborns of HBsAG positive mothers, simultaneously with immunoglobulin against Hepatitis B"
SVN,Slovenia,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Risk groups
SVN,Slovenia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Females; in the 6th grade of elementary school; males in 6th grade of elementary school from September 2021
SVN,Slovenia,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females; in the 6th grade of elementary school; males in 6th grade of elementary school from September 2021
SVN,Slovenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65 years of age or more
SVN,Slovenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
SVN,Slovenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
SVN,Slovenia,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents of long-term care facilities"
SVN,Slovenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-M23,"Adults with chronic conditions, residents of long-term care facilities"
SVN,Slovenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y2-Y18,"Adults with chronic conditions, residents of long-term care facilities"
SVN,Slovenia,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,Children with chronic conditions
SVN,Slovenia,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,Epidemiological indications
SVN,Slovenia,EURO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,"Epidemiological indications, risk groups"
SVN,Slovenia,EURO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,Risk groups
SVN,Slovenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y5,Risk groups
SVN,Slovenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M11-M18,Risk groups
SVN,Slovenia,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Epidemiological indication
SVN,Slovenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Epidemiological indication
SVN,Slovenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Epidemiological indication
SVN,Slovenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11-M18,Epidemiological indication
SVN,Slovenia,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Risk groups
SVN,Slovenia,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M11-M18,Immunocompromised persons
SVN,Slovenia,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"Risk groups, older persons from 65 years"
SVN,Slovenia,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Risk groups, older persons from 65 years"
SVN,Slovenia,EURO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,In case of injury by an animal suspected of rabies
SVN,Slovenia,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,NATIONAL,Y49,Adults
SVN,Slovenia,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1-M3,Adults
SVN,Slovenia,EURO,2023,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,ADULTS,Adults,NATIONAL,+M5-M12,Adults
SVN,Slovenia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y1,Children born in 2020; Y3-Y3-Y4 children born from 1.1.2016 to 1.1.2020
SVN,Slovenia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1-M3,Children born in 2020; Y3-Y3-Y4 children born from 1.1.2016 to 1.1.2020
SVN,Slovenia,EURO,2023,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M5-M12,Children born in 2020; Y3-Y3-Y4 children born from 1.1.2016 to 1.1.2020
SVN,Slovenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,+M5-M12,Recommended every 10 years for adults
SVN,Slovenia,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M5-M12,In case of injury
SVN,Slovenia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_F,General/routine,NATIONAL,Y8,5th dose for children who were vaccinated with DTaP-Hib-IPV
SVN,Slovenia,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y8,Pregnant women
SVN,Slovenia,EURO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,PW,General/routine,NATIONAL,Y17,6th dose for those that were vaccinated with DTaP-Hib-IPV
SVN,Slovenia,EURO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y17,Risk groups
SVN,Slovenia,EURO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y17,Immunocompromised persons
SWE,Sweden,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6-M6,Risk groups
SWE,Sweden,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Risk groups
SWE,Sweden,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Risk groups
SWE,Sweden,EURO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Risk groups
SWE,Sweden,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,Risk groups
SWE,Sweden,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Children to HBsAg+ mothers (following doses are given as DTP-IPV-Hib-HepB at M3, M5 and M12)"
SWE,Sweden,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,"Children to HBsAg+ mothers (following doses are given as DTP-IPV-Hib-HepB at M3, M5 and M12)"
SWE,Sweden,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y11,Both females and males
SWE,Sweden,EURO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,Both females and males
SWE,Sweden,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Both females and males
SWE,Sweden,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y65,Health and care workers
SWE,Sweden,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y65,Pregnant women
SWE,Sweden,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,"Adults with chronic conditions, residents living in long-term care facilities"
SWE,Sweden,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Children with chronic conditions
SWE,Sweden,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
SWE,Sweden,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6-Y8,Children with chronic conditions
SWE,Sweden,EURO,2023,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y6-Y8,Risk groups
SWE,Sweden,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Risk groups
SWE,Sweden,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Risk groups
SWE,Sweden,EURO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Risk groups
SWE,Sweden,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M3,Risk groups
SWE,Sweden,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M5,Risk groups
SWE,Sweden,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,Risk groups
SWE,Sweden,EURO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Persons in medical risk groups with high risk for IPD, eg immunocompromised, asplenic and hyposplenic"
SWE,Sweden,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y75,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M5,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_W,General/routine,NATIONAL,Y14-Y16,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,SUBNATIONAL,Y14-Y16,"Pregnant women, from week 16"
SWZ,Eswatini,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,6 W - 23 M
SWZ,Eswatini,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y5,5 Y - 9 Y
SWZ,Eswatini,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,6 W - 23 M
SWZ,Eswatini,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,6 W - 23 M
SWZ,Eswatini,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,6 W - 23 M
SWZ,Eswatini,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,6 W - 23 M
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health care workers
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,Health care workers
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+W4,Health care workers
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,14 W - 23 W
SWZ,Eswatini,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,9 - 59 M
SWZ,Eswatini,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,9 - 59 M
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,All New Born Babies
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,All New Born Babies
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W10,All New Born Babies
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,W14,All New Born Babies
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M18,All New Born Babies
SWZ,Eswatini,AFRO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y5,All New Born Babies
SWZ,Eswatini,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,6 W - 23 M
SWZ,Eswatini,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,6 W - 23 M
SWZ,Eswatini,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,6 W - 23 M
SWZ,Eswatini,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,6 W - 23 M
SWZ,Eswatini,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,6 W - 23 M
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Pregnant women
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SWZ,Eswatini,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 months
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 months
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 months
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 months
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,6-59 months
SWZ,Eswatini,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,6-59 months
SWZ,Eswatini,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M36,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M4,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M3,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTIPV,DT-IPV (Diphtheria and tetanus toxoid and IPV) vaccine,6.0,B_2YL_W,General/routine,NATIONAL,Y9,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,DTIPV,DT-IPV (Diphtheria and tetanus toxoid and IPV) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Travellers
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M7,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,+M6,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y9-Y11,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,Y1,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,Y4,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,M6,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M15,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,M4,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,travellers to endemic countries
SYC,Seychelles,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,travellers to endemic countries
SYC,Seychelles,AFRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,travellers to endemic countries
SYC,Seychelles,AFRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers to endemic countries
SYC,Seychelles,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M3,travellers to endemic countries
SYC,Seychelles,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,travellers to endemic countries
SYC,Seychelles,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M5,travellers to endemic countries
SYC,Seychelles,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk
SYC,Seychelles,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk
SYC,Seychelles,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk
SYC,Seychelles,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,new born
SYC,Seychelles,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,females; P6
SYC,Seychelles,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,females; P6
SYC,Seychelles,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M4,females; P6
SYC,Seychelles,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M15,females; P6
SYC,Seychelles,AFRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,Y6,females; P6
SYC,Seychelles,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,Adults,NATIONAL,Y6,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,ADULTS,General/routine,NATIONAL,M3,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,ADULTS,General/routine,NATIONAL,M4,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,ADULTS,General/routine,NATIONAL,M5,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,ADULTS,General/routine,NATIONAL,M18,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),5.0,ADULTS,General/routine,NATIONAL,Y6,whole population
SYC,Seychelles,AFRO,2023,OPV,OPV (Oral polio vaccine),6.0,ADULTS,General/routine,NATIONAL,Y15,whole population
SYC,Seychelles,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3,whole population
SYC,Seychelles,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,whole population
SYC,Seychelles,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M5,whole population
SYC,Seychelles,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M3,whole population
SYC,Seychelles,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,whole population
SYC,Seychelles,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y25,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y15,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y25,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,General/routine,NATIONAL,Y15,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,Y15,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M12,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M12,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W8,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W16,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W24,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y55,travellers one dose for life
SYR,Syrian Arab Republic,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y55,"Adults with chronic conditions, other groups"
SYR,Syrian Arab Republic,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, other groups"
SYR,Syrian Arab Republic,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W8,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W16,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W24,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,RISKGROUPS,General/routine,NATIONAL,M12,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,RISKGROUPS,General/routine,NATIONAL,M18,"For adults, pregnant women & risk groups"
TCA,Turks and Caicos Islands,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B-M24,"For adults, pregnant women & risk groups"
TCA,Turks and Caicos Islands,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y11,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_F,General/routine,NATIONAL,Y3,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_F,General/routine,NATIONAL,M2,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_F,General/routine,NATIONAL,M4,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_F,General/routine,NATIONAL,M6,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,>=Y15,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,General/routine,NATIONAL,B,"Introduction began 4th quarter of 2019, disrupted by COVID-19 outbreak"
TCA,Turks and Caicos Islands,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"Quadrivalent vaccine for girls 9+ years, but focus on 11 year old girls up to 26 years old women. The first HPV vaccine was bivalent and it was introduced on February 1st 2019 to girls only.  The quadrivalent is being to administered to both male and females."
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents in long-term care facilities, other groups"
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents in long-term care facilities, other groups"
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents in long-term care facilities, other groups"
TCA,Turks and Caicos Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,Y1,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y3,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y3,Children with chronic conditions
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_A,Catch-up adults,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M9,Only for travelers to endemic countries. Can be administered to travelers as young as 9/12
TCD,Chad,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 mois
TCD,Chad,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 mois
TCD,Chad,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 mois
TCD,Chad,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 mois
TCD,Chad,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 mois
TCD,Chad,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 mois
TCD,Chad,AFRO,2023,MEASLES,Measles vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,0-23 mois
TCD,Chad,AFRO,2023,MEASLES,Measles vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M15,0-23 mois
TCD,Chad,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M9,0-11 mois
TCD,Chad,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,General/routine,NATIONAL,B,0-11 mois
TCD,Chad,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,TRAVELLERS,General/routine,NATIONAL,W6,0-11 mois
TCD,Chad,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,W10,0-11 mois
TCD,Chad,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,W14,0-11 mois
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
TCD,Chad,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,0-11 mois
TGO,Togo,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,naissances vivantes
TGO,Togo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,W14,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,PW,General/routine,NATIONAL,M9,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,MEN_A_CONJ,Meningococcal A conjugate vaccine,1.0,PW,General/routine,NATIONAL,M15,15 à 23 M
TGO,Togo,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,PW,General/routine,NATIONAL,M9,enfants 9-23 mois
TGO,Togo,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,PW,General/routine,NATIONAL,M15,enfants 9-23 mois
TGO,Togo,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,B,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W6,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W10,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,PW,General/routine,NATIONAL,W14,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,enfants survivants (0-11 mois)
TGO,Togo,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,M9,enfants 9-11 mois
THA,Thailand,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,M2,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,M4,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,M6,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,Y1.5,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,enfants 9-11 mois
THA,Thailand,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,enfants 9-11 mois
THA,Thailand,SEARO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,HW,General/routine,NATIONAL,B,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Given at 1 month for children with carrier mother
THA,Thailand,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,"Female students grade 5, 2 doses - 6 months apart"
THA,Thailand,SEARO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Female students grade 5, 2 doses - 6 months apart"
THA,Thailand,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65Y+
THA,Thailand,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
THA,Thailand,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
THA,Thailand,SEARO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,JE_LIVEATD,JE-Livatd (Japanese Encephalitis live-attenuated) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y2.5,"Adults with chronic conditions, other groups"
THA,Thailand,SEARO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9-Y55,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M9-Y55,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y5,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M9,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,Y1.5,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,HW,Health workers,NATIONAL,Y1.5,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,HW,General/routine,NATIONAL,M6,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,HW,General/routine,NATIONAL,Y1.5,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,OPV,OPV (Oral polio vaccine),5.0,HW,General/routine,NATIONAL,Y4,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,HW,General/routine,NATIONAL,M2,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,HW,General/routine,NATIONAL,M4,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,HW,General/routine,NATIONAL,M6,Healthcare workers and all University students of first-year in Faculty of Medical and Public Health
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Adult age 20Y above booster dose every 10 years
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y12,All school children in grade 6
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M9,Travellers
TJK,Tajikistan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,D3-D5,Новорождённые дети
TJK,Tajikistan,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Дети 6 лет
TJK,Tajikistan,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,М16-M23,Дети 16-23 месяца
TJK,Tajikistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,М2,Дети до 1 года
TJK,Tajikistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,М3,Дети до 1 года
TJK,Tajikistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,М4,Дети до 1 года
TJK,Tajikistan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,"При рождении  вакцина Гепатита В водится отдельно, а  в 2, 3 и 4 месячном  возрасте  вводится в составе Пентавалентной вакцины"
TJK,Tajikistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,B,Health and care workers
TJK,Tajikistan,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,HW,General/routine,NATIONAL,М3,Дети до 1 года
TJK,Tajikistan,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,HW,General/routine,NATIONAL,M9,Дети до 1 года
TJK,Tajikistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,General/routine,NATIONAL,M12,Дети 1 года и в 6 лет
TJK,Tajikistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,HW,General/routine,NATIONAL,Y6,Дети 1 года и в 6 лет
TJK,Tajikistan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,HW,General/routine,NATIONAL,B,дети до 1 года
TJK,Tajikistan,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,HW,General/routine,NATIONAL,М2,дети до 1 года
TJK,Tajikistan,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,HW,General/routine,NATIONAL,М3,дети до 1 года
TJK,Tajikistan,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,HW,General/routine,NATIONAL,М4,дети до 1 года
TJK,Tajikistan,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,HW,General/routine,NATIONAL,М12,дети до 1 года
TJK,Tajikistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,HW,General/routine,NATIONAL,М2,"Дети до 1 года, 1 год"
TJK,Tajikistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,HW,General/routine,NATIONAL,М4,"Дети до 1 года, 1 год"
TJK,Tajikistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,HW,General/routine,NATIONAL,М12,"Дети до 1 года, 1 год"
TJK,Tajikistan,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,HW,General/routine,NATIONAL,М2,Дети до 1 года
TJK,Tajikistan,EURO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,HW,General/routine,NATIONAL,М3,Дети до 1 года
TJK,Tajikistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y26,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y36,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y46,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y56,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,Y16,Взрослые  в возрасте 16-26-36-46-56 лет.
TKL,Tokelau,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,B,birth
TKL,Tokelau,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5,birth
TKL,Tokelau,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,6w.10w.14w
TKL,Tokelau,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,6w.10w.14w
TKL,Tokelau,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,6w.10w.14w
TKL,Tokelau,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,birth
TKL,Tokelau,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,birth
TKL,Tokelau,WPRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,birth
TKL,Tokelau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,BOTH,General/routine,NATIONAL,W6,6w.10w.14w
TKL,Tokelau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,BOTH,General/routine,NATIONAL,W10,6w.10w.14w
TKL,Tokelau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,BOTH,General/routine,NATIONAL,W14,6w.10w.14w
TKL,Tokelau,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,BOTH,General/routine,NATIONAL,M18,6w.10w.14w
TKL,Tokelau,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,BOTH,General/routine,NATIONAL,M12,"12m, 15m"
TKL,Tokelau,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,BOTH,General/routine,NATIONAL,M15,"12m, 15m"
TKL,Tokelau,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y11,"12m, 15m"
TKL,Tokelau,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y11,pregnant women
TKM,Turkmenistan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,D2-D3,pregnant women
TKM,Turkmenistan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,2.0,PW,General/routine,NATIONAL,Y14,pregnant women
TKM,Turkmenistan,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,pregnant women
TKM,Turkmenistan,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,pregnant women
TKM,Turkmenistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,pregnant women
TKM,Turkmenistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,pregnant women
TKM,Turkmenistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,pregnant women
TKM,Turkmenistan,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,с октября 2019
TKM,Turkmenistan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,с октября 2019
TKM,Turkmenistan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,с октября 2019
TKM,Turkmenistan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,с октября 2019
TKM,Turkmenistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons 65+
TKM,Turkmenistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>=Y18,Health and care workers
TKM,Turkmenistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>=Y18,выше 22-х недель
TKM,Turkmenistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
TKM,Turkmenistan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,and 3-16 years
TKM,Turkmenistan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12-M15,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,D2-D3,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
TKM,Turkmenistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,с октября 2019
TKM,Turkmenistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,с октября 2019
TKM,Turkmenistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,с октября 2019
TKM,Turkmenistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,с октября 2019
TKM,Turkmenistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,с октября 2019
TKM,Turkmenistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M4,с октября 2019
TKM,Turkmenistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,с октября 2019
TLS,Timor-Leste,SEARO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,U1Y
TLS,Timor-Leste,SEARO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,6Y
TLS,Timor-Leste,SEARO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,1-2Y
TLS,Timor-Leste,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,U1Y
TLS,Timor-Leste,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,U1Y
TLS,Timor-Leste,SEARO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,U1Y
TLS,Timor-Leste,SEARO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Administered within 24 hours
TLS,Timor-Leste,SEARO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,W14,U1Y
TLS,Timor-Leste,SEARO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,U2Y
TLS,Timor-Leste,SEARO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M18,U2Y
TLS,Timor-Leste,SEARO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,B,U1Y
TLS,Timor-Leste,SEARO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,W6,U1Y
TLS,Timor-Leste,SEARO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,W10,U1Y
TLS,Timor-Leste,SEARO,2023,OPV,OPV (Oral polio vaccine),4.0,B_2YL_W,General/routine,NATIONAL,W14,U1Y
TLS,Timor-Leste,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,U1Y
TLS,Timor-Leste,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,U1Y
TLS,Timor-Leste,SEARO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,U1Y
TLS,Timor-Leste,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,"Introduced in Q4 2019 and by end of December 2019, introduction nationwide"
TLS,Timor-Leste,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,"Introduced in Q4 2019 and by end of December 2019, introduction nationwide"
TLS,Timor-Leste,SEARO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,"Introduced in Q4 2019 and by end of December 2019, introduction nationwide"
TLS,Timor-Leste,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
TLS,Timor-Leste,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
TLS,Timor-Leste,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
TLS,Timor-Leste,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
TLS,Timor-Leste,SEARO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,U5Y
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,U5Y
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,U5Y
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,U5Y
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,U5Y
TLS,Timor-Leste,SEARO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,U5Y
TON,Tonga,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,U5Y
TON,Tonga,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,U5Y
TON,Tonga,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Y5 is at school entry at class 1
TON,Tonga,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Y5 is at school entry at class 1
TON,Tonga,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,Y5 is at school entry at class 1
TON,Tonga,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,Y5 is at school entry at class 1
TON,Tonga,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Y5 is at school entry at class 1
TON,Tonga,WPRO,2023,HPV,HPV (Human Papilloma Virus) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y17,10-17 Y female
TON,Tonga,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,10-17 Y female
TON,Tonga,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,10-17 Y female
TON,Tonga,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,10-17 Y female
TON,Tonga,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,10-17 Y female
TON,Tonga,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,10-17 Y female
TON,Tonga,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,10-17 Y female
TON,Tonga,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,10-17 Y female
TON,Tonga,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,10-17 Y female
TON,Tonga,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,10-17 Y female
TON,Tonga,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,10-17 Y female
TON,Tonga,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,10-17 Y female
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,Y16,Given to Form 6 students at school as school leavers vaccination
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TON,Tonga,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Pregnant women not vaccinated or incompletely vaccinated with primary series and boosters
TTO,Trinidad and Tobago,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,>=Y10,Health Care Workers
TTO,Trinidad and Tobago,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Health Care Workers
TTO,Trinidad and Tobago,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Health Care Workers
TTO,Trinidad and Tobago,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>M12,Given to children who do not receive DTP-HepB-Hib
TTO,Trinidad and Tobago,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y15,"Females and males; x2 doses 11-15 years (+6 months apart), x3 does >15 years (+6 weeks, +6 months apart) females (up to 45 years) and males (up to 26 years)"
TTO,Trinidad and Tobago,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females and males; x2 doses 11-15 years (+6 months apart), x3 does >15 years (+6 weeks, +6 months apart) females (up to 45 years) and males (up to 26 years)"
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
TTO,Trinidad and Tobago,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
TTO,Trinidad and Tobago,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
TTO,Trinidad and Tobago,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
TTO,Trinidad and Tobago,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y2,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4-Y5,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,General/routine,NATIONAL,M18,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,Health Care Workers / Students / High risk
TTO,Trinidad and Tobago,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,10+
TTO,Trinidad and Tobago,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y9-Y12,10+
TTO,Trinidad and Tobago,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,Y9-Y12,"Pregnant women in need of booster during 1st, 2nd or 3rd trimester"
TTO,Trinidad and Tobago,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,M12,>=M12
TTO,Trinidad and Tobago,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,M14,>=M12
TTO,Trinidad and Tobago,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,PW,General/routine,NATIONAL,Y1,>=M12
TUN,Tunisia,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,>=M12
TUN,Tunisia,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M12,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_2YL_W,General/routine,NATIONAL,Y6,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"ce vaccin est destiné aux enfants ayant une contre indication au composant coquelucheux , les vaccins du Penta leur sont administrés séparément dont le Dt"
TUN,Tunisia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
TUN,Tunisia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
TUN,Tunisia,EMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
TUN,Tunisia,EMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,Children with chronic conditions
TUN,Tunisia,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
TUN,Tunisia,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,Children with chronic conditions
TUN,Tunisia,EMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
TUN,Tunisia,EMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
TUN,Tunisia,EMRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
TUN,Tunisia,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
TUN,Tunisia,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
TUN,Tunisia,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,Y12,Children with chronic conditions
TUN,Tunisia,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y18,Children with chronic conditions
TUN,Tunisia,EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Depuis Avril 2019
TUN,Tunisia,EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Depuis Avril 2019
TUN,Tunisia,EMRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M11,Depuis Avril 2019
TUN,Tunisia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y18,Depuis Avril 2019
TUN,Tunisia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,Depuis Avril 2019
TUN,Tunisia,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,Depuis Avril 2019
TUR,Türkiye,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,Depuis Avril 2019
TUR,Türkiye,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,Depuis Avril 2019
TUR,Türkiye,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,Depuis Avril 2019
TUR,Türkiye,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M6,Depuis Avril 2019
TUR,Türkiye,EURO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Depuis Avril 2019
TUR,Türkiye,EURO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,M48,48 months old infants
TUR,Türkiye,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M18,48 months old infants
TUR,Türkiye,EURO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M24,48 months old infants
TUR,Türkiye,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Birth and 72 hours
TUR,Türkiye,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M1,Birth and 72 hours
TUR,Türkiye,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Birth and 72 hours
TUR,Türkiye,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,M12,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,B_CHILD_W,General/routine,NATIONAL,M48,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,M6,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,M18,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M12,12 months and 48 months old infants
TUR,Türkiye,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y13,13 years old children
TUR,Türkiye,EURO,2023,VARICELLA,Varicella vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M12,13 years old children
TUV,Tuvalu,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,Below one year
TUV,Tuvalu,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,School entry
TUV,Tuvalu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,Below one year
TUV,Tuvalu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,Below one year
TUV,Tuvalu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,Below one year
TUV,Tuvalu,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,At birth
TUV,Tuvalu,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Ten year females
TUV,Tuvalu,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,Up to five years
TUV,Tuvalu,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,Up to five years
TUV,Tuvalu,WPRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,Up to five years
TUV,Tuvalu,WPRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M12,Up to five years
TUV,Tuvalu,WPRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M12,Up to 14 years
TUV,Tuvalu,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,Up to 14 years
TUV,Tuvalu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Up to 14 years
TUV,Tuvalu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W14,Up to 14 years
TUV,Tuvalu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M12,Up to 14 years
TUV,Tuvalu,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Up to 24 months
TUV,Tuvalu,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W14,Up to 24 months
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TUV,Tuvalu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Pregnant mothers (as soon as the woman is pregnant) and trauma cases
TZA,United Republic of Tanzania,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,live birth
TZA,United Republic of Tanzania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y14,girls of 14 years
TZA,United Republic of Tanzania,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,girls of 14 years
TZA,United Republic of Tanzania,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,under 2 years
TZA,United Republic of Tanzania,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,under 2 years
TZA,United Republic of Tanzania,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,surviving infants
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st Contact,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,1st Contact,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st Contact,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,CBAW and pregnant women
TZA,United Republic of Tanzania,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,CBAW and pregnant women
UGA,Uganda,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,0-11 months
UGA,Uganda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,6 weeks - 11 months
UGA,Uganda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,6 weeks - 11 months
UGA,Uganda,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,6 weeks - 11 months
UGA,Uganda,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,Adults above 20 years
UGA,Uganda,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+M1,Adults above 20 years
UGA,Uganda,AFRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,SUBNATIONAL,+M5,Adults above 20 years
UGA,Uganda,AFRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,24 hours all live births
UGA,Uganda,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,10 year old females
UGA,Uganda,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,10 year old females
UGA,Uganda,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,14 weeks - 11 months
UGA,Uganda,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W14,14 weeks - 11 months
UGA,Uganda,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,9-11 months
UGA,Uganda,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,9-11 months
UGA,Uganda,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,B,0-11 months
UGA,Uganda,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W6,0-11 months
UGA,Uganda,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W10,0-11 months
UGA,Uganda,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,W14,0-11 months
UGA,Uganda,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,6 weeks - 11 months
UGA,Uganda,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,6 weeks - 11 months
UGA,Uganda,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,6 weeks - 11 months
UGA,Uganda,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,6 weeks - 11 months
UGA,Uganda,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,6 weeks - 11 months
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15-Y49,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,1st contact women of reproductive age (15-49years)
UGA,Uganda,AFRO,2023,YF,YF (Yellow fever) vaccine,1.0,ADULTS,General/routine,NATIONAL,M9,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,D3,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,DTWP,DTwP (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,DTWP,DTwP (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,D1,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M12,1st contact women of reproductive age (15-49years)
UKR,Ukraine,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
UKR,Ukraine,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
UKR,Ukraine,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
UKR,Ukraine,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
UKR,Ukraine,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
UKR,Ukraine,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
UKR,Ukraine,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
UKR,Ukraine,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
UKR,Ukraine,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Children with chronic conditions
UKR,Ukraine,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
UKR,Ukraine,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
UKR,Ukraine,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Children with chronic conditions
UKR,Ukraine,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y6,Children with chronic conditions
UKR,Ukraine,EURO,2023,OPV,OPV (Oral polio vaccine),6.0,RISKGROUPS,General/routine,NATIONAL,Y14,Children with chronic conditions
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y26,каждые 10 лет
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y36,каждые 10 лет
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y46,каждые 10 лет
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y56,каждые 10 лет
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y66,каждые 10 лет
UKR,Ukraine,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,Y16,каждые 10 лет
URY,Uruguay,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,B,каждые 10 лет
URY,Uruguay,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M15,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,Niños que no pueden recibir componente pertussis incluido en vacuna pentavalente
URY,Uruguay,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,M15,"A partir de los 10 años en grupos de riesgo (2 dosis separadas por 6 meses entre ellas): hepatopatía crónica (si suceptible: sin antecedente de enfermedad con serología negativa), hombres que tienen sexo con hombres, personas trans, trabajadores de la salud con riesgo de exposición"
URY,Uruguay,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y10,"A partir de los 10 años en grupos de riesgo (2 dosis separadas por 6 meses entre ellas): hepatopatía crónica (si suceptible: sin antecedente de enfermedad con serología negativa), hombres que tienen sexo con hombres, personas trans, trabajadores de la salud con riesgo de exposición"
URY,Uruguay,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y10,"A partir de los 10 años en grupos de riesgo (2 dosis separadas por 6 meses entre ellas): hepatopatía crónica (si suceptible: sin antecedente de enfermedad con serología negativa), hombres que tienen sexo con hombres, personas trans, trabajadores de la salud con riesgo de exposición"
URY,Uruguay,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M15,"A partir de los 10 años en grupos de riesgo (2 dosis separadas por 6 meses entre ellas): hepatopatía crónica (si suceptible: sin antecedente de enfermedad con serología negativa), hombres que tienen sexo con hombres, personas trans, trabajadores de la salud con riesgo de exposición"
URY,Uruguay,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M21,"A partir de los 10 años en grupos de riesgo (2 dosis separadas por 6 meses entre ellas): hepatopatía crónica (si suceptible: sin antecedente de enfermedad con serología negativa), hombres que tienen sexo con hombres, personas trans, trabajadores de la salud con riesgo de exposición"
URY,Uruguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M21,Trabajadores de salud y otros grupos de riesgo que no fueron inmunizados en las cohortes previas. El esquema se refiere que a partir de los 12 años se administra la dosis de adulto en aquellas personas quienes no hayan recibido la vacuna pentavalente (por ejemplo: población migrante) o aquellas personas nacidas antes de la implementación de la vacuna pentavalente que contiene componente contra Hepatitis B.
URY,Uruguay,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y12,Trabajadores de salud y otros grupos de riesgo que no fueron inmunizados en las cohortes previas. El esquema se refiere que a partir de los 12 años se administra la dosis de adulto en aquellas personas quienes no hayan recibido la vacuna pentavalente (por ejemplo: población migrante) o aquellas personas nacidas antes de la implementación de la vacuna pentavalente que contiene componente contra Hepatitis B.
URY,Uruguay,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Niños que no pueden recibir componente pertussis. Recién nacidos de madre seropositiva. Para este grupo, se indica media dosis de la vacuna empleada en adultos."
URY,Uruguay,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Niños que no pueden recibir componente pertussis. Recién nacidos de madre seropositiva. Para este grupo, se indica media dosis de la vacuna empleada en adultos."
URY,Uruguay,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Niños que no pueden recibir componente pertussis. Recién nacidos de madre seropositiva. Para este grupo, se indica media dosis de la vacuna empleada en adultos."
URY,Uruguay,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M15,"Niños que no pueden recibir componente pertussis. Recién nacidos de madre seropositiva. Para este grupo, se indica media dosis de la vacuna empleada en adultos."
URY,Uruguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Niños que no pueden recibir componente pertussis, esplenectomizados"
URY,Uruguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Niños que no pueden recibir componente pertussis, esplenectomizados"
URY,Uruguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Niños que no pueden recibir componente pertussis, esplenectomizados"
URY,Uruguay,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M15,"Niños que no pueden recibir componente pertussis, esplenectomizados"
URY,Uruguay,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"A partitr de 2022 la vacunación contra el VPH se administra entre los 11 y 26 años de vida tanto a mujeres como varones. El esquema tanto para hombres y mujeres inmunocompetentes entre 11 y 26 años es de 2 dosis. Para inmuncomprometidos a partir de los 9 años y hasta los 26, es de 3 dosis."
URY,Uruguay,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"A partitr de 2022 la vacunación contra el VPH se administra entre los 11 y 26 años de vida tanto a mujeres como varones. El esquema tanto para hombres y mujeres inmunocompetentes entre 11 y 26 años es de 2 dosis. Para inmuncomprometidos a partir de los 9 años y hasta los 26, es de 3 dosis."
URY,Uruguay,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y26,"A partitr de 2022 la vacunación contra el VPH se administra entre los 11 y 26 años de vida tanto a mujeres como varones. El esquema tanto para hombres y mujeres inmunocompetentes entre 11 y 26 años es de 2 dosis. Para inmuncomprometidos a partir de los 9 años y hasta los 26, es de 3 dosis."
URY,Uruguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=Y65
URY,Uruguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
URY,Uruguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
URY,Uruguay,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
URY,Uruguay,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y2,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
URY,Uruguay,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=Y3,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
URY,Uruguay,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y3,Children with chronic conditions
URY,Uruguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
URY,Uruguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,Children with chronic conditions
URY,Uruguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
URY,Uruguay,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y5,Children with chronic conditions
URY,Uruguay,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,HW,Health workers,NATIONAL,Y5,"Personal de salud en contacto con muestras (personal de laboratorio de microbiología), esplenectomizado, personas con asplenia funcional, usuarios de eculizumab"
URY,Uruguay,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Personal de salud en contacto con muestras (personal de laboratorio de microbiología), esplenectomizado, personas con asplenia funcional, usuarios de eculizumab"
URY,Uruguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Personal de salud en contacto con muestras (personal de laboratorio de microbiología), esplenectomizado, personas con asplenia funcional, usuarios de eculizumab"
URY,Uruguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15,"Personal de salud en contacto con muestras (personal de laboratorio de microbiología), esplenectomizado, personas con asplenia funcional, usuarios de eculizumab"
URY,Uruguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y5,Toda persona nacida a partir de 1967 deberá administrarse o completar 2 dosis de vacuna con componente anti sarampión con un intervalo de 4 semanas entre ellas.
URY,Uruguay,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y5,Toda persona nacida a partir de 1967 deberá administrarse o completar 2 dosis de vacuna con componente anti sarampión con un intervalo de 4 semanas entre ellas.
URY,Uruguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,Toda persona nacida a partir de 1967 deberá administrarse o completar 2 dosis de vacuna con componente anti sarampión con un intervalo de 4 semanas entre ellas.
URY,Uruguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,Toda persona nacida a partir de 1967 deberá administrarse o completar 2 dosis de vacuna con componente anti sarampión con un intervalo de 4 semanas entre ellas.
URY,Uruguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,Y1,Toda persona nacida a partir de 1967 deberá administrarse o completar 2 dosis de vacuna con componente anti sarampión con un intervalo de 4 semanas entre ellas.
URY,Uruguay,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,"Pacientes inmunodeprimidos, se administra 1 dosis de PCV 13"
URY,Uruguay,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,En personas con comorbilidades se administra un esquema combinado de 2 dosis de vacuna con componente antineumocócico: 1 dosis de PCV13 y 8 semanas después 1 dosis de PSV23.
URY,Uruguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y45,5 dosis registradas o más reciben una dosis a los 45 y a los  65 años.
URY,Uruguay,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,5 dosis registradas o más reciben una dosis a los 45 y a los  65 años.
URY,Uruguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,5 dosis registradas o más reciben una dosis a los 45 y a los  65 años.
URY,Uruguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,Y11,"Embarazadas, personal de salud y otros grupos de riesgo. Se administra 1 dosis a las embarazadas a partir de la semana 28 de gestación. En personal de salud y otros grupos de riesgo de administra 1 dosis como refuerzo del esquema antitetánico recibido."
URY,Uruguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11,"Embarazadas, personal de salud y otros grupos de riesgo. Se administra 1 dosis a las embarazadas a partir de la semana 28 de gestación. En personal de salud y otros grupos de riesgo de administra 1 dosis como refuerzo del esquema antitetánico recibido."
URY,Uruguay,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11,"Embarazadas, personal de salud y otros grupos de riesgo. Se administra 1 dosis a las embarazadas a partir de la semana 28 de gestación. En personal de salud y otros grupos de riesgo de administra 1 dosis como refuerzo del esquema antitetánico recibido."
URY,Uruguay,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y1,"Embarazadas, personal de salud y otros grupos de riesgo. Se administra 1 dosis a las embarazadas a partir de la semana 28 de gestación. En personal de salud y otros grupos de riesgo de administra 1 dosis como refuerzo del esquema antitetánico recibido."
URY,Uruguay,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y5,"Embarazadas, personal de salud y otros grupos de riesgo. Se administra 1 dosis a las embarazadas a partir de la semana 28 de gestación. En personal de salud y otros grupos de riesgo de administra 1 dosis como refuerzo del esquema antitetánico recibido."
URY,Uruguay,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M9-Y60,">9 meses y adultos hasta 60 años que viajan a zonas endémicas (Si bien la vacuna no se administra de forma sistemática, se pueden vacunar desde los 6 meses)"
USA,United States of America,AMRO,2023,ANTHRAX,Anthrax vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9-Y60,Persons at risk of or already exposed to disease either occupational or bioterroism
USA,United States of America,AMRO,2023,CHOLERA,Cholera vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,"at-risk persons, for travellers to cholera-epidemic or cholera-endemic areas"
USA,United States of America,AMRO,2023,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y2-Y18,"at-risk persons, for travellers to cholera-epidemic or cholera-endemic areas"
USA,United States of America,AMRO,2023,DENGUE,Dengue vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y9,"at-risk persons, for travellers to cholera-epidemic or cholera-endemic areas"
USA,United States of America,AMRO,2023,DENGUE,Dengue vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6,"at-risk persons, for travellers to cholera-epidemic or cholera-endemic areas"
USA,United States of America,AMRO,2023,DENGUE,Dengue vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6,"at-risk persons, for travellers to cholera-epidemic or cholera-endemic areas"
USA,United States of America,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,contraindication to pertussis component
USA,United States of America,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,contraindication to pertussis component
USA,United States of America,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,contraindication to pertussis component
USA,United States of America,AMRO,2023,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y4,contraindication to pertussis component
USA,United States of America,AMRO,2023,EBOLA,Ebola vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,"Only for persons working in Ebola treatment centers, Special Pathogen Treatment Centers, Biosafety Level 3 Laboratories, or Laboratory Response Network"
USA,United States of America,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,"Only for persons working in Ebola treatment centers, Special Pathogen Treatment Centers, Biosafety Level 3 Laboratories, or Laboratory Response Network"
USA,United States of America,AMRO,2023,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,"Only for persons working in Ebola treatment centers, Special Pathogen Treatment Centers, Biosafety Level 3 Laboratories, or Laboratory Response Network"
USA,United States of America,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,3 or 4 doses depending on usage: 4-dose travel series to expedite administration of early doses
USA,United States of America,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,3 or 4 doses depending on usage: 4-dose travel series to expedite administration of early doses
USA,United States of America,AMRO,2023,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,3 or 4 doses depending on usage: 4-dose travel series to expedite administration of early doses
USA,United States of America,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,3 or 4 doses depending on usage: 4-dose travel series to expedite administration of early doses
USA,United States of America,AMRO,2023,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,3 or 4 doses depending on usage: 4-dose travel series to expedite administration of early doses
USA,United States of America,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M4,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,ADULTS,General/routine,NATIONAL,M1,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,ADULTS,General/routine,NATIONAL,B,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,3 or 4 doses depending on vaccine
USA,United States of America,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,3 or 4 doses depending on vaccine
USA,United States of America,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,3 or 4 doses depending on vaccine
USA,United States of America,AMRO,2023,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,ADULTS,General/routine,NATIONAL,M12,3 or 4 doses depending on vaccine
USA,United States of America,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,Y4,"females and males; if 1st dose is administered at <15 years and no risk groups then x2 doses with interval 6-12 months; if the 1st dose is administered >=15 years or for risk groups x3 doses with an interval of 0, 1, 6 months"
USA,United States of America,AMRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,at-risk persons
USA,United States of America,AMRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,at-risk persons
USA,United States of America,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y11,at-risk persons
USA,United States of America,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y16,at-risk persons
USA,United States of America,AMRO,2023,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,at-risk persons
USA,United States of America,AMRO,2023,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MEN_B,Meningococcal B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y4,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"High risk for invasive meningococcal B disease, and at Y10, +M1, +M6 for high risk groups of meningococcal disease (3rd dose depend on vaccine brand)"
USA,United States of America,AMRO,2023,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y65,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,General/routine,NATIONAL,M2,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,ADULTS,General/routine,NATIONAL,M4,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,ADULTS,General/routine,NATIONAL,M6,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,ADULTS,General/routine,NATIONAL,M12,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y66,Administered as an option for children routinely as an alternative to PCV13
USA,United States of America,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y7,and at Y2 and Y7 for high risk for invasive pneumococcal disease
USA,United States of America,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,and at Y2 and Y7 for high risk for invasive pneumococcal disease
USA,United States of America,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M6,2 or 3 doses depending on vaccine
USA,United States of America,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y21,Tdap can be substituded
USA,United States of America,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Tdap can be substituded
USA,United States of America,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y21,"Can be substituded for Td vaccine for adults (Y21, +Y10)"
USA,United States of America,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,"Can be substituded for Td vaccine for adults (Y21, +Y10)"
USA,United States of America,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Can be substituded for Td vaccine for adults (Y21, +Y10)"
USA,United States of America,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y11-Y12,every pregnancy for women
USA,United States of America,AMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y6,For high-risk travelers - ongoing every 5 years if at continued high-risk
USA,United States of America,AMRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y5,For high-risk travelers - ongoing every 5 years if at continued high-risk
USA,United States of America,AMRO,2023,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,at-risk persons
USA,United States of America,AMRO,2023,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M12,at-risk persons
USA,United States of America,AMRO,2023,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,Y4,at-risk persons
USA,United States of America,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,at-risk persons
USA,United States of America,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y50,at-risk persons
USA,United States of America,AMRO,2023,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2,at-risk persons
UZB,Uzbekistan,EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,ADULTS,General/routine,NATIONAL,D3,новорожденные
UZB,Uzbekistan,EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M16,дети до 1 года
UZB,Uzbekistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,дети до 1 года и 1-2 года и дети школьного возраста
UZB,Uzbekistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,дети до 1 года и 1-2 года и дети школьного возраста
UZB,Uzbekistan,EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,дети до 1 года и 1-2 года и дети школьного возраста
UZB,Uzbekistan,EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,1 сутки; дети до 1 года
UZB,Uzbekistan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,девочки
UZB,Uzbekistan,EURO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,девочки
UZB,Uzbekistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
UZB,Uzbekistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
UZB,Uzbekistan,EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Residents living in long-term care facilities
UZB,Uzbekistan,EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,+M6,есть рекомендации по вакцинации детей 3-4 классы
UZB,Uzbekistan,EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M4,дети до 1 года
UZB,Uzbekistan,EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M9,дети до 1 года
UZB,Uzbekistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,дети 12 месяцев и 6 лет
UZB,Uzbekistan,EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6,дети 12 месяцев и 6 лет
UZB,Uzbekistan,EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,дети до 7 лет
UZB,Uzbekistan,EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,дети до 7 лет
UZB,Uzbekistan,EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,дети до 7 лет
UZB,Uzbekistan,EURO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M16,дети до 7 лет
UZB,Uzbekistan,EURO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y7,дети до 7 лет
UZB,Uzbekistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,дети до 2 лет
UZB,Uzbekistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,дети до 2 лет
UZB,Uzbekistan,EURO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M12,дети до 2 лет
UZB,Uzbekistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,дети до 1 года
UZB,Uzbekistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M3,дети до 1 года
UZB,Uzbekistan,EURO,2023,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M3,дети до 1 года
UZB,Uzbekistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7,дети школьного возраста
UZB,Uzbekistan,EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_F,General/routine,NATIONAL,Y16,дети школьного возраста
VCT,Saint Vincent and the Grenadines,AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,B-M12,Birth up to 1 year
VCT,Saint Vincent and the Grenadines,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Birth up to 1 year
VCT,Saint Vincent and the Grenadines,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Birth up to 1 year
VCT,Saint Vincent and the Grenadines,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,0-11 months
VCT,Saint Vincent and the Grenadines,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M4,0-11 months
VCT,Saint Vincent and the Grenadines,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M6,0-11 months
VCT,Saint Vincent and the Grenadines,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Adults with no doccumented evidence of HepB
VCT,Saint Vincent and the Grenadines,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Adults with no doccumented evidence of HepB
VCT,Saint Vincent and the Grenadines,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Adults with no doccumented evidence of HepB
VCT,Saint Vincent and the Grenadines,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,Adults with no doccumented evidence of HepB
VCT,Saint Vincent and the Grenadines,AMRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y12,Up to 20 years
VCT,Saint Vincent and the Grenadines,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,M2,and immunocompromised children
VCT,Saint Vincent and the Grenadines,AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M4,and immunocompromised children
VCT,Saint Vincent and the Grenadines,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Immunocompromised children
VCT,Saint Vincent and the Grenadines,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,Immunocompromised children
VCT,Saint Vincent and the Grenadines,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M18,Immunocompromised children
VCT,Saint Vincent and the Grenadines,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,Adults,NATIONAL,M18,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,General/routine,NATIONAL,>Y10,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y10,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,RISKGROUPS,General/routine,NATIONAL,M18,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,RISKGROUPS,General/routine,NATIONAL,Y4,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Adults (like seafarers going to study)
VCT,Saint Vincent and the Grenadines,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers travelling to countries endemic to Yellow Fever
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,< 1 año
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M6,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Embarazadas, Personal de Salud, Privados de Libertad, Trabajadores sexuales, Pacientes en Diálisis.  Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,DENTRO DE LAS PRIMERAS 24 HORAS DE NACIDO
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,< 1 año
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M4,< 1 año
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MEN_BC,Meningococcal BC vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Se usa para control de brotes a partir de los 2 años y en grupos de riesgo para poblaciones concentradas, Personal de Salud, contingente militar y viajeros internacional. No se dispone. Debido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,TRAVELLERS,General/routine,NATIONAL,M18,"12 MESES , 18 MESES"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,General/routine,NATIONAL,M12,"12 MESES , 18 MESES"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,Y6-Y39,Una dosis a viajeros internacionales según antecedente vacunal
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,TRAVELLERS,General/routine,NATIONAL,Y5,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,OPV,OPV (Oral polio vaccine),3.0,TRAVELLERS,General/routine,NATIONAL,M6,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,TRAVELLERS,General/routine,NATIONAL,M18,"MENORES 1 AÑO, 1 AÑO Y 5 AÑOS."
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M2,1 Año. En el año 2014 se introdujo la vacuna neumococo. Debido a las dificultades financieras de los últimos años esta vacuna no se ha podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,TRAVELLERS,General/routine,NATIONAL,M4,1 Año. En el año 2014 se introdujo la vacuna neumococo. Debido a las dificultades financieras de los últimos años esta vacuna no se ha podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,TRAVELLERS,General/routine,NATIONAL,M18,1 Año. En el año 2014 se introdujo la vacuna neumococo. Debido a las dificultades financieras de los últimos años esta vacuna no se ha podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Expuestos al virus por contacto con animales probablemente infectados, Profilaxis de trabajadores de salud. En el año 2006 se introdujo la vacuna contrDebido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,"Expuestos al virus por contacto con animales probablemente infectados, Profilaxis de trabajadores de salud. En el año 2006 se introdujo la vacuna contrDebido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Expuestos al virus por contacto con animales probablemente infectados, Profilaxis de trabajadores de salud. En el año 2006 se introdujo la vacuna contrDebido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,"Expuestos al virus por contacto con animales probablemente infectados, Profilaxis de trabajadores de salud. En el año 2006 se introdujo la vacuna contrDebido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,"Expuestos al virus por contacto con animales probablemente infectados, Profilaxis de trabajadores de salud. En el año 2006 se introdujo la vacuna contrDebido a las dificultades financieras de los últimos años estas vacunas no se han podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M4,< 1 año. En el año 2006 se introdujo la vacuna contra rotavirus. Debido a las dificultades financieras de los últimos años esta vacunas no se ha podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M2,< 1 año. En el año 2006 se introdujo la vacuna contra rotavirus. Debido a las dificultades financieras de los últimos años esta vacunas no se ha podido adquirir desde el 2018. Se hacen esfuerzos para la reintroducción al esquema de estos biológicos próximamente
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,10 AÑOS
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,HW,Health workers,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,HW,Health workers,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,TRAVELLERS,Travellers,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,TRAVELLERS,Travellers,NATIONAL,+Y1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Embarazadas, Personal de Salud Mujeres en edad fértil, Hombres, viajeros internacional"
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,M12,1 AÑO
VEN,Venezuela (Bolivarian Republic of),AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y2-Y59,"2 a 59 años y viajeros internacionales no vacunados. Cumpliendo con el reglamento sanitario internacional, se aplica una sola dosis. En el caso de los viajeros internacionales solo se le administra a aquellos que no han sido vacunados entre las edades de 2 a 59 años"
VGB,British Virgin Islands,AMRO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,CATCHUP_C,Catch-up children,NATIONAL,Y5,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M6,given to those who missed DTP at 4 years
VGB,British Virgin Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,M6,Healthcare workers
VGB,British Virgin Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y14,1st contact to persons >14 years based on need
VGB,British Virgin Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,1st contact to persons >14 years based on need
VGB,British Virgin Islands,AMRO,2023,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,1st contact to persons >14 years based on need
VGB,British Virgin Islands,AMRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,B,1st contact to persons >14 years based on need
VGB,British Virgin Islands,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y14,from April 2019; Target age group 11-12 females only 2 doses x 6m interval
VGB,British Virgin Islands,AMRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,from April 2019; Target age group 11-12 females only 2 doses x 6m interval
VGB,British Virgin Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,+M6,Older persons
VGB,British Virgin Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,+M6,Health and care workers
VGB,British Virgin Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
VGB,British Virgin Islands,AMRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults with chronic conditions, residents living in long-term care facilities"
VGB,British Virgin Islands,AMRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Children with chronic conditions
VGB,British Virgin Islands,AMRO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M6,Children with chronic conditions
VGB,British Virgin Islands,AMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,Children with chronic conditions
VGB,British Virgin Islands,AMRO,2023,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,Y15,college students on demand
VGB,British Virgin Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,college students on demand
VGB,British Virgin Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,M15,college students on demand
VGB,British Virgin Islands,AMRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,HW,Health workers,NATIONAL,M15,HCW
VGB,British Virgin Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),2.0,HW,General/routine,NATIONAL,M4,HCW
VGB,British Virgin Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),4.0,HW,General/routine,NATIONAL,M18,HCW
VGB,British Virgin Islands,AMRO,2023,OPV,OPV (Oral polio vaccine),5.0,HW,General/routine,NATIONAL,Y4,HCW
VGB,British Virgin Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,high-risk children
VGB,British Virgin Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,high-risk children
VGB,British Virgin Islands,AMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,high-risk children
VGB,British Virgin Islands,AMRO,2023,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"high-risk adults (i.e. DM dialysis pts, other chronic illnesses)"
VGB,British Virgin Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,CATCHUP_C,Catch-up children,NATIONAL,>Y7,Given also to children >7 years old who missed the DT(P)
VGB,British Virgin Islands,AMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14,Given also to children >7 years old who missed the DT(P)
VGB,British Virgin Islands,AMRO,2023,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,Y14,Pregnant women
VGB,British Virgin Islands,AMRO,2023,VARICELLA,Varicella vaccine,1.0,PW,General/routine,NATIONAL,Y1,Pregnant women
VGB,British Virgin Islands,AMRO,2023,VARICELLA,Varicella vaccine,2.0,PW,General/routine,NATIONAL,Y4,Pregnant women
VGB,British Virgin Islands,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y3,1st contact; persons >3 years on demand
VGB,British Virgin Islands,AMRO,2023,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y3,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,TRAVELLERS,General/routine,NATIONAL,B,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,M5,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,M9,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M12,travellers to endemic areas
VNM,Viet Nam,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M12,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,Y2,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,MEASLES,Measles vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M9,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M18,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_2YL_W,General/routine,NATIONAL,M2,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_2YL_W,General/routine,NATIONAL,M3,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_2YL_W,General/routine,NATIONAL,M4,2nd dose is administered +2 weeks after the 1st dose
VNM,Viet Nam,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,SUBNATIONAL,Y7,Children aged 7 years old or enrolled 2nd grade
VNM,Viet Nam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
VNM,Viet Nam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
VNM,Viet Nam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
VNM,Viet Nam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
VNM,Viet Nam,WPRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
VNM,Viet Nam,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6-M36,pregnant women
VUT,Vanuatu,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,pregnant women
VUT,Vanuatu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,PW,General/routine,NATIONAL,W6,pregnant women
VUT,Vanuatu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,PW,General/routine,NATIONAL,W10,pregnant women
VUT,Vanuatu,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,PW,General/routine,NATIONAL,W14,pregnant women
VUT,Vanuatu,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,PW,General/routine,NATIONAL,B,pregnant women
VUT,Vanuatu,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,PW,General/routine,NATIONAL,Y9,female only
VUT,Vanuatu,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,PW,General/routine,NATIONAL,W14,female only
VUT,Vanuatu,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,PW,General/routine,NATIONAL,M12,female only
VUT,Vanuatu,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,PW,General/routine,NATIONAL,M18,female only
VUT,Vanuatu,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,PW,General/routine,NATIONAL,W6,female only
VUT,Vanuatu,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,PW,General/routine,NATIONAL,W10,female only
VUT,Vanuatu,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,PW,General/routine,NATIONAL,W14,female only
VUT,Vanuatu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,female only
VUT,Vanuatu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,female only
VUT,Vanuatu,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,PW,General/routine,NATIONAL,W14,female only
VUT,Vanuatu,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,PW,General/routine,NATIONAL,W6,female only
VUT,Vanuatu,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,PW,General/routine,NATIONAL,W10,female only
VUT,Vanuatu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,female only
VUT,Vanuatu,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y11,female only
WLF,Wallis and Futuna,WPRO,2019,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M1,female only
WLF,Wallis and Futuna,WPRO,2019,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,M2,female only
WLF,Wallis and Futuna,WPRO,2019,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,M11,female only
WLF,Wallis and Futuna,WPRO,2019,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,M4,female only
WLF,Wallis and Futuna,WPRO,2019,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,female only
WLF,Wallis and Futuna,WPRO,2019,DTIPV,DT-IPV (Diphtheria and tetanus toxoid and IPV) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y11,female only
WLF,Wallis and Futuna,WPRO,2019,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,female only
WLF,Wallis and Futuna,WPRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,M12,female only
WLF,Wallis and Futuna,WPRO,2019,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,B_CHILD_W,General/routine,NATIONAL,M16,female only
WLF,Wallis and Futuna,WPRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M4,female only
WLF,Wallis and Futuna,WPRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M2,female only
WLF,Wallis and Futuna,WPRO,2019,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,M11,female only
WSM,Samoa,WPRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,B,Infants at birth
WSM,Samoa,WPRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,Infants 15 months
WSM,Samoa,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,Less than one year
WSM,Samoa,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,Less than one year
WSM,Samoa,WPRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,Less than one year
WSM,Samoa,WPRO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Babies at birth
WSM,Samoa,WPRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,"Females in school year 8, regardless of age"
WSM,Samoa,WPRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,Infants under one year
WSM,Samoa,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,FEMALE,General/routine,NATIONAL,M9,Infants under two years
WSM,Samoa,WPRO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,FEMALE,General/routine,NATIONAL,M15,Infants under two years
WSM,Samoa,WPRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,Less than two years
WSM,Samoa,WPRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,Less than two years
WSM,Samoa,WPRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,Less than two years
WSM,Samoa,WPRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M15,Less than two years
WSM,Samoa,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Infants under one year
WSM,Samoa,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Infants under one year
WSM,Samoa,WPRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,M9,Infants under one year
WSM,Samoa,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,Infants under 6 months
WSM,Samoa,WPRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,Infants under 6 months
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,School children year one and year six
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,School children year one and year six
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,First antenatal visit; pregnant mothers
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,First antenatal visit; pregnant mothers
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,First antenatal visit; pregnant mothers
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,First antenatal visit; pregnant mothers
WSM,Samoa,WPRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,First antenatal visit; pregnant mothers
WSM,Samoa,WPRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,PW,General/routine,NATIONAL,M9,Children under two years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,Children under five years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M15,Children under five years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,Y2,Children under five years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,Y2.5,Children under five years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,Y3,Children under five years
WSM,Samoa,WPRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,Y3.5,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y7,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M12,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M2,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,M3,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,M4,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,B_2YL_W,General/routine,NATIONAL,B,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,Children under five years
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y65,Health and care workers
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y65,Pregnant women
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y65,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6-Y5,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M2,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,M3,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,M4,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,General/routine,NATIONAL,Y6-Y7,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,M12,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,Y6-Y7,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,Y12-Y13,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y17-Y18,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,Y17-Y18,"Adults with chronic conditions, residents living in long-term care facilities"
XKX,Kosovo (in accordance with UN Security Council resolution 1244 (1999)),EURO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y12-Y13,"Adults with chronic conditions, residents living in long-term care facilities"
YEM,Yemen,EMRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,B,B
YEM,Yemen,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,W6 - 7 years
YEM,Yemen,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,W6 - 7 years
YEM,Yemen,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,W6 - 7 years
YEM,Yemen,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,W6 - 7 years
YEM,Yemen,EMRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y7,W6 - 7 years
YEM,Yemen,EMRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,W14,under 1 year
YEM,Yemen,EMRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,M9,under 1 year
YEM,Yemen,EMRO,2023,MR,MR (Measles and rubella) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,M9,9 months - 7 years
YEM,Yemen,EMRO,2023,MR,MR (Measles and rubella) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,M18,9 months - 7 years
YEM,Yemen,EMRO,2023,MR,MR (Measles and rubella) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y7,9 months - 7 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),1.0,B_CHILD_W,General/routine,NATIONAL,B,under 2 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),2.0,B_CHILD_W,General/routine,NATIONAL,W6,under 2 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),3.0,B_CHILD_W,General/routine,NATIONAL,W10,under 2 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),4.0,B_CHILD_W,General/routine,NATIONAL,W14,under 2 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),5.0,B_CHILD_W,General/routine,NATIONAL,M9,under 2 years
YEM,Yemen,EMRO,2023,OPV,OPV (Oral polio vaccine),6.0,B_CHILD_W,General/routine,NATIONAL,M18,under 2 years
YEM,Yemen,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,under 1 year
YEM,Yemen,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,under 1 year
YEM,Yemen,EMRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,B_CHILD_W,General/routine,NATIONAL,W14,under 1 year
YEM,Yemen,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,W6,under 1 year
YEM,Yemen,EMRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,B_CHILD_W,General/routine,NATIONAL,W10,under 1 year
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,General/routine,NATIONAL,+M1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,General/routine,NATIONAL,+M6,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,General/routine,NATIONAL,Y15-Y49,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,General/routine,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,General/routine,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant and unpregnant women 15-49 years
YEM,Yemen,EMRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M9,9 months - 7 years
YEM,Yemen,EMRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M18,9 months - 7 years
YEM,Yemen,EMRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,Y5-Y7,9 months - 7 years
ZAF,South Africa,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,Under 1 year population
ZAF,South Africa,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,PW,General/routine,NATIONAL,W6,Under 2 year population
ZAF,South Africa,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,PW,General/routine,NATIONAL,W10,Under 2 year population
ZAF,South Africa,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,PW,General/routine,NATIONAL,W14,Under 2 year population
ZAF,South Africa,AFRO,2023,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Under 2 year population
ZAF,South Africa,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females 9 years and older in Grade 4
ZAF,South Africa,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females 9 years and older in Grade 4
ZAF,South Africa,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65 years and above
ZAF,South Africa,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,>Y18,Health and care workers
ZAF,South Africa,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,>Y18,Pregnant women
ZAF,South Africa,AFRO,2023,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ZAF,South Africa,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ZAF,South Africa,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,>=M6,"Adults with chronic conditions, residents living in long-term care facilities, other groups"
ZAF,South Africa,AFRO,2023,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M6,Children with chronic conditions
ZAF,South Africa,AFRO,2023,MEASLES,Measles vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M6,<13 Month population
ZAF,South Africa,AFRO,2023,MEASLES,Measles vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M12,<13 Month population
ZAF,South Africa,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,B,Under 1 year population
ZAF,South Africa,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W6,Under 1 year population
ZAF,South Africa,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Under 1 year population
ZAF,South Africa,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W14,Under 1 year population
ZAF,South Africa,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,M9,Under 1 year population
ZAF,South Africa,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Under 1 year population
ZAF,South Africa,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W14,Under 1 year population
ZAF,South Africa,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,6 and 12 year population
ZAF,South Africa,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,6 and 12 year population
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,B_ADO_W,General/routine,NATIONAL,M6,Every 6 month till 59 months
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,B_ADO_W,General/routine,NATIONAL,M12,Every 6 month till 59 months
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,B_ADO_W,General/routine,NATIONAL,M18,Every 6 month till 59 months
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,B_ADO_W,General/routine,NATIONAL,M24,Every 6 month till 59 months
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,B_ADO_W,General/routine,NATIONAL,M30,Every 6 month till 59 months
ZAF,South Africa,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,B_ADO_W,General/routine,NATIONAL,M36,Every 6 month till 59 months
ZMB,Zambia,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W1,Live births
ZMB,Zambia,AFRO,2023,CHOLERA,Cholera vaccine,1.0,B_ADO_W,General/routine,SUBNATIONAL,>=Y1,Live births
ZMB,Zambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,W6,Surviving infants
ZMB,Zambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,W10,Surviving infants
ZMB,Zambia,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_ADO_W,General/routine,NATIONAL,W14,Surviving infants
ZMB,Zambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,Girls aged 9-14 years old (in school and out of school) reached through an HPV Multi Age Cohort Vaccination Campaign
ZMB,Zambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9,"In 2023, Zambia also conducted an HPV Multi Age Cohort (MAC) vaccination targeting girls aged 9 to 14 years. For HIV positive girls referred to a facility for the  second and third dose or through the ART clinic. The dose schedule for the non-immunocompromised girls is a one-dose schedule while those who are immunocompromised the schedule is a 3-dose schedule with 2 month interval after the first dose and 4 months after the second dose."
ZMB,Zambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"In 2023, Zambia also conducted an HPV Multi Age Cohort (MAC) vaccination targeting girls aged 9 to 14 years. For HIV positive girls referred to a facility for the  second and third dose or through the ART clinic. The dose schedule for the non-immunocompromised girls is a one-dose schedule while those who are immunocompromised the schedule is a 3-dose schedule with 2 month interval after the first dose and 4 months after the second dose."
ZMB,Zambia,AFRO,2023,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M4,"In 2023, Zambia also conducted an HPV Multi Age Cohort (MAC) vaccination targeting girls aged 9 to 14 years. For HIV positive girls referred to a facility for the  second and third dose or through the ART clinic. The dose schedule for the non-immunocompromised girls is a one-dose schedule while those who are immunocompromised the schedule is a 3-dose schedule with 2 month interval after the first dose and 4 months after the second dose."
ZMB,Zambia,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W14,Surviving infants
ZMB,Zambia,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,M9,Surviving infants
ZMB,Zambia,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,M18,Surviving infants
ZMB,Zambia,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,RISKGROUPS,General/routine,NATIONAL,W6,Surviving infants
ZMB,Zambia,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,RISKGROUPS,General/routine,NATIONAL,W10,Surviving infants
ZMB,Zambia,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,RISKGROUPS,General/routine,NATIONAL,W14,Surviving infants
ZMB,Zambia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Surviving infants
ZMB,Zambia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,Surviving infants
ZMB,Zambia,AFRO,2023,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,Surviving infants
ZMB,Zambia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,General/routine,NATIONAL,W6,Surviving infants
ZMB,Zambia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,General/routine,NATIONAL,W10,Surviving infants
ZMB,Zambia,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,3.0,RISKGROUPS,General/routine,NATIONAL,W14,Surviving infants
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"WCBA, pregnant women upon 1st contact"
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,6-59 months
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,6-59 months
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,6-59 months
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,6-59 months
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M36,6-59 months
ZMB,Zambia,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M48,6-59 months
ZWE,Zimbabwe,AFRO,2023,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,PW,General/routine,NATIONAL,B,<Y1
ZWE,Zimbabwe,AFRO,2023,CHOLERA,Cholera vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y1-Y45,outrbreak response
ZWE,Zimbabwe,AFRO,2023,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,<Y2
ZWE,Zimbabwe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,W6,<Y1
ZWE,Zimbabwe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,2.0,B_2YL_W,General/routine,NATIONAL,W10,<Y1
ZWE,Zimbabwe,AFRO,2023,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,3.0,B_2YL_W,General/routine,NATIONAL,W14,<Y1
ZWE,Zimbabwe,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Females - grade 5
ZWE,Zimbabwe,AFRO,2023,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,Females - grade 5
ZWE,Zimbabwe,AFRO,2023,IPV,IPV (Inactivated polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W14,<Y1
ZWE,Zimbabwe,AFRO,2023,IPV,IPV (Inactivated polio vaccine),2.0,FEMALE,General/routine,NATIONAL,M9,<Y1
ZWE,Zimbabwe,AFRO,2023,MR,MR (Measles and rubella) vaccine,1.0,FEMALE,General/routine,NATIONAL,M9,<Y2
ZWE,Zimbabwe,AFRO,2023,MR,MR (Measles and rubella) vaccine,2.0,FEMALE,General/routine,NATIONAL,M18,<Y2
ZWE,Zimbabwe,AFRO,2023,OPV,OPV (Oral polio vaccine),1.0,FEMALE,General/routine,NATIONAL,W6,<Y2
ZWE,Zimbabwe,AFRO,2023,OPV,OPV (Oral polio vaccine),2.0,FEMALE,General/routine,NATIONAL,W10,<Y2
ZWE,Zimbabwe,AFRO,2023,OPV,OPV (Oral polio vaccine),3.0,FEMALE,General/routine,NATIONAL,W14,<Y2
ZWE,Zimbabwe,AFRO,2023,OPV,OPV (Oral polio vaccine),4.0,FEMALE,General/routine,NATIONAL,M18,<Y2
ZWE,Zimbabwe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,<Y1
ZWE,Zimbabwe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,<Y1
ZWE,Zimbabwe,AFRO,2023,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,FEMALE,General/routine,NATIONAL,W14,<Y1
ZWE,Zimbabwe,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,FEMALE,General/routine,NATIONAL,W6,<Y1
ZWE,Zimbabwe,AFRO,2023,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,FEMALE,General/routine,NATIONAL,W10,<Y1
ZWE,Zimbabwe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
ZWE,Zimbabwe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
ZWE,Zimbabwe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
ZWE,Zimbabwe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
ZWE,Zimbabwe,AFRO,2023,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,pregnant women
ZWE,Zimbabwe,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
ZWE,Zimbabwe,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
ZWE,Zimbabwe,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
ZWE,Zimbabwe,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
ZWE,Zimbabwe,AFRO,2023,TT,TT (Tetanus toxoid) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,pregnant women
ZWE,Zimbabwe,AFRO,2023,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,PW,General/routine,SUBNATIONAL,+Y2,pregnant women
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,1.0,PW,General/routine,NATIONAL,M6,M6-M59
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,2.0,PW,General/routine,NATIONAL,M12,M6-M59
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,3.0,PW,General/routine,NATIONAL,M18,M6-M59
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,4.0,PW,General/routine,NATIONAL,M24,M6-M59
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,5.0,PW,General/routine,NATIONAL,M30,M6-M59
ZWE,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,M6-M59
Created: 2025-02-01 16:10 UTC,Zimbabwe,AFRO,2023,VITAMINA,Vitamin A supplements,6.0,PW,General/routine,NATIONAL,M36,M6-M59
